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1. Introduction 
1.1. Overview 
Damage to blood vessels and small capillaries occurs frequently after injuries or cuts, destroying 
the integrity of the vascular wall.  To minimize and arrest the loss of blood, platelets are recruited 
to the injured vessels.  The exposure of sub-endothelial matrix at the site of injury leads to the 
adhesion of circulating platelets to the damaged vessel wall during primary hemostasis.  Platelet 
adhesion promotes different platelet responses such as shape change, secretion of granule 
contents and the formation of platelet aggregates.  As a result, the platelet haemostatic plug heals 
the injured site.  Apart from the healing process, platelets are involved in atherogenesis and 
thrombotic complications occurring in atherosclerosis. Rupture of atherosclerotic plaques exposes 
pro-thrombotic substances to the circulating platelets leading to intra-arterial thrombus formation 
and vascular occlusion, which can cause acute coronary syndrome and myocardial infarction. 
Since long scientists are trying to understand the physiological and pathological activation of 
platelets using different in vitro, in vivo or ex vivo methods.  One of the important aspects of 
these studies is to understand the dynamic regulation and rearrangement of the platelet 
cytoskeleton during activation.  The morphological and functional changes of platelets require a 
drastic remodeling of the actin cytoskeleton.  Actin remodeling involves the depolymerization of 
existing filaments, and polymerization, branching and bundling of new filaments.  These 
processes are regulated by numerous actin-binding proteins and signaling molecules such as the 
family of Rho-GTPases.  The small GTPase Rho can regulate several aspects of cellular function, 
predominantly through its downstream effector p160ROCK (Rho-kinase).  One of the well 
established Rho-kinase-mediated signaling pathways is the phosphorylation of myosin light chain 
(MLC) and its counteracting MLC phosphatase.  Rho-kinase regulates a second pathway that 
involves activation LIM-kinases (LIMKs) and subsequent phosphorylation and inactivation of 
cofilin, an actin dynamizing protein.  This study is focused on the regulation of the Rho-
kinase/LIMKs/cofilin phosphorylation pathway for different morphological and functional 
platelet responses. As platelet stimuli, the physiological agonist thrombin and the 
pathophysiological relevant agonist lysophosphatidic acid (LPA), which is the main platelet-
activating lipid in atherosclerotic plaque, were studied. 
1.2. Platelets 
Blood platelets are produced from megakaryocytes in the bone marrow.  Although historically 
one of the first observations was the apparent shedding of platelets by megakaryocytes, the exact 
mechanism by which platelets are produced remains unclear.  Cultured megakaryocytes after 
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maturation are observed to produce platelet in two phases; firstly an extension of cytoplasm into 
multiple long structures called proplatelets and then platelet formation at the end of these 
proplatelets (Hartwig and Italiano 2003).  In vivo, each megakaryocyte produces an average of 
1000-3000 platelets (Chernoff et al. 1980), and it has been estimated that 35,000-40,000 platelets 
are produced per day per µl of blood (Ballem et al. 1992).  The physiological life span of human 
platelets is usually 7-10 days with a daily renewal rate of 20% of the total platelet count.  
Platelets from all common mammalian species are broadly similar in appearance; they are 
anucleated, discoid in shape and the smallest corpuscular component of circulating blood having 
a diameter of 2-4µm and an average surface area of 8µm² in non-activated state. 
1.2.1. Morphology of platelets 
The ultrastructure of platelets can be divided into four morphological regions: the peripheral 
zone, the structural zone, the zone of the organelles, and the membrane system (Figure 1.1) 
 
 
Figure 1.1 Schematic model of the platelet ultrastructure.  Platelets structure is morphologically divided into four 
zones: 1) Peripheral zone, 2) Cytoskeleton, 3) Zone of organelles and 4) Membrane system.  OCS, open canalicular 
system; DTS, dense tubular system. 
The peripheral zone consists of the plasma membrane composed of a bilayer of phospholipids 
and embedded membrane proteins.  The plasma membrane of platelets is covered on its 
extracellular side by a thin layer glycocalix (15-20nm), composed of various glycoproteins (GP), 
proteins, receptors and mucopolysaccharides.  These glycoproteins embedded in the glycocalix 
satisfy important roles in the stickiness and adhesion of platelets (Nurden and Caen 1975).  The 
phospholipids in the plasma membrane of platelets are asymmetrically organized; 
phosphotidylcholine and sphingomyelin are enriched in the outer monolayer, while 
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phosphatidylethanolamine and phosphatidylserine are more dominant in inner monolayer (Daniel 
1981).  Such kind of phospholipid arrangement in the plasma membrane is an important factor for 
platelet function (Gawaz 2001).  Platelet membrane also contains cholesterol whose 
concentration depends on the plasma cholesterol concentration (Carvalho et al. 1974; Shattil et al. 
1977). 
The cytoskeleton also known as sol-gel zone contains microtubules and widely differing 
structural proteins.  A single microtubule band goes around the circumference of platelets and is 
responsible for the discoid shape of non-activated platelets.  The disassembly of the microtubule 
coil results in the loss of discoid shape (White and Rao 1982).  Human platelets from 
heterozygous carriers of the Q43P point mutation in the microtubule subunit β1-tubulin (10% of 
normal population), which show normal levels of β1-tubulin expression, and platelets from β1-
tubulin knock-out mice, which showed substantial reduction in the level of β1-tubulin expression, 
have been reported to be spherocytic (Schwer et al. 2001; Freson et al. 2005).  The other main 
protein of the cytoskeleton is actin (15-20% of total platelet protein), which is regulated by 
numerous actin-binding proteins.  Actin filaments within the cytoplasm organize into a space-
filling network that gives form and strength to the cell.  Filaments of actin together with myosin 
furnish a contractile complex involved in shape change, pseudopod extension, internal 
contraction, and secretion (White 1984).  The actin cytoskeleton of platelets is described in detail 
in section 1.3. 
Platelets contain several organelles in their cytosol such as mitochondria, glycogen vesicles, 
peroxisomes and three different forms of storage granules containing proteins and other 
substances essential for platelet function: dense bodies, α-granules, and lysosomes.  The dense 
bodies (3-8 per platelet and mean diameter of 150 nm) are named after their characteristics 
inherent electron opacity; they contain high concentrations of ADP, ATP, Ca²+, pyrophosphate 
and serotonin, which are prothrombotic and secreted to recruit other platelets (McNicol and 
Israels 1999).  The α-granules represent the major granule population (50-80 in number) and are 
large organelles of 200-400 nm in diameter, enclosed by a membrane similar to the plasma 
membrane.  They contain proteins that play a critical role in different biological functions such as 
platelet adhesion and aggregation, chemotaxis of leukocytes, proliferation of different vascular 
cells, inflammation and coagulation (Rendu and Brohard-Bohn 2001).  The lysosomal bodies 
(175-200 nm in diameter) contain hydrolytic enzymes similar to the lysosomes of other cells.  
The components of all three granules are secreted during platelet activation, but lysosomal 
contents are more slowly and incompletely released than the contents of α-granules and dense 
bodies (Holmsen et al. 1982). 
Two types of intracellular platelet membrane systems can be distinguished: the surface connected 
open canalicular system (OCS) and the dense tubular system (DTS). The OCS is an elaborate 
series of conduits that begin as an indentation of the plasma membrane, courses throughout the 
interior of the platelet, and return back to the plasma membrane.  These conduits of OCS are 
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accessible from the extracellular space through pores.  The OCS provides a potential route for 
transport of granule contents outside or for external elements to the interior of platelets.  The 
OCS also serves as a storage site for the plasma membrane and plasma-membrane bound 
glycoproteins (Nurden et al. 1994).  Upon activation, the platelet surface membrane increases due 
to exposure of the OCS.  The DTS is a closed-channel network of residual endoplasmic reticulum 
from the megakaryocytes. The DTS is one of the main storage sites for free Ca2+.  Upon 
activation, Ca2+ is released from the DTS to the cytoplasm.  The increase of cytosolic Ca2+ 
concentration plays a major role in the regulation of platelet metabolism and activation. 
1.2.2. Platelet responses during hemostasis 
Platelets are crucial at the site of vascular injury where they interact with the sub-endothelial 
matrix to form the hemostatic plug.  The process of hemostatic plug formation is a complex 
multistep process that includes platelet tethering, adhesion, activation, spreading, aggregation, 
degranulation, procoagulant activation, and microparticle generation (Figure 1.2). 
              
 
Figure 1.2 Response of platelets during hemostasis. Platelets tether, role and finally adhere to exposed sub-
endothelial matrix at injured site. Platelets activation leads to shape change, secretion and recruitment of other 
platelets from circulation. Platelets aggregation and ultimate spreading result in closure of vessel wall.  
Platelet adhesion and spreading need a supportive substratum, whereas the other platelet 
responses can also occur independently in suspension in order to support the formation of a stable 
hemostatic plug.  The process of hemostatic plug formation starts with capturing of circulating 
platelets at the injury site.  Platelet adhesion to the exposed subendothelium is a multistep process 
involving a diverse array of adhesive ligands (von Willebrand factor [vWF], collagen, fibronectin 
and laminin) and their receptors on the platelet surface (glycoproteins and integrins) (Chen and 
Lopez 2005).  The high affinity interaction between GP-Ib-V-IX and vWF is required for the 
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initial platelet tether that slows down the velocity of circulating platelets, especially under high 
shear conditions.  This interaction is not sufficient to hold platelets and is reversible, however the 
deceleration in platelet velocity allows other receptor-ligand interactions (for e.g., GP-VI with 
collagen, integrin αIIbβ3 with fibrinogen and vWF) to mediate a firm platelet adhesion (Jackson et 
al. 2003).  These interactions upregulate signaling pathways that lead platelets into the activation 
phase.  The platelets loose their discoid shape, extent pseudopods and protrude their surface 
membrane over the extracellular matrix.  One important consequence is the activation of the 
integrin αIIbβ3 on the platelet surface. Integrin αIIbβ3 interaction with fibrinogen and vWF 
embedded in the subendothelial matrix help platelets to spread over the subendothelium.  Platelet 
activation includes a rise in cytosolic Ca2+, an enzymatic formation of thromboxane A2 (TxA2) 
from released arachidonic acid and the secretion of ADP from dense granules.  TxA2 and ADP 
release and their subsequent interaction with the respective G-protein coupled receptors reinforce 
platelet activation.  The surface of activated platelets serves as an integral part of the 
prothrombinase complex for generation of thrombin (Dorsam et al. 2004).  Locally accumulated 
thrombin and components released from granules, especially ADP, augment the adhesion process 
by autocrine mechanism.  They also stimulate resting platelets in the circulation and recruit them 
to the site of injury for further consolidation of adhesion by paracrine mechanism.  Recruitment 
of additional platelets to the adherent platelets causes them to interact with each other and to form 
aggregates, which are then eventually stabilized by a cross-linked fibrin clot to form a stable 
hemostatic plug.  The process of aggregation requires an activation integrin αIIbβ3 by inside-out 
signaling and subsequent interaction between integrin αIIbβ3 on adjacent platelets through 
fibrinogen, which acts as a bridge between two platelets.  Platelet aggregation in vitro can occurs 
in two phases; a primary reversible aggregation without secretion and a secondary irreversible 
aggregation usually associated with large secretion from granules. 
A similar multistep process as described for hemostasis also underlies the pathological process of 
intravascular plug formation after rupture or erosion of atherosclerotic plaques.  Platelet 
activation is initiated as they encounter matrix proteins and atherogenic substances exposed 
beneath ruptured or eroded atherosclerotic plaques (Ruggeri 2002), for example LPA (Siess et al. 
1999; Rother et al. 2003), which induces platelet shape change, and platelet aggregation in 
synergism with ADP secreted from dense granules of platelets or released from erythrocytes 
(Haseruck et al. 2004). 
1.2.3. Signaling pathways for platelet activation 
Most of the physiological platelet stimuli like ADP, TxA2, LPA, or thrombin act through seven 
transmembrane domain receptors that are coupled to heterotrimeric G proteins (α, β, and γ 
subunits).  These G proteins are important mediators for intracellular signaling pathways in 
platelets.  Receptor activation mediates a conformational change of G proteins leading to an 
exchange of GDP to GTP on their α-subunit, which then dissociates from their βγ subunits.  G 
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proteins are defined by the identity of their α-subunits and are grouped into four families, Gαs, 
Gαi, Gαq, and Gα12/13 (Offermanns 2000).  Members of all four families are present in platelets.  
ADP through its receptors P2Y1 and P2Y12 activates Gq and Gi, respectively (Gachet 2001; 
Kunapuli et al. 2003), TxA2 receptor is functionally coupled to Gq and G12/13 proteins, LPA 
activates G12/13 (Siess and Tigyi 2004), and protease-activated receptors (PARs) activated by 
thrombin are coupled to Gq, G12/13, and Gi (Offermanns et al. 1994; Klages et al. 1999).  While Gi, 
Gq, and G12/13 transmit signals for platelet activation, Gs mediates platelet inhibition by coupling 
to the prostacyclin receptor and increasing intracellular cAMP levels.  Studies on mouse platelets 
deficient in Gαq, Gα13, or Gi2 proteins show that signaling through multiple G-protein pathways 
are necessary for secretion from dense granules and platelet aggregation.  Gαq-deficient platelets 
show shape change but fail to secrete and aggregate in response to thrombin or TxA2, while ADP 
causes neither shape change nor aggregation (Offermanns et al. 1997).  Platelets from mouse 
deficient in Gα13 do not show a shape change response to low concentration of TxA2 and 
thrombin and have impaired platelet aggregation and granule secretion responses after exposure 
to high concentrations of these agonists (Moers et al. 2003).  Gαi2-deficient platelets were 
irresponsive to ADP and showed a reduced aggregation in response to TxA2 and thrombin, 
possibly due to the absence of additive stimulation induced by secreted ADP through the P2Y12 
receptor (Jantzen et al. 2001).  Although the G12/13-mediated signaling pathway mainly 
contributes to Ca2+-independent platelet shape change, co-stimulation of G12/13- and Gi-mediated 
signaling pathways in Gαq-deficient platelets were sufficient to result in a small increase of 
intracellular Ca2+ and activate integrin αIIbβ3 leading to irreversible aggregation.  Thus, Gq-
mediated signaling alone or co-stimulation of G12/13- and Gi-mediated signaling is needed for 
secretion and platelet aggregation (Dorsam et al. 2002; Nieswandt et al. 2002).   
The α-subunit of Gq activates phospholipase C (PLC)-β, which in turn results in the formation of 
inositol 1,4,5 triphosphate (IP3) and diacylglycerol leading to an elevation of free cytoplasmic 
Ca2+ and activation of protein kinase C (PKC), respectively (Offermanns et al. 1997).  The 
activation of Gi leads to dissociation of its subunits, which results in inhibition of adenylyl 
cyclase and activation of PI3-kinase by αi-subunit and released βγ subunits, respectively 
(Offermanns 2000).  Platelets from mice deficient in Akt, a downstream molecule of PI3-kinase, 
showed defects in secretion, aggregation and thrombus formation (Chen et al. 2004; Woulfe et al. 
2004).  An increase of intracellular Ca2+ and activation of PKC and PI3-kinase are involved in 
secretion, initial activation of the integrin αIIbβ3 by inside-out signaling and the subsequent 
stabilization of platelet aggregates (Shattil and Brass 1987).   
Platelet shape change observed in Gαq-deficient platelets suggested a role of G12/13-mediated 
signaling for platelet shape change in a Ca2+-independent manner (Offermanns et al. 1997).  
Furthermore, platelets of mice deficient in G13 and G12 alone showed that platelet shape change is 
due to activation of G13, but not G12.  A significant reduction in platelet aggregation and the 
inability of G13-deficient platelets to adhere on collagen matrix under high shear rates suggested 
Introduction 
 
7
an important role of G13 in hemostasis and thrombosis (Moers et al. 2003).  The signaling 
pathway induced by G13 involves Rho/Rho-kinase-mediated shape change of human platelets.  
Inactivation of Rho or inhibition of Rho-kinase blocked the Ca2+-independent shape change in 
human platelets and Gq-deficient mice platelets (Bauer et al. 1999; Klages et al. 1999).  The 
activation of Rho-kinase leads to phosphorylation of myosin light chain and thereby increases the 
actinomyosin contraction underlying platelet shape change.  These studies indicate that Gq, Gi 
and G13 alone may still activate platelets, but signaling pathways via all three G proteins seem to 
be required for efficient platelet activation under physiological and pathological conditions 
(Figure 1.3). 
 
 
Figure 1.3 G-protein-mediated signaling pathways involved in platelet activation. Several agonists activate 
platelets through GPCRs coupled to G-proteins, which operate alone or in synergy with each other during platelet 
activation. Signaling pathways mediated by these G-proteins regulate shape change, secretion and aggregation. 
1.3. Regulation of platelet function by the cytoskeleton 
Changes in actin cytoskeleton of platelets play a central role in the different functional and 
morphological platelet responses induced by agonists.  The cytoskeleton is rigid as well as 
dynamic.  The rigid cytoskeleton keeps the unstimulated platelet in discoid shape, whereas its 
dynamic nature underlies the morphological and functional changes like shape change, secretion, 
aggregation and spreading after platelet activation.  The dynamics in platelet cytoskeleton 
comprise the depolymerization, polymerization and crosslinking of cytoskeletal components such 
as actin and microtubules, and the interaction between myosin and actin filaments. 
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1.3.1. The actin cytoskeleton in platelets 
The platelet actin cytoskeleton is a component of the structural zone.  It is comprised of various 
elements that remain insoluble after lysis of platelets with Triton X-100.  This insoluble fraction 
is further divided into two different forms depending on their structural organization and location: 
an actin network just beneath the plasma membrane (membrane skeleton) and a cytosolic actin 
network.  The actin filaments of the membrane skeleton are shorter and require higher g-forces 
(100,000x g) to sediment than the longer filaments of the cytosolic network, which sediments at 
low g-forces (15,000x g).   
Cytoskeleton 
proteins 
Mol wt 
(kDa) 
Properties 
 
Actin 
 
42 
 
Building blocks of the actin filament, possesses ATPase 
activity; depolymerization and polymerization of actin 
filaments is involved in cytoskeleton based cell motility. 
Gelsolin 91 Severs actin filaments; binds to barbed end of F-actin and 
facilitates nucleation 
Cofilin 20 Binds with G-actin (1:1 ratio) and to the subunits of F-actin; 
accelerates depolymerization and treadmilling of the actin 
filaments 
Arp2/3 complex Complex of 7 
proteins 
Nucleates new actin filaments and accelerates actin 
polymerization; induces branching of filaments leading to 
dendritic actin network  
Profilin 19 Forms 1:1 reversible complex with actin monomers; promotes 
exchange of ADP→ATP in actin monomers and enhances 
filament elongation 
CapZ 36 and 32 Heterodimer; binds barbed end of actin filaments and inhibits 
actin polymerization 
Thymosin β4 5 Sequesters actin monomers and inhibits ADP→ATP exchange 
WASP 62 Enhances Arp2/3 complex activity; binds profilin and 
signaling proteins 
VASP 50 Exist as tetramer in vivo; binds profilin, vinculin and zyxin 
α-Actinin 100 and 102 Dimer; binds actin at 1:10 stoichiometry; cross-links filaments 
and promotes actin polymerization 
Filamin I 260 Binds actin protomers in filament with 1:14 ratio; cross-links 
actin filaments; binds cytoplasmic domains of gylcoproteins 
Talin 235 Binds to other actin binding proteins like vinculin and α-
actinin; binds integrin receptors 
Spectrin 240 and 220 Dimer; forms a head to head associated tetramer; cross-links 
actin; interacts with integrin αIIbβ3; and possesses sites for 
calpain cleavage 
Vinculin 130 Binds to talin; participates in actin to membrane proteins 
interaction at adhesion sites 
Tropomyosin 28 Binds along the groove of actin filament helix in 1:7 ratio; 
plays a role in Ca2+-mediated skeletal muscle contraction 
Myosin II 480 Dimer of one heavy chain (200kDa) and two light chain 
(20kDa each); 2-5% of platelet protein; provides contractility 
to the actin filaments 
Caldesmon 80 Binds actin, tropomyosin, myosin and calmodulin; may 
control actin filaments bundling 
Fimbrin 68 Bundles actin filaments 
Table 1.1 Proteins of the platelet cytoskeleton (Fox 1993; Hartwig et al. 1999; Fox 2001) 
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The short filaments of membrane skeleton associate with several proteins (e.g., spectrin) and 
glycoproteins (e.g., GP-Ib-V-IX and integrin αIIbβ3) known to cross-link actin filaments and 
regulate their interaction with the membrane, respectively.  The distribution of membrane 
skeleton proteins and glycoproteins based on their differential sedimentation suggested that 
different components of membrane skeleton exist (Fox 2001).  The longer filaments in the 
cytosol are cross-linked into a network that traverses throughout the body of the platelet.  The 
filaments in cytosolic actin network are associated with another set of proteins such as α-actinin, 
tropomyosin, and cladesmon that regulate cross-linking of these filaments or the association with 
other proteins.  Although, much of the information on the composition of the actin filament 
networks has come from studies on detergent-lysed platelets, a more intensive work towards 
knowledge of all proteins and their functions regulating actin cytoskeleton is needed.  Some of 
the major components of the platelet contractile system are listed in table (Table 1.1).  These 
elements are thought to contribute towards different platelet functions. 
1.3.2. Resting platelets 
In the unstimulated platelet, the actin cytoskeleton is thought to exist throughout the cytoplasm 
and in connection with the spectrin-based membrane skeleton that laminates the cytoplasmic side 
of the plasma membrane.  The bipolar tetrameric strands of spectrin interconnect into a network 
using the ends of the filaments that are in proximity of the membrane.  In this way the entire 
cytoskeleton functions together to support the plasma membrane and direct its contours.  
Compared to activated platelets, the actin filaments in unstimulated platelets are relatively stable 
and filament turnover is slow because the filamentous actins are capped on their barbed ends by 
the capping protein CapZ, whereas the monomeric actins are captured by the protein thymosin β4, 
and thus, prevent the actin dynamics. 
Actin filaments in unstimulated platelets are also fastened directly to the membrane 
glycoproteins.  One important interaction is between the cytoplasmic tail of the GP-Ibα chain of 
the vWF receptor (vWFR) and the actin cross-linking and protein scaffolding protein, filamin1 
(Okita et al. 1985).  This interaction helps to align vWFRs into linear arrays, to stabilize the 
plasma membrane (Hartwig et al. 1999) and to regulate the function of vWFRs during platelet 
activation (Cunningham et al. 1996; Williamson et al. 2002).  The importance of this interaction 
has been established in studies of platelets from patients with Bernard-Soulier syndrome, who 
possess qualitative and quantitative abnormalities in the GPIb/IX/V complex.  These platelets are 
fragile, abnormally large in size and circulate poorly because of the absence of the GPIb-filamin 
linkage (Kanaji et al. 2002).  Integrin αIIbβ3 associated with the membrane skeleton is supposed to 
be constrained in a quiescent low-affinity form by the actin cytoskeleton in unstimulated 
platelets.  Evidences showing that disruption of actin cytoskeleton in either direction 
(stabilization or destabilization) affect the affinity of integrin αIIbβ3 for its ligand fibrinogen 
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suggested an important role of the actin cytoskeleton in regulating the integrin αIIbβ3 activation 
(Fox et al. 1996; Bennett et al. 1999).  
1.3.3. Stimulated platelets 
1.3.3.1. Shape change 
Platelet shape change is the earliest response after activation.  Platelets loose their normal discoid 
shape and transform into spiny spheres with long pseudopods.  The microtubule ring responsible 
for maintaining platelet discoid shape disassembles rapidly during platelet activation.  However, 
this process does not seem to be required for platelet shape change as it occurs even in the 
presence of microtubule destabilizing and stabilizing agents.  An other established phenomenon 
observed during platelet shape change is the rapid reorganization of the actin filaments and 
increase in F-actin content (Nachmias 1980; Escolar et al. 1986).  Several actin filament-severing 
and -depolymerizing proteins are activated depending on the type of stimulus, such as gelsolin 
(Lind et al. 1982), scinderin (Rodriguez Del Castillo et al. 1992) and cofilin (Davidson and 
Haslam 1994).  Gelsolin, a Ca2+-dependent actin severing protein, increases the number of short 
actin filaments after severing the existing filaments, and remains associated with the new barbed 
ends thereby substituting CapZ as the capping protein (Barkalow et al. 1996).  Severing of actin 
filaments releases the constraints on the spectrin network and allows the incorporation of 
membranes from OCS into the plasma membrane in order to bring spherocytic change in platelet 
shape (but not to produce pseudopodia).  The changes in actin cytoskeleton such as an increased 
F-actin content had been observed during Ca2+-independent shape change (Bauer et al. 1999; 
Klages et al. 1999).  However, the role of actin-binding proteins in reorganizing the actin 
cytoskeleton in the absence of Ca2+ is not clear. 
The reorganization of the actin cytoskeleton is also accompanied by the activation of myosin via 
phosphorylation of one of its two light chains by Ca2+-dependent MLC-kinase and Rho-kinase 
(Daniel and Adelstein 1976; Bauer et al. 1999), which contributes to the actomyosin contraction 
required for shape change and centralization of granules (Cohen 1979).  The protrusive force for 
pseudopodial developments then comes from the subsequent actin polymerization onto newly 
severed and uncapped actin filaments.  Gelsolin uncapping of actin filaments is accomplished by 
gelsolin binding to phosphoinositides (PIs), which are produced during platelet activation 
(Hartwig et al. 1995).  Profilin that competes with thymosinβ4 for G-actin binding facilitates actin 
polymerization by transferring monomeric actins from the pool of actin-thymosinβ4 complex to 
the barbed ends of the actin filaments (Goldschmidt-Clermont et al. 1992).  Furthermore, the 
activation of the Arp2/3 complex initiates de novo actin nucleation, and branching and 
polymerization of the actin filaments contributing to the platelet shape change (Li et al. 2002).  
Other proteins and signaling molecules implicated in platelet shape change with varied functions 
are the small GTPases (Rho, Rac, and Cdc42), WASP, VASP, vinculin, and zyxin (Fox 2001). 
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1.3.3.2. Secretion 
The contractile mechanism involving actin and myosin is also thought to mediate granule 
secretion but the details remain obscure.  Platelet activation leads to the granules coalesce in the 
center.  Centralized granules then fuse with each other, with the OCS and with the plasma 
membrane in order to release the granule contents outside in the extracellular environment 
(Escolar and White 1991; Flaumenhaft 2003).  Studies correlating the cytoskeletal rearrangement 
with granule secretion suggest that actomyosin contraction and the reorganization of actin 
cytoskeleton, but not the microtubule dynamics, might regulate secretion.  The microtubule 
stabilizing agent taxol does not inhibit secretion (White and Rao 1983), whereas inhibitors of 
kinases involved in actin cytoskeleton dynamics such as the Rho-kinase inhibitor Y-27632 
(Suzuki et al. 1999) and the MLC-kinase inhibitors, W-7 and ML-9 (Saitoh et al. 1986; 
Lokeshwar and Bourguignon 1992) inhibit secretion.  However, cytochalasins, fungal metabolites 
that impair actin polymerization, have yielded conflicting results regarding the role of the actin 
cytoskeleton in secretion.  One study showed an augmentation of collagen-induced secretion by 
cytochalasin-B, whereas another study demonstrated only little effect of cytochalasin-B on 
collagen-induced dense granule secretion (Haslam et al. 1975; Kirkpatrick et al. 1980).  Studies 
using other agonists such as thrombin, phorbol esters, calcium ionophore, or ADP have also 
demonstrated either inhibition or augmentation of secretion by cytochalasins (Hashimoto et al. 
1986; Cox 1988; Diaz-Ricart et al. 2002).  Hence, it is not clear whether actin polymerization 
inhibits or facilitates secretion.  A recent study suggested that the actin cytoskeleton differentially 
regulates platelet α-granule and dense granule secretion.  Platelet exposures to low concentrations 
of actin-disrupting agents accelerated and augmented α-granule secretion, and decreased the 
agonist concentration required.  In contrast, high concentrations of actin-disrupting agents 
inhibited α-granule secretion, but stimulated dense granule secretion (Flaumenhaft et al. 2005). 
1.3.3.3. Aggregation 
During aggregation of platelets, the bi-directional signaling through the integrin αIIbβ3 involves 
many proteins that regulate the dynamics of the actin cytoskeleton.  It has been observed that 
inhibition of actin polymerization by cytochalasin-D or latrunculin-A can induce fibrinogen 
binding to the integrin αIIbβ3, whereas the actin-stabilizing agent jasplakinolide inhibited platelet 
aggregation.  This study suggests a role of the actin cytoskeleton in integrin αIIbβ3-mediated 
platelet aggregation (Bennett et al. 1999).  The different signaling pathways after platelet 
stimulation with agonists are supposed to converge at one point to transform the integrin αIIbβ3 
from a low affinity to a high affinity state (inside-out signaling), which modulate the efficient 
fibrinogen binding to the receptors.  An actin binding protein talin, which also binds to the 
cytoplasmic domain of the integrin β-subunit, is supposed to be the terminal point for integrin 
αIIbβ3 activation (Tadokoro et al. 2003).  Another protein VASP has been suggested to keep 
integrin αIIbβ3 into the low-affinity state.  Platelets from VASP knock-out mice showed an 
enhanced aggregation induced by different agonists (Aszodi et al. 1999; Hauser et al. 1999).  The 
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binding of fibrinogen to the integrin αIIbβ3 mediates additional activation of signaling pathways 
(outside-in signaling) that are important for the stabilization of platelet aggregates, the release of 
procoagulant molecules, the further reorganization of the cytoskeleton, and later for fibrin clot 
retraction.  The cytoskeleton reorganization by the activation of Ca2-dependent calpain has been 
proposed to be important for clot retraction (Phillips and Jakabova 1977; Fox et al. 1993).  This 
thiol protease cleaves several cytoskeleton proteins such as talin, spectrin, filamin, dystrophin-
related protein, and protein 4.1 superfamily members, including several signaling proteins and the 
cytoplasmic tail of β3-subunit of integrin itself (Schoenwaelder et al. 1997; Fox 1999). 
1.4. Actin dynamics 
Actin is an extremely conserved and an essential cytoskeletal component of eukaryotic cells.  It is 
the most abundant protein of molecular mass of 43 kDa and exists in different isoforms 
throughout the eukaryotes.  So far, six actin isoforms are known to be expressed as muscle 
specific (α- and γ-smooth muscle actins, α-skeleton actin and α-cardiac actin) and non-muscle 
specific (cytoplasmic β- and γ-actins) types and these are functionally specialized for the tissue in 
which they predominate (Khaitlina 2001; Chaponnier and Gabbiani 2004).  The single actin 
molecule is a relatively flat (~67 x 40 x 37 Ǻ), with four quasi-subdomains arranged to form a 
two-lobed molecule with two subdomains in each lobe and a central cleft between these two 
lobes (dos Remedios et al. 2003).  The central cleft contains the binding sites for a nucleotide 
(ATP or ADP) and a divalent cation (Mg2+ or Ca2+), which are essential cofactors of actin (De La 
Cruz and Pollard 1995; Kabsch and Holmes 1995).  Actin monomers also known as globular 
actin (G-actin) are able to assemble spontaneously into polar helical filamentous actin (F-actin) 
under physiological salt conditions.  The structure of F-actin is yet to determine but highly 
plausible models have been proposed based on the model of Holmes et al. (Holmes et al. 1990; 
dos Remedios et al. 2003).  
1.4.1. Actin filament assembly and disassembly 
The polymerization of G-actin to F-actin is an energy demanding process driven by actin’s 
ATPase activity.  Binding of ATP and Mg2+ to the cleft of monomeric actin (activation) is the 
initial step in this process, which is then followed by an oligomerization of actin molecules that 
act as nucleus for further elongation.  This nucleation process is relatively slow due to the 
instability of these oligomers and contributes to the lag phase for actin polymerization and hence, 
described as the rate-limiting step.  A rapid growth phase occurs as monomers are added bi-
directionally to the actin nucleus causing filament elongation.  The rate of filament elongation 
gradually reduces as the concentration of remaining free G-actin reaches a point where available 
monomers become exhausted.  Since all these processes are reversible, an equilibrium is then 
established where the rate of subunit addition to the filament ends is exactly balanced by the rate 
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of subunit dissociation from the ends.  The concentration of G-actin at this steady state is called 
critical concentration (Cc).  Net polymerization occurs when the G-actin concentration is higher 
than Cc, and net depolymerization occurs when the G-actin concentration is lower than Cc 
(Pollard and Cooper 1986).  
The chemical switch between polymerization and depolymerization of the actin filament is the 
hydrolysis of ATP.  Each actin monomer carries a tightly bound ATP molecule, which gets 
hydrolyzed to a tightly bound ADP molecule soon after its assembly into the filament.  
Hydrolyses of ATP reduces the binding affinity of the subunit for its neighboring subunits and 
makes it more likely to dissociate from each ends of the filament.  In rapidly assembling 
filaments, the hydrolysis lags behind the assembly, thus the hydrolysis of ATP is uncoupled from 
the fast growing assembly site (plus end), and the hydrolysis occurs at the rear ends of filaments, 
yielding first ADP-F-actin that leaves the filament from the slow growing disassembly site 
(minus end).  At the steady state where rate of subunit addition at plus end is identical to the rate 
of subunit disassembly from minus end, the polymer maintains a constant length and this process 
is termed as treadmilling (Wegner 1976). 
Due to the polar nature of each actin monomer, actin filaments created by the regular and parallel 
orientation of their subunits also have a unique polarity.  This polarity can be detected by 
decorating actin filaments with fragments of myosin, which binds to the fast growing assembly 
site (plus end).  Projections of myosin are tilted in one direction and appear as arrowheads.  Thus, 
this end of the actin filaments is also called as the barbed end (plus end), whereas the slow 
growing is the pointed end (minus end) (Moore et al. 1970). 
1.4.2. Proteins regulating actin dynamics  
The process of treadmilling is thought to be responsible for protrusive motility in cells, however 
in vitro at steady state under physiological ion conditions this process is relatively slower than the 
cellular motility.  In the steady state, growth at the barbed end is limited by dissociation from the 
pointed end resulting in effective growth rate of ~0.04 µm/min, which is 100-200 times slower 
than in cells (Pollard and Borisy 2003; Disanza et al. 2005).  The higher rate of treadmilling in 
vivo is due to proteins that interact with actin filaments or monomers, known as actin-binding 
proteins (ABPs).  A plethora of ABPs (approximately 162 distinct proteins) present in vivo 
regulates different aspects of the actin filaments like assembly, disassembly and organization of 
the filaments into functional higher order networks (dos Remedios et al. 2003).  These proteins 
are classified into more than 60 different classes leaving behind many "orphan" proteins that do 
not fit into these classes.  Following important ABP groups are distinguished based on their 
function to regulate actin dynamics.  1) Monomer binders, proteins binding to ADP- or ATP-
bound G-actin, sequestering them and preventing or facilitating actin polymerization (e.g., 
thymosin β4, profilin, and ADF/cofilin).  2) Capping proteins, which bind to one of the two end 
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of the actin filament; they prevent the exchange of actin monomers at the pointed end (e.g., 
tropomodulin) or at the barbed end (e.g., CapZ and gelsolin).  3) Severing and depolymerizing 
proteins, which shorten the average length of filaments by dissociating the subunits from either 
end or severing the filament at any place (e.g., ADF/cofilin, gelsolin, and scinderin).  4) Cross-
linking proteins, which contain at least two actin-binding sites; they facilitate the nucleation of 
new filaments, and induce bundling and branching of filaments into two- or three-dimensional 
networks (e.g., Arp2/3, formins, and α-actinin).  5) Filament-stabilizing proteins that bind to the 
sides of the actin filaments and prevent their depolymerization (e.g., tropomyosin).   
Some of these ABPs are not limited to one specific function, for e.g., gelsolin severs and caps the 
barbed end of the actin filaments, the Arp2/3 complex that consists of seven proteins nucleates 
and elongates the filaments and establishes branching points in actin networks, and ADF/cofilin 
not only severs and depolymerizes the actin filament, but also amplifies the local actin 
polymerization by acting synergistically with the Arp2/3 complex (DesMarais et al. 2005).  
Functional overlap of these ABPs makes their classification difficult; a more broadened picture of 
these ABPs is presented in Figure 1.4 and Table 1.1. 
 
 
Figure 1.4 Actin-binding proteins and their function.  Proteins involved in regulating the actin filament assembly 
and disassembly (center) are grouped into monomer binders and capping and severing proteins class. Proteins 
engaged in branch formation, cross-linking and bundling help the actin filaments to obtain higher-order structures. 
Proteins in classes like myosins, cytoskeletal linkers and membrane anchors contribute to the mechanical properties 
of the actin scaffold, (Winder and Ayscough 2005). 
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1.4.3. Signaling for actin dynamics 
The integration and coordination of the activities of all ABPs and the proteins affecting different 
steps of actin reorganization are needed to promote the cytoskeleton based cellular functions, 
which are 100-200 times faster than the in vitro actin dynamics under physiological ionic 
conditions.  Actin regulatory proteins are also the targets for a number of signaling pathways, 
which transmit the signals in a temporally and spatially controlled fashion.  Among the signaling 
proteins involved in actin dynamics, the Rho-GTPases family proteins of Ras superfamily 
GTPases have emerged as central players.  Signaling through Rho-GTPases can be initiated by 
activation of different plasma membrane receptors such as tyrosine kinase receptors, G-protein-
coupled receptors (see section 1.2.3), and integrins. 
The family of Rho-GTPases consists of 25 members divided roughly into 6 subfamilies based on 
their primary sequence and known functions: Rho-like, Rac-like, Cdc42-like, Rnd, RhoBTB and 
Miro, except RhoD, Rif and TTF/RhoH, which do not obviously fall into any of these subfamilies 
(Wennerberg and Der 2004).  Like all GTPases, Rho-GTPases cycle between active (GTP-bound) 
and inactive (GDP-bound) conformations regulated by guanine-nucleotide exchange factors 
(GEFs), and GTPase activating proteins (GAPs).  In addition, Rho-GTPases are regulated further 
by guanine-nucleotide dissociation inhibitors (GDIs) that inhibits both the exchange of GTP and 
the hydrolysis of bound GTP (Van Aelst and D'Souza-Schorey 1997).  Although, platelets lack a 
complete enlisting and characterization of its GTPases, Rac, Cdc42 and Rho are the three 
important Rho-GTPase subfamilies that regulate different signaling pathways underlying distinct 
actin dynamics based processes in platelets (see section 1.4.4).  Although the presence of 
different isoforms of Rho (RhoA, RhoB, and RhoC) and Cdc42 proteins in platelets are yet to be 
characterized, RhoA expression seems to be dominant in platelets (Nemoto et al. 1992).  
Recently, it was found that Rac1 but neither Rac2 nor Rac3 isoforms is expressed in human and 
murine platelets (McCarty et al. 2005).  Apart from the Rho-GTPases family proteins, some 
members of other GTPase families such as Ras (e.g., Rap1B, Rap2B) and Arf (Arf6) have been 
suggested to regulate cytoskeletal dynamics in activated platelets (Torti et al. 1999; 
Chrzanowska-Wodnicka et al. 2005; Choi et al. 2006). 
1.4.4. Effectors of Rho-, Rac- and Cdc42-like GTPases 
Members of the Rho family GTPase including Rho, Rac, and Cdc42 that are highly expressed in 
platelets regulate different dynamic actin structures underlying platelet activation.  Rho is known 
for spheration and contractility (Klages et al. 1999), Rac1 regulates the formation of lamellipodia 
(McCarty et al. 2005), whereas Cdc42 controls the formation of filopodia during platelet 
activation (Chang et al. 2005).  These Rho-GTPases regulates these distinct actin-related 
processes through specific downstream effector proteins.  Rac and Cdc42 possess mainly 
common (Cotteret and Chernoff 2002) targets, whereas Rho effectors are specific albeit some of 
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them are influenced by Rac and Cdc42 also.  Common targets for Rac and Cdc42 include serine-
threonine kinases (e.g., p21 activated kinases, PAKs), lipid-kinases (e.g., PI3-kinase), and 
IQGAPs (Teo et al. 1995; Carpenter et al. 1997; Schmidt et al. 2003).  Some of the Rac and 
Cdc42 effector proteins are different and specific however, the signaling pathways later converge 
onto a common target for regulating distinct functions.  The best example of this intriguing 
complexity is the indirect activation of the Arp2/3 complex by both Rac and Cdc42, but through 
different effectors WAVEs and WASP that lead to morphologically distinct protrusions at the 
plasma membrane, lamellipodia and filopodia, respectively (Falet et al. 2002; Jaffe and Hall 
2005). 
The most prominent and common target of Rac and Cdc42 are PAKs.  All PAKs identified to 
date share a similar 18-amino acid CRIB (Cdc42/Rac interactive binding) motif that mediates the 
interaction with Rac and Cdc42 (Bokoch 2003).  Activation  of PAK regulates several processes: 
an activation of LIMK-1 with the subsequent inactivation of cofilin (Arber et al. 1998; Dan et al. 
2001); and an inhibition of MLC-kinase thereby inhibiting MLC phosphorylation and reducing 
the actomyosin structures (Sanders et al. 1999; van Leeuwen et al. 1999).  So far, the 
characterization and specific role of PAK isoforms in platelets remain to be elucidated.  Another 
common target of Rac and Cdc42 are IQGAPs that are able to bind to both Rac and Cdc42, and 
hence thereby facilitating the actin filament cross-linking activity of these proteins (Brill et al. 
1996). The two homologous isoforms of IQGAPs (IQGAP1 and IQGAP2) are present in human 
platelets.  IQGAP1 binds specifically to GTP-bound forms of Rac1 and Cdc42, whereas IQGAP2 
can bind to both the inactive (GDP) and active (GTP) forms of Rac1/Cdc42; therefore they could 
mediate divergent actin-related responses (Schmidt et al. 2003).  
Rho stimulates several signaling proteins such as the Rho-kinases (ROCKs), protein kinase novel 
(PKN), myosin binding subunit, kinectin, mDia and citron kinase (Van Aelst and D'Souza-
Schorey 1997).  Furthermore, Rho directly or indirectly stimulates lipid kinases (PIP5-kinase and 
PI3-kinase), which are also targets for Rac and Cdc42.  The well elucidated Rho target in 
platelets is Rho-kinase (Ishizaki et al. 1996) and to some extent the lipid kinases that are observed 
to be activated through Rho, however direct interaction of these lipid kinases with Rho is still 
questionable (Zhang et al. 1993; Yang et al. 2004).  The presence of other Rho targets and 
whether they could influence actin dynamics in activated platelets is not known.  Rho interaction 
with mDia, a member of the formin family of proteins, stimulates actin polymerization by 
binding with the profilin/actin complex and delivering it to the barbed end of the filament (Li and 
Higgs 2003). Citron kinase, which like Rho-kinase stimulates MLC phosphorylation and 
enhances myosin activity, appears to function primarily during mitosis, specifically at the 
cleavage furrow in other cell types (Madaule et al. 1998).  
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1.4.5. Rho-kinase 
Rho-kinases or ROCKs, a serine/threonine protein kinases, were the first effectors of Rho to be 
discovered, and were initially characterized for the formation of RhoA-induced stress fibers and 
focal adhesions (Leung et al. 1996).  Two isoforms of Rho-kinases have been identified that are 
encoded by different genes; ROCKI (also known as ROKβ or p160 ROCK) and ROCKII (also 
known as ROKα).  These two proteins share an overall sequence similarity at amino-acid level of 
65% and in their kinase domains of 92% (Nakagawa et al. 1996).  These kinases consist of an 
amino terminal kinase domain followed by a coiled-coil region and a Rho-binding domain, and a 
pleckstrin homology (PH) domain at C-terminal.  Rho-kinase (p160ROCK; ROCKI) was firstly 
isolated from human platelets as a 160 kDa protein homologous to myotonic dystrophy kinase 
(Ishizaki et al. 1996).  Since no attempt to identify ROCKII in platelets has been performed and 
Rho-kinase inhibitors cannot differentiate between these two isoforms, most of the studies in 
platelets use Rho-kinase as general term to indicate both isoforms. 
 
Figure 1.5 The structure of Rho-kinases.  The kinase domain of Rho-kinases is situated in the N-terminus, and it 
possesses high homology between the two isoforms (92% identity). The sequence of the Rho-binding domain (RBD) 
of ROCKI (amino acids 934-1015) is highly homologous in ROCKII.  In the C-terminus of Rho-kinases there is a 
pleckstrin homology (PH) domain with an internal cysteine-rich region/domain (CRD).  The region between the 
kinase domain and the PH domain is predicted to form coiled-coil structure. 
The kinase activity of Rho-kinases is enhanced after binding with Rho-GTP.  ROCKI but not 
ROCKII, is also activated in vivo by caspase-3 cleavage causing membrane blebbing (Coleman et 
al. 2001).  The activated Rho-kinases phosphorylate several substrates in particular proteins 
involved in regulation of actin-filament assembly and contractility, such as Myosin Phosphatase 
Targeting subunit (MYPT), LIMKs, and ERM (ezrin-radixin-moesin) proteins. In platelets, three 
of these Rho-kinase effectors, MLC, MYPT and moesin have been studied in part extensively and 
suggested to be important for regulating platelet responses during activation.  During shape 
change, the activation of Rho-kinase elevates MLC phosphorylation either directly by 
phosphorylating MLC or indirectly by phosphorylating MYPT thereby inhibiting myosin 
phosphatase.  This leads to an increased actin-myosin driven contractility (Amano et al. 1996; 
Kureishi et al. 1997; Shimizu et al. 2005).  Also during shape change, Rho-kinase stimulates the 
phosphorylation of moesin (Retzer and Essler 2000).  Recently, it has been stated that Rho-kinase 
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mediates the destabilization of the cytoskeletal microtubule ring leading to shape change; 
however the exact mechanism of this process is not known (Paul et al. 2003). 
One of the important physiological targets of Rho-kinase is the MYPT subunit of myosin 
phosphatase (Hartshorne 1998).  Myosin phosphatase is a heterotrimeric phosphatase composed 
of a 38-kDa protein phosphatase (PP) 1cδ type catalytic subunit and two regulatory subunits, a 
110-kDa MYPT subunit (Figure 1.6) and a 20-kDa small regulatory subunit (M20).  MYPT 
subunit interacts with PP1cδ type catalytic phosphatase at the N-terminus and with regulatory 
M20 subunit at the C-terminus, thereby forming the holoenzyme of myosin phosphatase.  At the 
N-terminus, MYPT contains ankyrin repeats that are involved in binding to the target protein, 
phosphorylated MLC.  The PP1cδ-binding motif (KVKF) at the N-terminus margin of the first 
ankyrin repeat allows the access of PP1cδ phosphatase to dephosphorylate MLC.  An alternative 
myosin binding site also exists at the C-terminal sequence of MYPT.  Binding of myosin to both 
the N-terminal and C-terminal regions of MYPT suggests that the myosin head binds to the N-
terminus and the myosin rod portion binds to the C-terminus thereby aligning phosphorylated 
myosin to the holoenzyme of myosin phosphatase.  The function of small M20 subunit has not 
been established. 
 
 
Figure 1.6 Domain structure of human MYPT.  MYPT contains PP1cδ-binding domain composed of binding 
motif (KVKF) and ankyrin repeats, and M20-binding domains. Two major phosphorylation sites shown here are 
targets of various kinases that regulate MYPT functions. 
Multi-phosphorylation site in MYPT are regulatory for inhibiting myosin phosphatase activity, 
however, the molecular basis for this inhibition is not understood.  Human MYPT has two major 
sites for phosphorylation by Rho-kinase, which contribute for inactivation of myosin 
phosphatase, the inhibitory phosphorylation site (Thr696) and the myosin-binding regulatory 
phosphorylation site (Thr853).  Phosphorylation of Thr696 is also regulated by several other 
kinases like ZIP-kinase (more recently termed MYPT1 kinase), integrin-linked kinase, myotonic 
dystrophy protein kinase (DMPK) and PAK, whereas Thr853 is known to be phosphorylated 
specifically by Rho-kinase (Ito et al. 2004). 
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Rho-kinase also phosphorylates LIMKs and enhances their ability to phosphorylate cofilin at 
Ser3 (Maekawa et al. 1999).  Cofilin phosphorylation blocks its actin binding and F-actin 
depolymerization activity. 
1.4.6. LIM-kinases 
LIM (for Lin11, Isl1 and Mec3) kinases are serine/threonine kinases involved in the regulation of 
actin-filament dynamics (Khurana et al. 2002), which were initially identified in a screen for 
novel members of the c-Met/HGF receptor tyrosine kinase family (Mizuno et al. 1994).  LIMKs 
(~70-kDa) are unique protein kinases that have two repeats of the LIM domain at N-terminus, 
followed by a PDZ domain, a proline/serine-rich region, and an unusual protein kinase domain at 
the C-terminus.  The LIMK protein family is comprised of two members, LIMK-1 and LIMK-2 
(Okano et al. 1995).  Comparisons of these LIMK homologue protein sequences reveal variations 
in amino acid conservation between domains.  The kinase domains are most highly conserved 
between LIMK-1 and LIMK-2 (~70%), followed by the LIM (~50%) and PDZ domains (~46%). 
The N-terminal LIM domains play an inhibitory role in the regulation of the kinase activity of 
LIMK-1 by direct interaction with the kinase domain (Nagata et al. 1999).  The LIM domains 
may fix the kinase domain in an inactive conformation, or inhibit the access of substrates by 
masking the kinase catalytic site or substrate-binding site.  Many serine/threonine kinases are 
phosphorylated on a residue(s) in the activation loop, which regulates their activity.  LIMK-1 and 
LIMK-2 have Thr508 and Thr505 residues, respectively, in the activation loop as regulatory 
phosphorylation sites. Rho-kinase phosphorylates LIMK-1 at Thr508 (Ohashi et al. 2000), and 
LIMK-2 at Thr505 (Sumi et al. 2001) and activates them (Figure 1.7).  
 
Figure 1.7 Structure and regulatory phosphorylation of LIMKs. LIMKs contain two zinc finger LIM, a PDZ and 
a kinase domain. LIMK-1 can be phosphorylated and activated by Rho-kinase as well as PAK1/PAK4. 
As mentioned above (see section 1.5.1), in addition to the Rho/Rho-kinase pathway, Cdc42 and 
Rac effectors PAK1 and PAK4 can phosphorylate LIMK-1 at Thr508 (Edwards et al. 1999; Dan 
et al. 2001).  Furthermore, MRCKα a protein downstream of Cdc42 is able to phosphorylate 
LIMK-1 and LIMK-2 at their respective sites leading to enhanced cofilin phosphorylation (Sumi 
et al. 2001). 
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The physiological substrate known for Rho GTPases mediated LIMKs activation is cofilin, an 
actin dynamizing protein.  The knowledge of regulation and activation of cofilin has become an 
important area to understand actin dynamics underlying different physiological responses by 
cells. 
1.5. Cofilin 
Cofilin is a member of actin depolymerization factor (ADF)/cofilin (A/C) family, firstly purified 
from porcine brain (Maekawa et al. 1984).  Proteins in the A/C family are generally small (13-20 
kDa), exist in multiple forms, and expressed ubiquitously in all eukaryotic cells.  Their main 
functions include rapid recycling of actin monomers thereby dynamizing the actin scaffold 
needed for various cellular events such as cell motility, membrane protrusions, polarity of cell 
migration, or during cytokinesis.  The first member of A/C family was the ADF protein, 
identified and purified from embryonic chick brain extract (Bamburg et al. 1980).  Since then, 
over 30 members of the A/C proteins family have been discovered that are named after their 
observed functions e.g., ADF or destrin (destroys F-actin), depactin (depolymerizes actin) and 
cofilin (co-sediments with filamentous actin) (Bamburg 1999).  All of these proteins exhibit 
considerable homology in their amino acids sequence.  Proteins of the A/C family from a single 
organism share about 70% sequence identity.  A similar sequence identity is also observed when 
A/C proteins from mammals are compared with their counterparts in avians.  However, the 
homology decreases to 20-40% when vertebrates are compared with lower eukaryotes.  Despite 
the variation in identity between homologs, vertebrates have genes for only two forms, ADF and 
cofilin (dos Remedios et al. 2003).  Although names of the two proteins indicate a behavioral 
difference, they are functionally related proteins, as they both can bind and depolymerize F-actin.  
To differentiate these related proteins, efforts for knowing the kinetic of their activities are in 
progress.  For my thesis, the term cofilin includes both ADF and cofilin.  Mammalian A/C family 
is comprised of one ADF and two cofilin isomers.  Cofilin 1 is expressed in most embryonic 
tissues and adult cells, cofilin 2 is only expressed in muscle cells, and ADF expression is limited 
to the epithelia and endothelia (Vartiainen et al. 2002).  The differential location of these 
isoforms might be a reason for their specific requirement for actin dynamics in different cell 
types.  
1.5.1. Structure of cofilin 
Human cofilin has 72% sequence identity with human ADF.  The multiple sequence alignment of 
human cofilin with other proteins of A/C family shows the conservation of primary sequence and 
secondary structure elements within the family (Figure 1.8). 
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Among the most highly conserved regions are the two actin-binding domains, including the 
single regulatory phosphorylation site.  The region of non-homology between divergent members 
likely occurs in loops between the conserved secondary structures.  These insertions are thought 
merely to increase the length of a protein without having any impact on their three-dimensional 
structures.  Human cofilin (166aa) is larger than its counterpart in plant (139aa) and yeast 
(143aa).  Some of the additional residues contributing to the large size are the nuclear localization 
signal (NLS) and the extended C-terminus.  Similar to other A/C members, human cofilin is 
made up of a unique actin-binding module, the ADF homology (ADF-H) domain, which is 
present in three distinct classes of actin binding proteins: ADF/cofilins, twinfilins (two ADF-H 
domains), and Abp1/drebrins (Lappalainen et al. 1998).  ADF-H domain is a ~150 amino acid 
motif, folds with a central 4 to 6-stranded mixed β-sheet sandwiched between two pairs of α-
helices, one on each face.  Recently, the structure of human cofilin in solution was determined by 
multi-dimensional NMR spectroscopy (Figure 1.8B) (Pope et al. 2004). 
 
Figure 1.8.A) Sequence alignment of A/C family with known three-dimensional structures. The alignment 
shows homologous sequences (boxed), basic/acidic residues (blue/red, respectively), α-helices (green) and β-strands 
(yellow; above for human cofilin with residue numbering and below for yeast cofilin. The salt bridge (red arrows), 
the phosphorylation site (circled P) and the NLS (blue dotted line, residues 18-34) are some important features of 
cofilin for its activity. B) Ribbon diagram of cofilin structure. The G/F site is involved in G-/F-actin binding and 
the F site is involved in F-actin binding (brown rings). Residues involved in the salt bridge, Asp98 and His133 are 
labeled in red. (Pope et al. 2004). 
The ADF-H fold in human cofilin possesses the core of a five-stranded mixed β-sheet with four 
strands anti-parallel and the final pair parallel in arrangement.  Four helices (α1-α4) surround the 
central β-sheet, and a fifth helix (α5) packs against β5-strand.  Additionally the C-terminal 
residue 159-161 forms a short strand (β6), which is unique to cofilin, and results in tighter 
packing of module.  In contrast to the C-terminal β6-strand of cofilin, the corresponding residue 
in human ADF forms part of a slightly helical coil that might contribute to the different actin 
depolymerizing activity of these proteins.  A salt bridge in cofilin between His133 and Asp98 
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(Glu98 in ADF), which are conserved in human A/C members, may explain the pH sensitivity of 
human cofilin and ADF. 
1.5.2. Properties and functions of cofilin 
Cofilin associates stoichiometrically with actin and reaches saturation at a 1:1 molar ratio 
(Nishida et al. 1984).  The ADF-H domain in cofilin contributes to its role in binding monomeric 
(G/F site) as well as filamentous actin (G/F site and F site, see Fig 1.6B).  The G/F site is covered 
by the N-terminus, α4-helix and β5-strand, and is responsible for both G-and F-actin binding.  
The F site includes the C-terminus, α5-helix and β5-strand, and is responsible for F-actin binding 
and severing activity.  The specific amino acid residues participating in these interactions have 
not been entirely elucidated.  However, the recent study by Pope et al. interpreted that the 
environment of hydrophobic pockets in these sites is important for binding of cofilin with actin 
(Pope et al. 2004).  Residues identified by site directed mutagenesis, Ser3, Lys112 and Lys114 
for G/F site and Lys96 for F site, are considered as critical for providing the favorable 
environment.  Phosphorylation of cofilin at Ser3 position or S3D mutation (Moriyama et al. 
1996), and replacement of Lys112 and Lys114 by glutamine (Moriyama et al. 1992) inhibited 
cofilin interaction with actin. 
 
 
 
 
 
 
 
 
Figure 1.9 Effect of cofilin on actin filament structure.  (a) Structure of actin with axial rise per subunit (1-2) of 
2.75 nm and a rotation of ~167°.  A crossover segment in actin filament is generally observed after ~13 residues.  (b) 
Cofilin binding to actin changes the rotation per subunit to ~162° but the axial rise remains unchanged.  After cofilin 
binding, a crossover is observed after ~10 actin subunits. (Bamburg et al. 1999).  Blue and red numbers indicate actin 
monomers of the intertwined actin helix. 
At physiological ionic strength, cofilin binds with the ADP-bound G- or F-actin with an affinity 
~100 fold higher than the ATP- or ADP-Pi-bound forms (Carlier et al. 1997).  The preferential 
binding of cofilin with ADP-bound actins makes the pointed end (slowly growing region) of the 
filament, a more favorable target for cofilin action than the barbed end. Cofilin binds with two 
actin protomers adjacent to each other along the two-start, polar, and helical actin filament.  The 
interaction of the G/F-site of cofilin with actin domains 1 and 3 (comprise site1) and of the F-site 
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with the actin domains 1 and 2 (comprise site2) twists the actin filament with a reduction of 
rotation per actin subunit by about 5°, but no shrinkage in overall length of the filament 
(McGough et al. 1997), Figure 1.9. 
This reduction in twist and a new closed packing of protomers provide intrinsic strength to the 
actin filament where cofilin is bound (Galkin et al. 2001; Dedova et al. 2004).  However, this 
modification in filament’s topology destabilizes both longitudinal and lateral actin-actin contacts 
in adjacent subunits that are free from cofilin (McGough and Chiu 1999; Bobkov et al. 2002).  
The weakening of these contacts results in the release of actin protomers and depolymerization of 
the actin filament.  It is not clear whether the actin protomers are released as single forms, with or 
without cofilin, or whether they exist in an actin pair associated with cofilin.  The higher affinity 
of cofilin for ADP-actin also inhibits the released actin monomer from nucleotide exchange and 
limits their recycling back to the filament during the process of treadmilling (Nishida 1985; 
Teubner and Wegner 1998).  Thus, cofilin accelerates the off-rate from pointed end of the 
filament by about 30-fold and on-rate at the barbed end by about 10-fold, under physiological 
condition (Carlier et al. 1997).  
Cofilin binding to actin filaments is highly cooperative (Hawkins et al. 1993; Hayden et al. 1993).  
Cofilin binding to the site1 on G-actin or F-actin exposes the site2 of actin for additional cofilin 
binding, which might explain its cooperative binding behavior and intercalation into F-actin 
(Blondin et al. 2001).  Cooperative changes in the conformation of F-actin brought by cofilin 
binding may modulate the binding of other proteins to actin filament or sequester the F-actin 
from interaction with these proteins (McGough et al. 1997).  Actin filament decorated with 
cofilin makes the filament brittle at the juncture of decorated and undecorated regions and 
contribute to the severing activity of cofilin.  However, severing activity of cofilin is weaker than 
gelsolin and raises an argue for cofilin being a true severing protein (Ichetovkin et al. 2000).  
Furthermore, severing does not occur on short (less than 0.7µm or 250 subunits) gelsolin-capped 
filaments, suggesting that cofilin requires longer filament with greater flexibility (Yeoh et al. 
2002) or gelsolin modulates the filament structure and cofilin binding with actin filament (Ressad 
et al. 1998).  Severing of actin filaments can accelerate the rate of actin depolymerization by 
increasing the number of depolymerizing ends (Maciver et al. 1998; Moriyama and Yahara 
1999).  Although, both severing and depolymerizing activities are presumably due to the 
additional strain on actin filaments, some groups suggested a separation between severing and 
depolymerizing activities based on residues involved in cofilin-actin complexes (Pope et al. 2000; 
Ono et al. 2001).  Severing of actin filament by cofilin can also generate free barbed ends that can 
act as nuclei for efficient enhancement of actin polymerization needed for cell motility.  Cofilin 
produces newly polymerized actin filaments that are preferred for dendritic nucleation by the 
Arp2/3 complex (Ichetovkin et al. 2002).  Antibody that blocks the nucleation activity of Arp2/3 
complex inhibited the lamellipodia protrusion but did not inhibited the appearance of barbed ends 
(Chan et al. 2000), whereas function-blocking antibody against cofilin inhibited barbed end 
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generation (Bailly et al. 2001), indicating that both act together to produce the actin-based 
motility at the leading edge (DesMarais et al. 2004).  Furthermore, recent studies showed that 
cofilin alone is sufficient to generate free barbed ends leading to actin polymerization and 
protrusion. These results support a direct role for cofilin severing in initiating and defining the 
polarity of cell motility (Ichetovkin et al. 2002; Ghosh et al. 2004).  
1.5.3. Regulation of cofilin activities 
There are several factors that can regulate cofilin activities; these are intracellular pH, competitor 
proteins for actin binding, interacting proteins, kinases and phosphatases.  Some but not all 
cofilin isoforms are pH-dependent, which regulate cofilin binding, severing and filament 
depolymerization.  At low pH (~6.7), cofilin binds filaments and changes their twist but does not 
promote disassembly (De La Cruz 2005).  At increased pH (7.0-7.5), the critical concentration for 
the assembly of cofilin-actin complex increases resulting in depolymerization of actin filament 
(Ressad et al. 1998).  The actin-binding and depolymerizing activities of cofilin can also be 
regulated by PI(4)P and PI(4,5)P2, which inhibit cofilin binding to actin in vitro (Yonezawa et al. 
1990) because the binding site for the phospholipids and actin overlap on the surface of cofilin 
(Ojala et al. 2001).  Tropomyosin competes with cofilin for actin binding, increases filament 
stiffness and protects F-actin from depolymerizing effects of cofilin, thus, it is thought to be a 
physiological inhibitor for cofilin-dependent actin dynamics (Gunning et al. 2005).  Profilin 
competes with cofilin for G-actin binding and enhances exchange of actin-bound nucleotide in 
the presence of cofilin, thereby increasing the rate of pointed-end disassembly (by 125 fold) and 
rate of actin turnover synergistically with cofilin (Didry et al. 1998).  Actin-interacting protein 1 
(Aip1), which interacts functionally with cofilin as well as actin, actively enhances 
depolymerizing activity of cofilin (Ono et al. 2004).  Cyclase-associated protein (CAP) sequesters 
G-actin and stimulates nucleotide exchange (ADP to ATP) through C-terminal domain, and 
accelerates actin depolymerization by binding to actin-cofilin complex through its N-terminal 
domain (Hubberstey and Mottillo 2002; Moriyama and Yahara 2002).  Thus CAP1 speeds up the 
turnover of actin filaments through its effect on both ends of the actin filament (Figure 1.10).  
Cofilin from most organisms are regulated by phosphorylation/dephosphorylation on a highly 
conserved serine residue; Ser3 in human cofilin isoforms.  This phosphorylation inhibits the 
activity of cofilin by reducing its affinity for actin by 20-fold (Ressad et al. 1998).  Several 
kinases responsible for this inactivation have been characterized.  In vertebrates, LIMKs and 
testicular protein kinases (TESKs) are specific for cofilin and mediate various signals for 
remodeling of the actin cytoskeleton, for detail of LIMKs see section 1.4.6.  TESK-1 and -2 also 
phosphorylate cofilin on the same serine residue (Toshima et al. 2001), but these kinases seem to 
be controlled by integrin mediated signaling pathways through 14-3-3 proteins for their activity 
and subcellular localization (Toshima et al. 2001).  14-3-3zeta proteins interact also with LIMK1 
and phosphocofilin, and negatively regulate cofilin by protecting it from phosphatases-mediated 
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Ser3 dephosphorylation (Gohla and Bokoch 2002; Birkenfeld et al. 2003).  Other kinases that 
phosphorylate cofilin include a neutrophil-specific Ser3 cofilin kinase (Lian et al. 2000), a 
calmodulin-like domain protein kinase in plants (Allwood et al. 2001) and a NRK/NIK-like 
embryo-specific kinase (NESK) that belong to the germinal center kinase family (Nakano et al. 
2003). 
 
 
Figure 1.10  Biochemical activity of cofilin and proteins involved in regulating these activities.  Cofilin binds 
cooperatively to F-actin, with highest affinity for ADP-actin subunits at the pointed end of actin filaments. Cofilin 
sever and depolymerizes actin filaments, and in cooperation with other proteins accelerates the treadmilling process. 
LIM- or TES-kinases and phosphatases regulate cofilin phosphorylation and dephosphorylation cycle respectively, 
and thereby regulate cofilin activity.  
The activation of cofilin phosphatases can dephosphorylate and activate cofilin.  In some cell 
types, activation of cofilin kinases after cell stimulation induced an increase in net phosphocofilin 
levels, while in other cells a significant increase in phosphocofilin turnover was observed with no 
significant change in total phosphocofilin pool (Meberg et al. 1998).  This observation suggested 
that the activity of both cofilin kinases and cofilin phosphatase might are regulated by common 
upstream stimulatory signals.  Cofilin dephosphorylation has been observed in response to 
various stimuli such as growth factors, chemotactic peptides and agents that increase the 
intracellular levels of Ca2+ and cAMP.  Suggested phosphatases for cofilin dephosphorylation 
include type PP1, PP2A, and calcium-dependent protein phosphatase type PP2B (Meberg et al. 
1998; Ambach et al. 2000).  However, the effects of pharmacological phosphatase inhibitors on 
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dephosphorylation of cofilin were not consistent and lead to the suggestion of a specific cofilin 
phosphatase (Okada et al. 1996; Takuma et al. 1996).  Thus, so far two types of cofilin-specific 
phosphatases have been identified: the Slingshot family of phosphatases, and Chronophin (Niwa 
et al. 2002; Gohla et al. 2005). A current model for regulation of actin dynamics by cofilin and 
other proteins is showed above in Figure 1.10. 
1.5.4. Cell biological functions of cofilin 
The activity of cofilin is fundamental to cells, because inactive mutants of cofilin isoforms from 
different organisms tested so far are lethal (Moon et al. 1993; McKim et al. 1994; Gunsalus et al. 
1995).  Cofilin is essential for those cellular processes that require a dynamic actin cytoskeleton 
such as cell movement (Chen et al. 2001), cytokinesis (Gunsalus et al. 1995; Nagaoka et al. 
1995), phagocytosis (Bierne et al. 2001) and endocytosis (Lappalainen and Drubin 1997).  
Overexpression of cofilin enhances cell motility (Aizawa et al. 1996; Meberg and Bamburg 
2000), whereas genetic ablation of cofilin impairs cell motility in vivo (Chen et al. 2001).  
Furthermore, the importance of cofilin as key regulators of actin dynamics is demonstrated by the 
fact that cofilin is indispensable for the motility of the small intracellular pathogen Listeria 
monocytogenes in living cells (Loisel et al. 1999).  In cells, cofilin is predominantly cytoplasmic, 
but upon activation it concentrates at the leading edge and ruffling membranes of motile cells.  
Cofilin also localizes to other structures displaying high actin filament turnover rates such as the 
contractile ring and neuronal growth cones (Bamburg 1999).  Cofilins can be transported to the 
nucleus after dephosphorylation in response to various stress factors (Ohta et al. 1989; Nebl et al. 
1996).  Cofilin acts as nuclear transporter for actin, and in the nucleus it forms rods with actin.  It 
has been postulated that rod formation is a mechanism to conserve the nuclear pool of ATP in 
stress situations by decreasing actin filament dynamics, which is a major consumer of ATP 
(Bamburg 1999). 
It might be important to study the role of cofilin in various human diseases where intracellular or 
intercellular aberrations due to altered actin structures have been observed.  Cofilin might initiate 
or support cognitive impairment, inflammation, infertility, immune deficiencies, 
neurodegenerative diseases, Alzheimer’s, ischemic kidney diseases, and other pathological 
defects (Bamburg and Wiggan 2002).  Rho-kinase activation has important effects on several 
cardiovascular diseases therefore regulation of cofilin through Rho-kinase and LIM-kinases 
cannot be neglected for its possible role in cardiovascular diseases. 
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2. Aim of the study 
Stimulation of platelets with various physiological agonists leads to the different morphological 
and functional platelet responses such as shape change, spreading, secretion and aggregation.  
These platelet responses require a dynamic remodeling of the actin structure.  A key protein 
regulating the actin remodeling is cofilin, which has been shown to regulate various important 
functions in cells, however, the role and regulation of cofilin activity during platelet activation is 
not known.  Cofilin activity is regulated by LIMKs and cofilin phosphatases.  The effectors of 
Rho family GTPases, such as Rho-kinase and PAK can activate LIMKs.  So far, only PAK2 has 
been identified in platelets. Thus, the need for identifying the signaling molecules and pathways 
regulating cofilin and subsequent importance of cofilin in regulating actin dynamics underlying 
platelet activation is one of the prime targets of this study.  In this study, following questions 
were raised to answer the role of cofilin in platelets physiological activation.  
 
a) Which forms of LIMKs are expressed in platelets? 
b) How is the activation of LIMKs regulated, and whether LIMKs activation leads to cofilin 
phosphorylation? 
c) Whether the cofilin phosphorylation pathway is stimulated during physiological activation 
of platelets? 
d) Which signaling pathways are involved in the regulation of cofilin activity? 
e) How does the regulation of cofilin phosphorylation affect its actin binding and filament 
depolymerizing activities during platelet shape change and secretion/aggregation induced 
by physiological agonists? 
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3. Materials and methods 
All solutions and media were prepared with ultra-pure water (Milli-Q Plus ultra purification pak, 
Milli-RO Plus purification pak; Millipore, Molsheim, France). Chemicals otherwise not 
mentioned are from Sigma, Munich, Germany. 
3.1. General equipments 
Name Types and Suppliers 
Aggregometers LABOR aggregometer, Labor GmbH (Hamburg, Germany), PICA® 
(Platelet Ionized Calcium Aggregometer), Chrono-Log Corp. 
(Havertown, PA) 
Autoclave Autoclave 23; MELAG Medizintechnick (Berlin, Germany) Bioclav; 
Schütt Labortechnik GmbH (Göttingen, Germany) 
Centrifuges Biofuge pico, Omnifuge 2.OR, Megafuge 1.ORS, Heraeus (Osterode, 
Germany) Centrikon H-401, with Rotors A8.24 and A6.9; Kontron-
Hermle (Gosheim, Germany) 
Chart recorder Servogor 102 chart recorder, Kipp & Zonen (Röntgenweg, The 
Netherlands) 
Chromatography 
System 
Automated Econo System; Biorad (Hercules, CA) 
Confocal microscope LSM 510META confocal microscope, Zeiss (Jena, Germany) 
Densitometer Pharmacia LKB (Sweden) 
Freezes, 4-8 and -20°C Robert Bosch GmbH (Stuttgart, Germany) 
Freezer, -70°C ULT1706; Revco Scientific (Asheville, NC) 
Gel documentation 
camera 
Polaroid MP-4 land camera; Polaroid USA 
Gel Electrophoresis Biorad (Hercules, CA) 
Incubators WTB Binder (Tuttlingen, Germany), Forma Scientific JULABO 
Labortechnik GmbH 
Magnetic stirrer MR3001; Heidolph (Kelheim, Germany) 
Microscope IX50; Olympus Optical GmbH (Hamburg, Germany) 
Model RI60P; Sartorius (Göttingen, Germany) 
pH meter Model 765 Calimatic; Knick (Berlin, Germany) 
Shaker Labquake rotating shaker; Lab Extreme, Inc (Kent City, MI)  
Unimax 2010; Heidolph Instruments GmbH (Schwabach, Germany) 
Sonicator SONOPLUS Bandelin electronic GmbH (Berlin, Germany) 
Spectrophotometer UVICON 930; Kontron instruments (Echingen, Germany) 
Thermocycler Mastercycler gradient; Eppendorf (Hamburg, Germany) 
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Thermomixer Thermomixer compact; Eppendorf (Hamburg, Germany) 
Ultracentrifuge OptimaTM TLX with rotor TLA 100.4; BeckMan Instruments 
(Fullerton, CA) 
Vortexer REAX top; Heidolph (Kelheim, Germany) 
Water baths GFL GmbH (Burgwedel, Germany) 
UV illuminator Model N90M; UniEquip (Martinsried, Germany) 
3.2. Materials 
3.2.1. Chemicals 
Name Suppliers 
Acetic acid Merck Biosciences GmbH, Schwalbach, Germany 
Acetylsalicylic acid Fluka AG, Buchs, Switzerland 
Acryl/Bis 37.5:1; 40% (w/v) solution AMRESCO Inc. USA 
Agar Mo Bio Laboratories, USA 
Agarose Sigma, Munich, Germany 
Ammonium persulphate Sigma, Munich, Germany 
Ampicillin Sigma, Munich, Germany 
Apyrase Sigma, Munich, Germany 
ATP Amersham Biosciences, Freiburg, Germany 
Bromophenol blue Sigma, Munich, Germany 
BSA (bovine serum albumin) Sigma, Munich, Germany 
Citric acid Merck Biosciences GmbH, Schwalbach, Germany 
Coomassie Brilliant Blue G250® Serva, Heidelberg, Germany 
Chrono-lumi luciferase luciferin 
reagent 
Chrono-Log, Havertown, PA 
Dideoxynucleotides Stratagene Inc USA 
DMSO  Sigma, Munich, Germany 
EDTA Sigma, Munich, Germany 
EGTA Sigma, Munich, Germany 
Ethanol Merck Biosciences GmbH, Schwalbach, Germany 
Ethidium Bromide Sigma, Munich, Germany 
Isopropanol Sigma, Munich, Germany 
Formaldehyde Sigma, Munich, Germany 
Glycerol Merck Biosciences GmbH, Schwalbach, Germany 
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HEPES Sigma, Munich, Germany 
IPTG peqLab Biotechnologie, Erlangen, Germany 
Kanamycin Sigma, Munich, Germany 
KCl Sigma, Munich, Germany 
Methanol Merck Biosciences GmbH, Schwalbach, Germany 
2-Mercaptoethanol Sigma, Munich, Germany 
MnCl2 Sigma, Munich, Germany 
Protein A Sepharose CL-4B Sigma, Munich, Germany 
Polylysine Sigma, Munich, Germany 
SDS Serva, Heidelberg, Germany 
Sodium Azide  Serva, Heidelberg, Germany 
Sodium Fluoride Sigma, Munich, Germany 
Sodium Orthovanadate Merck Biosciences GmbH, Schwalbach, Germany 
TEMED Sigma, Munich, Germany 
Tris-HCl Serva, Heidelberg, Germany 
Triton X-100 Sigma, Munich, Germany 
Tryptone Sigma, Munich, Germany 
Tween-20 Sigma, Munich, Germany 
3.2.2. Enzymes and reagents for molecular biology 
 
Name Suppliers 
Restriction enzymes New England Biolabs GmbH, Frankfurt, Germany 
Taq DNA polymerase  New England Biolabs GmbH, Frankfurt, Germany 
Pfu Ultra HF DNA polymerase Stratagene, Netherlands 
Thermoscript reverse transcriptase Invitrogen GmbH, Karlsruhe, Germany 
Calf intestine alkaline phosphatase Roche Diagnostic, Mannheim, Germany 
T4 DNA ligase New England Biolabs GmbH, Frankfurt, Germany 
DNase I Roche Diagnostic, Mannheim, Germany 
Lysozyme Sigma, Munich, Germany 
dNTPs Stratagene, Netherlands 
T4 Polynucleotide kinase New England Biolabs GmbH, Frankfurt, Germany 
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3.2.3. Antibodies and fluorescent probes 
3.2.3.1. Primary antibodies 
 
a) Anti-actin (Chemicon International, Inc. Temecula, CA) 
Immunogen: Purified chicken gizzard actin. 
Source: Mouse    Application: IB (1:50,000) 
b) Anti-cofilin (Cytoskeleton, Denver, CO) 
Immunogen: N-terminal 13-22 amino acids of human cofilin. 
Source: Rabbit    Application: IB (1:20,000) 
c) Anti-phospho-cofilin (Cell Signaling Tech, Baverly, MA) 
Immunogen: Synthetic phospho-peptide (KLH coupled) corresponding to residues 
surrounding Ser3 of human cofilin.  
Source: Rabbit    Application: IB (1:1000) 
d) Anti-LIMK1 (Cell Signaling Tech, Baverly, MA) 
Immunogen: Synthetic peptide (KLH coupled) corresponding to the C-terminal residues 
of LIMK-1. 
Source: Rabbit    Applications: IB (1:1000) and IP (1:25) 
e) Anti-LIMK2 (Cell Signaling Tech, Baverly, MA) 
Immunogen: Synthetic peptide (KLH coupled) corresponding to the C-terminal residues 
of LIMK-2. 
Source: Rabbit    Application: IB (1:1000) 
f) Anti-phospho-LIMK1 (Thr508)/LIMK2 (Thr505)                    
(Cell Signaling Tech, Baverly, MA) 
Immunogen: Synthetic phospho-peptide (KLH coupled) corresponding to residues 
surrounding Thr508 of LIMK-1. 
Source: Rabbit    Application: IB (1:1000) 
g) Anti-phospho-MYPT1 (Thr696) (Upstate Biotech, Lake Placid, NY) 
Immunogen: KLH conjugated synthetic peptide (CQSRRTPQGVTL) corresponding to 
amino acids 691-701 of human MYPT1. 
Source: Rabbit    Application: IB (1:3000) 
h) Anti-phospho-MYPT1 (Thr853) (Upstate Biotech, Lake Placid, NY) 
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Immunogen: Synthetic peptide corresponding to amino acid residues 848-858 (C-
EKRRSTPGVSFW) human MYPT1 with an N-terminal cysteine added for 
conjugation purposes. 
Source: Rabbit    Application: IB (1:3000) 
i) Anti-PAK1/2/3 (Cell Signaling Tech, Baverly, MA) 
Immunogen: Synthetic peptide (KLH coupled) corresponding to the C-terminal residues 
of human PAK1. 
Source: Rabbit    Application: IB (1:1000) 
j) Anti-phospho-PAK1 (Thr423)/PAK2 (Thr402) (Cell Signaling Tech, Baverly, MA) 
Immunogen: Synthetic phospho-peptide (KLH coupled) corresponding to residues 
surrounding Thr423 of human PAK1. 
Source: Rabbit    Application: IB (1:1000) 
k) Anti-human CD41a, FITC-conjugated (BD-Biosciences, Franklin Lakes, NJ) 
Clone: HIP8    Source: Mouse IgG1 
Application: Immunofluorescence (1:1000) 
3.2.3.2. Secondary antibodies 
a) Anti-rabbit IgG peroxidase-linked F(ab’)2 fragment            
(Amersham Biosciences, Freiburg, Germany). 
Immunogen: Purified immunoglobulin fractions from normal rabbit serum.  
Source: Donkey    Application: IB (1:5000) 
b) Anti-mouse IgG peroxidase-linked F(ab’)2 fragment           
(Amersham Biosciences, Freiburg, Germany). 
Immunogen: Purified immunoglobulin fractions from normal mouse serum.  
Source: Sheep     Application: IB (1:5000) 
3.2.3.3. Fluorescents probes  
a) Alexa Fluor-546 phalloidin (Molecular Probes, Eugene, OR) 
Usage:  20 U/ml for 15 minutes to immunostain F-actin 
3.2.3.4. IgG isotype controls and sera 
Rabbit IgG     Sigma, Munich, Germany 
Mouse IgG     Sigma, Munich, Germany 
Goat serum     Sigma, Munich, Germany 
FITC-conjugated Mouse IgG1  BD Biosciences, Franklin Lakes, NJ 
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3.2.4. Inhibitors, blockers and agonists 
3.2.4.1. Inhibitors and blockers 
Merck Biosciences GmbH, Schwalbach, Germany 
Compound Specifications Conditions (at 37°C) 
Y-27632 A highly potent, cell permeable and selective 
inhibitor of Rho-kinase 
20 µM for 30 min 
H-1152 A cell-permeable isoquinolinesulfonamide 
compound that acts as a highly specific, potent, 
and ATP-competitive inhibitor of Rho-kinase  
20 µM for 30 min 
Okadaic acid An ionophore-like polyether derivative of a C38 
fatty acid compound. Potent inhibitor of PP1A 
and PP2B type phosphatases. 
0.75 µM for 10 min 
Latrunculin A A cell-permeable marine toxin that disrupts actin 
polymerization 
10 µM for 10 min 
Na3VO4 A broad spectrum potent inhibitor of protein 
tyrosine phosphatases 
1 µM for 10 min 
11R-Can-AID 
(CAID) 
A cell-permeable peptide composed of the 
calcineurin (CaN) autoinhibitory domain (AID) 
fused to a poly-arginine-based protein 
transduction domain (11R) 
20 µM for 20 min 
11R-VIVIT 
(NFAT) 
A highly selective NFAT (Nuclear Factor of 
Activated T-cells) inhibitor coupled to 11R 
20 µM for 20 min 
Wortmannin A cell-permeable, fungal metabolite that acts as 
irreversible inhibitor of PI3-kinase 
50 nM for 20 min 
Akt inhibitor IV A cell-permeable benzimidazole compound that 
inhibits Akt 
10 µM for 20 min 
Triciribine A cell-permeable tricyclic nucleoside that inhibits 
Akt1/2/3 
50 µM for 20 min 
BAPTA-AM Intracellular calcium chelator 20 µM for 5 min 
RGDS Blocks fibrinogen binding to the integrin αIIbβ3 
(Bachem Biochemica, Heidelberg, Germany) 
0.5 mM for 2 min 
3.2.4.2. Inhibitor cocktails 
Phosphatase inhibitor cocktail   Roche Diagnostic, Mannheim, Germany 
Proteases inhibitor cocktail    Roche Diagnostic, Mannheim, Germany 
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3.2.4.3. Agonists 
Thrombin (T7009)      Sigma, Munich, Germany 
18:1 Lysophosphatidic acid (LPA) 
1-Oleoyl-2-Hydroxy-sn-Glycero-3-Phosphate   Avanti polar lipids Inc. USA 
3.2.5. Commercial kits and other materials 
QIAquickTM PCR-Purification kit   Qiagen, Hiden, Germany 
QIAquickTM Gel-extraction kit   Qiagen, Hiden, Germany 
QIA®Spin Miniprep kit    Qiagen, Hiden, Germany 
Rapid DNA ligation kit    Roche Diagnostic, Mannheim, Germany 
Expend High Fidelity PCR system   Roche Diagnostic, Mannheim, Germany 
ThermoscriptTM RT-PCR system   Invitrogen GmbH, Karlsruhe, Germany 
DotMetricTM-1µl Protein assay kit   Genotech Inc. USA 
HybondTM-C extra blotting membrane  Amersham Biosciences, Germany 
SuperSignal®West Pico chemiluminiscent   Pierce, Rockland, USA 
Substrate  
Photographic film     Polapan; Polaroid, Offenbach, Germany 
ChariotTM transfection reagent   Active Motif, California, USA 
3.2.6. Softwares 
a) CELLQuest software for flow cytometry. 
b) National Institutes of Health (NIH) ImageJ (1.34s) software for densitometry. 
c) Zeiss LSM510 Meta software for confocal microscopy. 
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3.3. In vitro studies of human platelets 
3.3.1. Isolation of washed human platelets 
The isolation of human platelets was performed using multi-step centrifugation methods.  The 
principle behind these methods is to separate blood cells based on their differential sedimentation 
velocity.  Platelets, being smaller in size, settle down at high centrifugation speed as compared to 
other cells. 
Method A 
Buffer B 20 mM HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM 
MgCl2.6H20, 0.36 mM NaH2PO4, and pH 6.2 
Buffer C Composition same as buffer B except pH 7.4 
Both buffers B and C were pre-warmed at 37°C before use. 
Blood from healthy volunteers, who did not take any medication, was drawn by cubital 
venepuncture into a propylene syringe containing tri-sodium citrate (3.13% w/v) in a ratio 1:10 of 
blood (v/v).  The anticoagulant-treated blood was immediately transferred into 50 ml polystyrene 
tubes and centrifuged at 160x g for 20 minutes (without brake) to separate the platelet rich plasma 
(PRP) from other blood cells.  The top layer of PRP was aspirated carefully without disturbing 
the buffy coat and the red blood cells layer.  The COX inhibitor (aspirin, 1 mM), and ADPase 
(apyrase, 0.3 U/ml) was added to the PRP and incubated at 37°C for 15 minutes to avoid platelet 
activation by TxA2 and ADP released during the isolation, respectively.  Subsequently, in order 
to prevent clotting of the PRP induced by Ca2+ released calcium chelators like citric acid (citrate; 
9 mM) and EDTA (5 mM) were added to the PRP.  The platelets from PRP were isolated by 
centrifugation at 800x g for 20 minutes (with brake).  The platelet pellet was then washed once 
with buffer B containing apyrase (0.3 U/ml).  The volume of buffer B was determined by 10% of 
the original blood volume.  Before the final centrifugation at 800x g for 20 minutes, 10 µl of 
platelet suspension was mixed with THROMBO PLUS for calculating the number of platelets/µl. 
The final platelet pellet was resuspended in a volume of buffer C required to obtain the final 
platelet count of 400,000/µl.  Apyrase (0.6 U/ml) and glucose (5 mM) were added prior to the 
resuspension of platelet pellet.  
Method B 
ACD buffer 111 mM glucose, 85 mM tri-sodium citrate and 65 mM citric 
acid 
Tyrode buffer 10 mM HEPES, 137 mM NaCl, 2 mM KCl, 0.3 mM NaH2PO4, 
12 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, 5 mM glucose and 
0.35% (w/v) BSA and pH 7.6 
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Working buffer Composition same as of Tyrode buffer, but with 0.1% BSA 
All buffers were pre-warmed at 37°C before use. 
Washed platelet suspension used to study platelet aggregation induced by LPA was prepared 
according to Cazenave et al (Cazenave JP 1993) and Haserück et al (Haseruck et al. 2004) with 
some modifications.  Tyrode buffer as described by Cazenave et al. was used, except the 
omission of heparin from first wash buffer and the use of 0.1% albumin concentration in final 
suspension.  The blood anti-coagulated with acid-citrate-dextrose (ACD; 1:6) was centrifuged at 
160x g for 20 minutes to prepare PRP.  Prostacyclin (PGI2, 25 nM) was added to PRP and 
incubated at 37°C for 20 minutes in order to prevent the platelet activation during subsequent 
centrifugation at 1100x g for 8 minutes.  The platelets were resuspended in Tyrode buffer (one 
fifth of initial blood volume) containing PGI2 (1 µM) and incubated at 37°C for 10 minutes and 
then re-supplemented with PGI2 (1 µM).  Subsequently, platelets were resuspended in Tyrode 
buffer containing PGI2 (1 µM) for a second time and incubated for 10 minutes at 37°C prior to 
the final centrifugation step (1100x g for 8 minutes).  Meanwhile, 10 µl of the platelet suspension 
was used for calculating the concentration of platelets/µl, in a similar manner as described in 
method A.  Finally, platelets were resuspended in working buffer, and the platelet concentration 
was adjusted to 400,000/µl.  Apyrase (0.02 U/ml) was added to the suspension.  The platelet 
suspension was stored at 37°C under an atmosphere of 5% CO2 and 95% humidity in a cell 
incubator, in order to avoid pH changes, during experiment. 
3.3.2. Platelet shape change and aggregation by turbidimetric method 
This method is based on obstruction or augmentation of the light transmitted through a platelet 
suspension during activation. During shape change, the turbidity increases due to the discoid-
spheroid transformation of discoid platelets and hence the light transmission decreases.  During 
aggregation, an augmentation of the light transmission is observed due to the decrease in number 
of particulate matters, such as single platelets.  Platelet shape change and aggregation were 
measured in a two-channel LABOR aggregometer.  Aliquots of platelet suspension (400,000 
platelets/µl) were incubated at 37°C for 5 minutes in translucent plastic cuvettes containing a 
magnetic stirrer.  The platelet suspensions were stirred and further incubated at 37°C for 2 
minutes prior to the addition of agonists, antagonists or inhibitors.  The change in light 
transmission was recorded using an analog chart recorder.  Unstimulated and stimulated platelet 
suspensions (100 µl) were transferred from the aggregometer cuvette to an eppendorf cups 
containing an equal volume of appropriate buffer for performing flow cytometry, biochemical or 
microscopic studies.  During aggregation, the reactions were quenched at a given time point by 
adding an equal volume of appropriate buffer directly to the platelet suspension. 
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3.3.3. Measurement of ATP secretion 
The ATP secretion during platelet activation was measured in a PICA® (Platelet Ionized Calcium 
Aggregometer) lumi-aggregometer that simultaneously monitors aggregation and secretion of 
ATP within the same platelet sample.  This instrument uses the same turbidimetric principle 
implied for measuring platelet aggregation.  In addition, secretion of ATP is measured by 
coupling ATP to the firefly luciferase system for obtaining luminescence.  This luminescence is 
detected at the right angle to the aggregometer light path.  The lumi-aggregometer was pre-
adjusted for 37°C temperature, 1000 rpm stirring and for appropriate luminescence gain.  Two 
platelet suspensions of varying concentrations were prepared from the initial platelet suspension 
(400,000 platelets/µl) for calibrating the instrument.  Namely, the platelet rich suspension (PRS) 
by mixing 15 µl of buffer C to 385 µl of initial platelet suspension and the platelet poor 
suspension (PPS) by mixing 100 µl of buffer C to 300 µl of platelet suspension.  The lumi-
aggregometer was set for the base line correction using PRS and PPS.  The ATP secreted from 
dense granules during platelet stimulation with various agonists was measured after addition of 
15 µl of Chrono-Lumi luciferase/luciferin reagent.  The emitted luminescence converted to 
electronic signals was recorded using an analog chart reader. 
3.4. Flow cytometric analysis of human platelets 
The flow cytometry uses the principle of light scattering in combination with light 
excitation/emission of fluorochrome molecules to generate specific multi-parameter data from 
particles and cells in the size range of 0.5 µm to 40 µm diameter.  The cells are hydro-
dynamically focused in a sheath of buffer before intercepting an optically focused light source 
thereby producing data for each single cell.  Lasers are most often used as a light source in flow 
cytometry.  As cells or particles of interest intercept the light source they scatter light and 
fluorochromes are excited to a higher energy state.  Fluorochromes release energy in the form of 
photons of light with specific spectral properties, which is unique to each fluorochrome.  
Scattered and emitted light from cells and particles are collected and redirected by a beam splitter 
to appropriate detectors, which convert the light into electrical pulses.  The beam splitter splits 
the collected light into different wavelengths, which are routed to band pass filters of specified 
wavelengths that allow them to designated optical detectors.  For example, a 525 nm band pass 
filter placed in the light path prior to the detector will only allow “green” light received by the 
detector.  The most common type of detector used in flow cytometry is the photomultiplier tube 
(PMT). 
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3.4.1. Shape change measurement 
In flow cytometry, the cells are characterized individually by their physical and/or chemical 
properties. The physical profile of cells can be observed by combining the forward light scatter 
(FSC) and the orthogonal or side light scatter (SSC) that are produced by cells intercepting the 
light beam.  In forward light scatter, the intensity of laser beams uninterrupted by the cells and 
beams that passes around the cells, are measured. This measurement is an indication of the cell’s 
unique refractive index, which depends on its size, organelles, and water and molecular contents.  
The refractive index (FSC) of a cell can change through cell cycle progression, activation and 
fixation.  The cellular side scatter light is the light that is reflected orthogonal to the laser beam 
and it is an indication of internal complexity or cell surface granularity (Figure 3.1). 
 
Figure 3.1 Light scattering properties of a cell. The detector in the path of light source detects forward scatter light 
while the detector placed at 90° to the interception point detects side scatter light. 
The side and forward light scatter profiles of unstimulated platelets are different from those of 
platelets undergoing shape change (Ruf and Patscheke 1995).  During shape change, the mean 
FSC of platelets increases due to a decrease in average cell size, while the mean SSC decreases 
due to a reduction of surface granularity caused by the centralization of granules after platelet 
activation.  Thus, the ratio of FSC/SSC increases proportionally to the extent of platelet shape 
change.  Aliquots (100 µl) of the stimulated and unstimulated platelet suspensions were 
transferred to an equal volume of 0.15 M phosphate buffer (pH 7.4) containing 0.2% (w/v) 
glutaraldehyde for fixation.  After 10 minutes, the samples were centrifuged in a microfuge (800x 
g for 5 minutes) and washed twice with 0.5 ml of Dulbecco’s phosphate buffered saline (PBS).  
The platelet pellets were resuspended in the residual volume and were incubated for 15 minutes in 
the dark at room temperature with following antibodies: anti-CD41a–FITC antibody binding to 
the glycoprotein IIb to label platelets and isotype-matched IgG1-FITC (6 µL diluted 1:100) to 
determine unspecific binding.  Subsequently, platelet samples were then diluted with PBS to get a 
concentration of platelets less than 106 cells/µl.  Platelets labeled with anti-CD41a–FITC antibody 
and showing negative staining for IgG1-FITC isotype were gated and the mean FSC/SSC ratio of 
10,000 platelet events was calculated using the CELLQuest software.  The shape change induced 
by agonists was calculated as an increase in FSC/SSC ratio compared to that of the unstimulated 
platelets. 
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3.4.2. F-actin measurement using flow cytometry 
Phalloidin, a toxin from the toadstool "Death Cap" (Amanita phalloides mushroom) that binds 
with F-actin in a stoichiometric ratio of 1:1 (Lengsfeld et al. 1974) has provided a very 
convenient tool to study the distribution of F-actin in permeabilized cells, since fluorescent 
analogs of phalloidin can be synthesized that retain its actin binding property (Wulf et al. 1979).  
Phalloidin binds to actin at the junction between subunits and because this is not a site at which 
many actin-binding proteins bind, most of the F-actin in cells is available for phalloidin labeling.  
In the same fixed platelet samples prepared for shape change measurement by flow cytometry, 
the F-actin content in resting or activated platelets was determined.  The fixed platelets were 
permeabilized with 0.1% Triton X-100 containing 20 U/ml Alexa Fluor-546 phalloidin at 25°C 
and in dark for a minimum of 15 minutes.  The labeled platelets were washed two times with PBS 
and incubated with anti-CD41a-FITC antibody as described above (section 3.4.1).  The samples 
were resuspended in PBS (1.2 ml), and the platelets labeled with anti-CD41a-FITC were gated 
and analyzed for Alexa Fluor-546 phalloidin fluorescence to estimate F-actin content in these 
platelets.  The mean fluorescence intensity of Alexa Fluor-546 from 10,000 platelet events was 
quantified using the CELLQuest software.  The correlation of changes in F-actin content after 
stimulation was calculated by considering F-actin in unstimulated platelets as 40% of the total 
actin present in platelets. 
3.5. Biochemical analysis of human platelets  
3.5.1. Platelet lysates for measuring phosphorylation of proteins 
SDS-PAGE sample buffer (2x):  100 mM Tris-HCl (pH 6.8), 20% (v/v) glycerol, 4% (w/v) 
SDS, 0.01% (w/v) bromophenol blue, 10% (v/v) β-
mercaptoethanol 
During shape change, aliquots (100 µl) of unstimulated and stimulated platelet suspensions were 
transferred from the aggregometer cuvettes to eppendorf tubes containing equal volume of 2x 
SDS-PAGE sample buffer.  In case of aggregation, the reactions were quenched at given time 
points by adding an equal volume of 2x SDS-PAGE sample buffer directly to the platelet 
suspension.  Platelet lysates were denatured at 95°C for 5 minutes and immediately used for 
immunoblotting or stored at -20°C. 
3.5.2. Isolation of the total F-actin and actin cytoskeleton from platelets 
Lysis buffer (2x): 2% (v/v) Triton X-100, 100 mM Tris-HCl, 10 mM EGTA, 10 
mM NaF, 2 mM Na3VO4, phosphatase cocktail inhibitor-I (1:100 
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dilution), complete-mini protease inhibitor (1 tablet/10 ml of 
buffer) and pH adjusted to 7.4 
The F-actin cytoskeleton of platelets based on its structure can be subdivided into two fractions: a 
membrane skeleton and a cytoskeleton (see section 1.3.1).  The membrane skeleton can be 
isolated at a high g-force (100,000x g) while the actin cytoskeleton can be isolated at a low g-
force (15,000x g), Figure 3.2. 
 
Figure 3.2  Schematic representation for the separation of platelet F-actin fractions. Platelets after lysis with 
Triton X-100 retain their cytoskeletal contours. Total F-actin comprises the actin cytoskeleton and membrane 
skeleton. Proteins engaged in these structures also remain associated with actin F-actin fractions.  
To isolate the total F-actin content of platelets, a method as described previously (Kovacsovics 
and Hartwig 1996) was used with slight modifications such as platelet lysis time, centrifugation 
speed and omission of phalloidin from the platelet lysis buffer.  The F-actin isolated from 
platelets was also used for analyzing proteins associated with F-actin during shape change and 
secretion.  Aggregation of platelets was blocked using integrin αIIbβ3 blocker RGDS to avoid 
possible artifacts such as unspecific trapping of protein in the platelet aggregates and inefficient 
lysis of platelets.  Aliquots (100 µl) of unstimulated and stimulated platelet suspensions were 
lysed with an equal volume of lysis buffer.  After 5 minutes of lysis, the total F-actin was 
separated from the Triton X-100 insoluble fraction by centrifugation at 100,000x g for 30 minutes 
at 4°C using a tabletop ultracentrifuge.  For isolating only the actin cytoskeleton, samples were 
centrifuged at 15,000x g for 15 minutes at 4°C in a tabletop centrifuge.  The residual pellets were 
washed twice with ice cold PBS and dissolved in SDS-PAGE sample buffer.  The proteins were 
separated on polyacrylamide gels and detected by Coomassie staining or by immunoblotting. 
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3.5.3. Immunoprecipitation of LIMK-1 from platelets 
Beads swelling buffer:  20 mM NaH2PO4, 0.15 M NaCl, and 0.1% (w/v) NaN3, 2% (w/v) 
BSA, and pH 8.0. 
Lysis buffer (2x): 2% (v/v) NP40, 300 mM NaCl, 20 mM Tris, 2 mM EGTA, 2 
mM EDTA, 5 mM Na3VO4, 0.1% (w/v) SDS, phosphatase 
cocktail (1:100 dilution), complete mini protease inhibitor (1 
tablet/10 ml of buffer), and pH 7.5. 
The underlying strategy behind making the immunoprecipitation a successful method for 
isolating and characterizing an antigen or for identifying protein-protein interactions is the use of 
antibodies high affinity for their antigens.  Protein A or protein G, which interacts specifically 
with the Fc-regions of antibodies, are covalently linked to a matrix like agarose or sepharose 
beads, and utilized to isolate and purify antibody-antigen complexes.  The unspecific molecules 
interacting with the beads or with the antibody-antigen complexes are removed by applying 
different stringent conditions during immunoprecipitation. 
The experiments were carried out in the presence of RGDS to avoid platelet aggregation.  The 
platelet suspensions (4 x 108/mL, 0.4 ml) stimulated with agonists in the presence or absence of 
inhibitors were lysed in an equal volume of 2x-immunoprecipitation lysis buffer for 45 minutes 
on ice.  The lysates were clarified by centrifugation at 16,000x g for 15 minutes.  To preclear the 
supernatant, 40 µl 50% protein A-sepharose slurry was added to the supernatants and incubated 
for 1 hour at 4°C with an end to end rotation using a rotating shaker.  The protein A-sepharose 
slurry was prepared by incubating the beads in swelling buffer that contained 2% BSA to block 
unspecific binding.  The precleared supernatants were incubated overnight with anti-LIMK-1 
antibody (1:50 dilution) followed by addition of 80 µl 50% protein A-sepharose slurry and 
incubation at 4°C for 1 hour with an end to end rotation using a rotating shaker.  The 
immunoprecipitates were collected by centrifugation at 16,000x g for 25 seconds, washed 3 times 
with 1 ml ice-cold 1x immunoprecipitation lysis buffer, and processed for immunoblot analysis or 
for the kinase assay. 
3.5.4. LIMK-1 kinase assay 
Kinase buffer: 50 mM HEPES, 5 mM MgCl2, 5 mM MgCl2, 10 mM NaF, 1 mM 
Na3VO4, and pH 7.5 
Preparation of cofilin as substrate:  
His-tagged cofilin (section 3.7) was incubated with 20 units of λ-phosphatase for 30 minutes at 
37°C to dephosphorylate cofilin and to ensure that cofilin is present only in its non-
phosphorylated state.  The λ-phosphatase was then heat inactivated at 65°C for 1 hour. 
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LIMK-1 immunoprecipitates from unstimulated or stimulated platelets were washed twice with 
kinase buffer prior to performing the kinase reaction.  The protein concentration of the 
immunoprecipitated samples was measured using dotMETRICTM protein assay kit and equal 
amount of corresponding immunoprecipitated beads suspended in 100 µl of kinase buffer was 
taken to perform the kinase reaction.  The reaction was started by adding ATP (10 mM) and λ-
phosphatase-treated His-tagged cofilin (16 µg), and incubating the reaction mixture for 1 hour at 
37°C.  The reactions were quenched by adding 100 µl 2x SDS-PAGE sample buffer.  The 
samples were then immunoblotted with anti-phospho-cofilin and anti-cofilin antibodies.  The 
activity of LIMK-1 was measured by cofilin phosphorylation. 
3.5.5. Measurement of protein concentration 
dotMETRICTM 1μl Protein assay 
This is a chromatographic capture method where the flat surface of the test strip acts as the solid 
matrix or support.  Protein solution is applied to a specific protein binding test strip by point of 
contact capillary action. As the protein enters into the matrix of the test strip it binds instantly and 
saturates the matrix.  The protein solution diffuses into the test strip in a uniform manner to 
produce a circular spot.  The circular protein imprint is developed into visible protein spots using 
a protein specific dye, whose diameter is proportional to the concentration of protein applied.  By 
measuring the diameter of the protein spots with a pre-developed measuring gauge, the amount of 
protein in the spot can be estimated (as shown in Figure 3.3).  This method requires only 1 µl of 
the sample and is resistant to most common laboratory reagents such as Triton-X100, Triton-
X114, Thesit, Tween-20, NP-40 and SDS, reducing agents such as β-mercaptoethanol and DTT, 
sugars, cobalt, EDTA, Tris buffers, and others.  This assay is independent of protein-to-protein 
variation and can be performed even if the protein sample is in a SDS-PAGE gel-loading buffer. 
 
 
Figure 3.3 Steps involved in protein estimation: Protein solution (1-5µl) is applied to the test strip (1), Protein 
imprints are developed into compact and symmetrical spots on the strip (2), and the diameter of protein spots 
proportional to their protein concentration is measured using dotMETRICTM scale (3). The dotMETRICTM scale, 
supplied with each kit, is calibrated for diameter of spots per µg of protein. 
The protein amount was estimated by dotMETRICTM protein assay kit according to the 
manufacturer’s instructions.  A small volume (2 µl) of protein sample was diluted to 10 µl with 
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the dilution buffer provided in the kit.  Using the common pipette man with ultra fine tip, 2 µl and 
4 µl of diluted sample was spotted on the test strip.  The loaded protein sample was then fixed on 
the test strip by incubating the strip in a diluted fixer (0.8 ml of Fixer-A stock + 7.0 ml of water) 
for 2 minutes at room temperature.  The fixed strip was transferred to the diluted developer 
solution (0.8 ml of developer-B stock + 7.0 ml of water) containing an unknown protein stain.  
The strips were gently shook for 30 seconds and incubated for 2-4 minutes or longer at room 
temperature to develop the spots. The spots were read for their diameter and corresponding 
protein concentrations using the dotMETRICTM scale.  To neglect pipetting errors and to 
reproduce the results, 2 spots for each sample were produced and each spot was read twice, 
measured a long and a short diameter of each spot, and calculated the mean average diameter for 
each sample. 
3.5.6. SDS-PAGE 
Electrophoresis buffer (10x): 30 gm Tris-base, 142 gm glycine and 10 gm SDS dissolved in 1 
liter of double distilled water. 
 
Table 3.1  Composition of stacking and resolving gel. 
Components Stacking gel 5% 
(5ml final vol.) 
Resolving gel 10% 
(10ml final vol.) 
Resolving gel 12% 
(10ml final vol.) 
Water 3.2 ml 4.0 ml 3.3 ml 
40% (w/v) acrylamide/bis-
acrylamide ratio 37.5:1 
0.83 ml 3.3 ml 4.0 ml 
1.5 M Tris (pH8.8)  2.5 ml 2.5 ml 
1.0 M Tris (pH6.8) 0.63ml   
10% (w/v) SDS 0.05 ml 0.1 ml 0.1 ml 
10% (w/v) APS 0.05 ml 0.1 ml 0.1 ml 
TEMED 0.005 ml 0.004 ml 0.004 ml 
The protein samples were resolved for analytical purposes by polyacrylamide gel electrophoresis 
(PAGE).  The principle behind resolving proteins on SDS-PAGE is the very strong interaction 
between the dodecylsulphate detergent and the protein peptide chain that causes the SDS-protein 
complexes to migrate as one well-defined identity.  The migration of proteins on SDS-PAGE is 
directly proportional to their molecular mass.  The polyacrylamide gels were prepared by 
polymerization of acrylamide in the presence of a bi-functional cross-linking agent such as N,N'-
methylene bisacrylamide.  N,N,N',N'-tetramethylethylenediamine (TEMED) catalyzes the 
formation of free radicals from chemical decay of ammonium persulphate (APS) and accelerates 
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the polymerization.  This process gives a three dimensional network within the gels.  Varying the 
ratio of acrylamide to the crosslinking agent permits the formation of gels with predictable 
average pore size and texture.  The electrophoresis towards the anode was carried out in a 
discontinuous system where SDS-protein complexes were first concentrated within a stacking gel 
before they migrate into the resolving gel.  The size of different proteins was determined by 
comparing their mobility with that of a protein standard. 
The preparation of polyacrylamide gels and the electrophoretic separation were done using Mini-
PROTEAN 3 electrophoresis system (Bio-Rad, Hercules, CA).  Clean glass plates with 
permanent bonded spacers were aligned and clamped into a casting frame. The resolving gel 
solution was prepared according to composition given in Table 3.1, poured between two glass 
plates and overlaid with water.  After polymerization, the top of the gel was washed with water 
and the residual water was removed by soaking with filter papers.  A freshly prepared stacking 
gel solution was poured on top of the polymerized resolving gel.  A plastic comb of appropriate 
well dentures was inserted in poured stacking gel and allowed to polymerize.  After the stacking 
gel was polymerized, the comb was removed and the wells were flushed with water to remove 
traces of unpolymerized acrylamide.  Subsequently, the gel was placed in a vertical 
electrophoresis apparatus filled with 1x electrophoresis buffer.  A denatured protein standard and 
protein samples were loaded into the wells of the SDS-PAGE gel.  The electrophoresis was 
carried out at a constant voltage of 200 V.  The resolving gel was subsequently subjected to 
western blot analysis or gel staining.  Low molecular weight proteins (<55 kDa) were resolved 
with 12% SDS-PAGE gels, whereas high molecular weight proteins (>55 kDa) were resolved 
with 10% SDS-PAGE gels. 
3.5.7. Isoelectric focusing (IEF) 
IEF is an electrophoretic technique in which compounds are fractionated according to their pIs 
along a continuous pH gradient.  The gradient is created and maintained by the passage of current 
through a solution of amphoteric compounds with closely spaced pIs, encompassing a given pH 
range.  The surface charge of an amphoteric compound in IEF keeps decreasing, as it moves 
along the pH gradient approaching its equilibrium position where pH matches its pI and stops 
moving further.  
Cofilin and phosphocofilin in resting platelets were separated by isoelectric focusing 
electrophoresis.  The isoelectric focusing gels of 0.4 mm thickness consisting a mixture of 
ampholytes (Serva, Heidelberg, Germany) of pH range 7-9 (4%) and pH range 3-10 (1%), 5% 
glycerol, 6% acrylamide and 6 M urea were polymerized with 0.015% ammonium persulphate, 
0.0005% riboflavin 5-phosphate and 0.03% TEMED. Lysates of unstimulated platelets were 
loaded on these gels and were separated electrophoretically for 30 minutes at 100 V, 30 minutes 
at 200 V, and 2 hours at 450 V.  The separated proteins were detected by anti-cofilin immunoblot. 
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3.5.8. Detection of protein on gel 
3.5.8.1. Silver staining of the polyacrylamide gels 
Fixing solution: Ethanol: glacial acetic acid: H2O (30:10:60) 
Silver nitrate solution: 1% (w/v) AgNO3 
Developing solution: 2.5% (w/v) Na2CO3 and 0.02% (w/v) formaldehyde 
*All solutions were prepared freshly. 
Silver staining of polyacrylamide gels allows the detection of proteins separated by SDS-PAGE 
to a limit of 0.1-1 ng of polypeptide in a single band. In silver staining, the gel is impregnated 
with soluble silver ions and developed by treatment with formaldehyde, which reduces silver ions 
to form an insoluble brown precipitate of metallic silver. This reduction of silver ions is promoted 
by the side chains of amino acids in proteins. 
The proteins separated by SDS-PAGE were fixed by incubating the gel with a fixing solution for 
4 hours at 25°C or overnight at 4°C with gentle shaking.  The fixing solution was discarded, and 
at least 5 gel volumes of 30% ethanol was added to dehydrate the gel by incubating it for 30 
minutes at room temperature with gentle shaking.  This step was repeated once more to ensure 
complete dehydration of gel.  The gel was then washed thrice with 10 gel volumes of deionized 
H2O for 10 minutes at 25°C with gentle shaking.  The gel swells during rehydration.  Carefully, a 
silver nitrate solution was added and the gel was incubated for 30 minutes at 25°C.  After 
incubation, the silver nitrate solution was discarded and both sides of the gel were washed (20 
seconds each) under a stream of deionized H2O.  A sufficient volume of a developing solution 
was added and the gel was incubated with gentle agitation until stained bands of protein with 
desired contrast are obtained.  Subsequently, the reaction was quenched by washing the gel in 1% 
(v/v) acetic acid for a few minutes and several times with deionized H2O. 
For storage purpose, the stained polyacrylamide gel was placed between a wet Whatman 3MM 
paper (bottom) and a cellophane sheet (top), and dried under vacuum for 2 hours at 85°C. 
3.5.8.2. Coomassie staining of the polyacrylamide gels 
Staining solution: 0.25 gm Coomassie Brilliant Blue R-250 dissolved in 100ml of 
methanol, H2O and acetic acid solution (50:40:10 v/v ratio) and 
filtered through Whatman No. 1 filter to remove any particulate 
matter 
Destaining solution: Methanol, H2O and acetic acid solution in a ratio of 30:60:10 
(v/v) 
Coomassie Brilliant Blue is an aminotriarylmethane dye that forms strong but not covalent 
complexes with proteins, most probably by a combination of van der Waals forces and 
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electrostatic interactions with NH3+ groups.  Coomassie blue binds to proteins approximately 
stoichiometrically, thus this staining method is preferable when relative amounts of protein need 
to be determined by densitometry.  Coomassie staining allows the detection of proteins to a limit 
of 0.1-0.5 µg of polypeptide in a single band. 
The polyacrylamide gel was immersed in at least 5 gel volumes of the coomassie staining 
solution and placed on a slow rotating platform for 15-30 minutes at room temperature.  The gel 
was destained in destaining solution with three to four changes of fresh destaining solution.  The 
rapid destaining can also be achieved by placing the stained gel in hot water (80°C).  The 
remaining background was removed by leaving the gel overnight in water. 
3.5.9. Immunoblotting 
Transfer buffer: 48 mM Tris-base, 39 mM glycine, and 20% (v/v) methanol. 
TBST buffer: 10 mM Tris-base, 150 mM NaCl, 0.1% (v/v) Tween-20, and pH 
adjusted to 7.6 
Blocking solution: 5% (w/v) non-fat dry milk (BioRad) in TBST 
Immunoblotting combines the resolution of proteins by gel electrophoresis with the specificity of 
immunochemical detection and can detect proteins levels down to 0.1 ng.  The strategy behind 
the immunoblotting technique is to transfer the proteins electrophoretically out of the gel onto a 
membrane support, thus making a replica of the separated proteins.  The nitrocellulose membrane 
is the most commonly used support although it does have certain disadvantages such as non-
covalent binding of the proteins and brittleness, especially when it is dry.  The target protein 
immobilized on membrane is identified by probing the membrane with a specific primary 
antibody and a horseradish peroxidase (HRP)-conjugated secondary antibody directed against the 
primary antibody.  The detection of the antigen-antibody-antibody complex occurs by HRP-
mediated oxidation of the chemiluminescent substrate luminol, a cyclic diacylhydrazide.  The 
reaction product exhibits an excited state which decays to ground state via a light emitting 
pathway, and is detectable by exposure of the membrane to an autoradiography film. 
The proteins were blotted to nitrocellulose membranes using the Mini Trans-Blot electrophoresis 
cell (Bio-Rad, Hercules, CA).  After SDS-PAGE, the gel, nitrocellulose membrane pads and 
electrode papers were equilibrated with transfer buffer.  The gel and nitrocellulose membrane 
were sandwiched between 7 electroblotting papers and a fiber pad on each side, and clamped in 
the electroblotting cassette as shown in Figure 3.4. 
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Figure 3.4 Arrangement of the gel and the membrane in the cassette. 
The firmly closed cassette was put into the blotting module and then placed into the 
electroblotting buffer tank with an ice cooling unit. The proteins were transferred to the 
membrane at 200 mA for 1 hour at 4°C in ice-cooled transfer buffer with continuous stirring.  
The blotted membrane was blocked for the non-specific binding sites on the membrane by 
incubating it with gentle shaking in blocking solution for 2 hours at room temperature.  After 
blocking, the membrane was washed thrice with TBST for 5 minutes each wash.  The washed 
membrane was sealed in a polystyrene bag containing sufficient volume of the primary antibody 
and was incubated at 4°C for over night with an end-to-end shaking.  The membrane was washed 
thrice for 5 minutes each and incubated with the secondary antibody diluted in blocking solution 
for 1 hour.  The membrane was again washed thrice for 5 minutes each wash.  Subsequently, the 
freshly prepared Super Signal West Pico Chemiluminescent substrate solution (Pierce) was added 
to the upper surface of the blotted membrane (approx. 0.2 ml/cm2) and incubated for 3 minutes at 
room temperature.  The membrane was wrapped in plastic foil and exposed in the darkroom for 
an appropriate time to an autoradiographic film that was subsequently developed in dark room 
conditions.  
3.5.10. Densitometric analysis of immunoblots 
The films were scanned into TIF format using ScanJet 5300C (Hewlett-Packard Company, Palo 
Alto, CA).  The calibration of the scanner to an optical density scale (Kodak step tablet st34, 
Eastman Kodak Company, Rochester, NY) and the densitometric analysis of proteins were done 
using the public domain of National Institutes of Health (NIH) ImageJ (1.34s) software.  To 
measure the extent of protein phosphorylation, the densitometric values of phosphorylated 
proteins were divided by the corresponding values of unphosphorylated proteins, respectively.  
Absorption of proteins in unstimulated control samples was set to 100%.  Data were expressed as 
mean±S.D. of individual experiments from different blood donors. 
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3.6. Microscopic study of human platelets 
3.6.1. Principle of confocal microscopy 
In confocal laser scanning microscopes, a light beam with short wavelength generated by a laser 
is reflected by a beam-splitter/diachronic mirror and is led by flexible mirrors over the object 
field to scan a custom region.  Excited chromophores scatter light of a longer wavelength back 
through the beam-splitter/diachronic mirror and produce in the focal plane a characteristic 
diffraction pattern from which the center, the so called “Airy disc” is selected by a detector 
pinhole.  Because light beams projected from regions above and below the focal plane will not 
pass the detector pinhole, this step leads to a strong suppression of out of focus information, 
known as the confocal principle.  A laser beam scans the specimen pixel-by-pixel and line-by-
line.  The pixel data are then assembled into an image that is an optical section through the 
specimen, distinguished by high contrast and high resolution in x, y and z planes.  Number of 
images generated with the focal plane shifted in small steps can be combined into a 3-
dimensional image stack, which is available for digital processing. 
3.6.2. Preparation of poly-lysine coated coverslips 
Coating buffer: 150 mM NaCl, 50 mM Na2HPO4, 50 mM NaH2PO4, and pH 
adjusted to 8.0 
Glass coverslips were cleaned, rinsed with isopropanol and dried.  Poly-lysine (200 µg/ml) was 
diluted with an equal volume of coating buffer to get a concentration of 100 µg/ml.  On a plane 
surface of parafilm, drops of diluted poly-lysine (100 µl) were poured and glass coverslips were 
slowly mounted on these drops, and incubated for 20 minutes at room temperature.  Poly-lysine 
coated coverslips were inverted with coated surface facing up and then washed thrice with 4 ml 
of H2O and dried at room temperature for overnight.  
3.6.3. F-Actin staining of human platelets 
An equal volume of PBS containing 7.4% (w/v) formaldehyde was added to resting and activated 
platelet suspension for fixation and incubated for 10 minutes at room temperature.  Fixed platelet 
samples were directly spun onto polylysine-coated coverslips at 800x g for 5 minutes.  The 
coverslips were washed thrice with 1 ml of PBS.  Because phalloidin probes for F-actin staining 
are not cell permeable, platelets were permeabilized with PBS containing 0.2% Triton X-100 for 
5 minutes and washed thrice with PBS.  In a humid chamber, the coverslips were inverted and 
loaded on drops of Alexa Fluor 546 phalloidin (60 nM) and incubated for 15 minutes to stain F-
actin.  The platelet immunofluorescence was observed using a Zeiss LSM510 confocal laser-
scanning microscope. 
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3.7. Expression and purification of recombinant cofilins 
3.7.1. Work with E.coli 
3.7.1.1. Bacterial strains 
Escherichia coli DH5α F−φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 
hsdR17(rk−, mk+) phoA supE44λ−thi-1 
Escherichia coli M15 Nals strs rifs thi- lac- ara+ gal+ mtl- F- recA+ uvr+ lon+ contains 
pREP4 (KanR) plasmid 
3.7.1.2. Media for bacterial culture 
LB-medium  1.0% (w/v) tryptone, 0.5 % (w/v) yeast extract, 1.0 % (w/v) NaCl, 
pH 7.2.  
(1.5% agar was added to the LB medium to make agar plates) 
The following concentrations of the antibiotics were used if required: 
Antibiotic Stock solution Working concentration 
Ampicillin 
Kanamycin 
100 mg/ml in water 
10 mg/ml in water 
100 µg/ml 
30 µg/ml 
 
Table 3.2 Antibiotic stock solutions and its working concentration 
3.7.1.3. General 
E. coli was cultured at 37°C in LB medium.  Bacteria transformed with an antibiotic resistance-
conferring plasmid were selectively propagated in the LB medium supplemented with respective 
antibiotic (see Table 3.2).  All solutions and supplements used for work with E. coli were 
autoclaved for 20 minutes at 121°C or filter-sterilized.  Bacterial strains were long-term stored at 
-70°C in the LB medium supplemented with glycerol to a final concentration of 15%. 
3.7.1.4. Culturing bacteria 
3.7.1.4.1 Growth on solid media 
The solidified LB agar plates were used for platting bacterial culture.  Single bacterial colony or 
bacterial suspension was platted with even spreading using a sterile inoculation loop or a glass 
spreader, respectively, to achieve single colony growth.  The plates were incubated inverted 
overnight at 37°C. 
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3.7.1.4.2 Growth of liquid cultures 
For small liquid culture, 5-10 ml of LB or LB/antibiotic medium was inoculated with a single 
bacterial colony and incubated overnight at 37°C on a shaking platform.  Starter culture was 
incubated for 8-12 hours and used to inoculate fresh and large volume of liquid medium.  For a 
liquid culture of 100-250 ml of LB or LB/antibiotic medium, a starter culture to a dilution of 
1:50-1:100 was inoculated and incubated overnight at 37°C with shaking.  Bacteria were 
harvested by centrifugation at 2500x g for 15 minutes. 
3.7.1.4.3 Monitoring the bacterial growth 
The growth of the bacteria in liquid culture was measured at a wavelength of 600 nm (OD600) in 
plastic cuvettes against pure medium as a blank in a spectrophotometer.  Each OD600 unit of 0.1 
corresponds to approximately 108cells/ml, valid until OD600 < 1. 
3.7.1.5. Preparation of ultra-competent cells by Inoue method 
Inoue transformation buffer:  55 mM MnCl2.H2O, 15 mM CaCl2.2H2O, 250 mM KCl, 10 mM 
PIPES (pH 6.7) and sterilized by filtration through a 0.4 µM 
Nalgene filter. 
LB medium (100 ml) was inoculated with an overnight culture of E. coli cells and grown at 37°C 
with shaking to an OD600 of 0.55.  The culture vessel was immediately transferred to an ice water 
bath and incubated for 10 minutes.  Cells were harvested by centrifugation at 2500x g for 10 
minutes at 4°C.  The cell pellet was washed once with 8 ml ice-cold Inoue transformation buffer 
and finally resuspended in 2 ml ice-cold Inoue transformation buffer and 150 µl of glycerol was 
added to the cell suspension.  Working quickly, aliquots of 200 µl were dispensed into chilled 
and sterile microfuge tubes, and snap-froze by immersing the tightly closed tubes in a bath of 
liquid nitrogen, which were later stored at -70°C until needed. 
3.7.1.6. Heat shock transformation of plasmid into E.coli 
Treatment of competent bacterial cells with a brief heat shock enables transformation of DNA.  
Plasmid DNA or a plasmid ligation reaction mixture (not more than 15 ng or 2.5 µl in volume) 
was mixed with 50 µl of thawed competent bacteria and incubated for 30 minutes on ice.  The 
bacterial suspension was then subjected to heat shock at 42°C for 90 seconds and placed 
immediately on ice for 1-2 minutes.  The transformed bacterial suspension was diluted 10-fold 
with 950 µl of LB medium and incubated for 1 hour at 37°C with shaking to recover bacteria 
from the heat shock.  An aliquot of 50-200 µl of this bacterial suspension was spread on 
LB/antibiotic agar plate and incubated overnight at 37°C in order to select transformed bacteria.  
In case of ligation mixtures, the transformed cells were pellet down by centrifugation at 13,000 
rpm for 30 seconds, and resuspended in the residual LB medium. The whole resuspended 
bacterial cells were spread on the agar plate. 
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3.7.2. Sub-cloning of cofilin and GFP cDNA 
3.7.2.1. Cofilin and GFP cDNA amplification 
The polymerase chain reaction (PCR) constitutes an enzymatic in vitro amplification of specific 
cDNA segments.  Amplification occurs in automated, temperature-controlled cycles of 
denaturation, annealing and elongation in a thermal cycler.  Initially, double-stranded template 
DNA is separated into its complementary single strands by heating (denaturation).  At a lower 
temperature two oligonucleotides primers, flanking the DNA region to be amplified, hybridize to 
their respective complementary sequences on opposite strands (annealing) and serve as primers 
for DNA synthesis in a 5'→3' direction (elongation).  Primer extension is catalyzed at a slightly 
increased temperature by a thermostable DNA polymerase that add deoxyribonucleotide 
triphosphates (dNTPs) to the recessed 3'-hydroxyl end of extending strands, thereby generating 
new double-stranded DNA across the primer-flanked region.  The products of each reaction cycle 
are then denatured to permit a new amplification cycle.  Theoretically, for n cycles a 2n-fold 
amplification of a specific DNA sequence is obtained. 
Primer for amplification of cofilin cDNA was commercially synthesized (MWG Biotech, 
Ebersberg, Germany).  It was designed corresponding to the DNA segment to be amplified, 
provided with restriction sites for endonuclease digestion. Pairs of primers were designed to have 
equivalent melting temperatures (Tm), calculated according to the formula  
Tm [°C] = (A+T) ×2 + (G+C) ×4.  
Where A, T, G, and C are the 2’-deoxyribonucleosides; adenosine (A), thymidine (T), guanosine 
(G) and cytidine (C) with in the primer sequence. 
Following cofilin primers containing respective sites for restriction endonuclease (underlined) 
were designed to amplify cofilin cDNA from plasmid pEGFP-C1-cofilin: 
Sense primer (Nco I)  5'-ATTATTCCATGGATGGCCTCCGGTGTGGC-3' 
Antisense primer (BamH I) 5'-TTATTGGATCCTCACAAAGGCTTGCCC-3' 
 
Whereas to amplify GFP cDNA from same plasmid (pEGFP-C1-cofilin), following GFP primers 
were used: 
Sense primer (BamH I) 5'-ATTAGGATCCCCGGTCGCCACCATG-3' 
Antisense primer (Bgl II) 5'-AGAATTCGAAGCTTGAGCTCGAGATCTGAGTCC-3' 
 
The annealing temperature for each PCR was typically estimated experimentally.  For preparative 
DNA amplification as part of cloning strategies, High fidelity DNA polymerase was used in 
preference to Taq DNA polymerase, due to its 3'→5' proofreading exonuclease activity which 
minimizes the risk of nucleotide miss-incorporation during elongation. 
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PCR reaction composition for DNA amplification was as follows: 
Template DNA  20-50 ng (Plasmid pEGFP-C1-cofilin) 
Sense primer (forward) 100 pmoles 
Antisense primer (reverse) 100 pmoles 
dNTPs    200 µM each 
PCR reaction buffer  1x 
DMSO    5-10% (Optional, to increase yield, specificity, consistency)  
DNA polymerase  1-2.5 units 
Final reaction volume  100 µl (preparative PCR), 20-50 µl (analytical PCR) 
 
 
Thermal cycle parameters for PCR were as follows: 
 
Lid temperature  105°C 
Initial denaturation  94°C, 5 minutes 
Denaturation   94°C, 30 seconds 
Annealing   50-55°C (primer pair and template specific), 1minute 
Elongation   72°C, 1 minute/kb 
Cycles    30 
Final elongation  72°C, 10 minutes 
The PCR amplified products were analyzed by agarose gel electrophoresis. Cofilin cDNA was 
further processed for cloning into the pQE-60 vector (Qiagen, Hiden, Germany).  The resultant 
pQE-60-cofilin plasmid was used as backbone to ligate the GFP cDNA between the C-terminus 
of cofilin and the His-tag to get the pQE-60-cofilin-GFP plasmid.  
3.7.2.2. Agarose gel electrophoresis for isolating cDNA 
Buffers and solutions 
TBE buffer (0.5x): 45 mM Tris-base, 45 mM boric acid, 1 mM EDTA (pH 8.0) 
TE buffer: 10 mM Tris-base and 1 mM EDTA (pH 8.0) 
DNA loading buffer (6x): 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 30% 
(v/v) glycerol, and 50 mM EDTA 
Agarose gel electrophoresis was used separate and purify DNA fragments from PCR reaction 
mixtures. This method uses the migration of negatively charged DNA towards the anode in an 
electric field.  The fragments migrate through the gel matrix at rates inversely proportional to the 
logarithm (log10) of the number of base pairs.  The agarose gel was prepared by melting 1-2% 
(w/v) agarose in 0.5x TBE electrophoresis buffer, adding 0.5 µg/ml ethidium bromide to the 
melted agarose and casting in a tray of desired size.  A plastic comb of desired thickness and well 
number was inserted before the solidification of agarose gel.  After solidification, the gel was 
placed in an electrophoresis tank and submerged in 0.5x TBE buffer.  The DNA samples were 
mixed with DNA loading buffer and loaded into the gel wells.  In adjacent to the samples, 5 µl of 
a DNA standard (SmartLadderTM Eurogentec GmbH, Germany) was loaded.  Horizontal 
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electrophoresis was carried out at approximately 100 V.  DNA bands were visualized within 
agarose gel by illumination of DNA-intercalated fluorescent dye ethidium bromide under UV 
light.  The length of DNA fragments were determined by comparing their mobility with that of 
DNA standards.  The stained gel was photographed under UV light. 
3.7.2.3. DNA recovery from agarose gel 
For preparative purposes DNA fragments of interest were cut out from stained agarose gels with 
a sharp scalpel under UV illumination.  The gel slices were solubilized and DNA was purified by 
using the QIAquick Gel extraction kit (Qiagen) according to the manufacturer’s instructions.  
Agarose gel slices were weighed (1 volume) and dissolved in 3 volumes of solubilization buffer 
QG by incubating at 50°C for 10 minutes.  A volume of isopropanol was added and mixed.  The 
whole solution was applied to a silica-gel embedded in QIAquick spin column and centrifuged at 
13,000 rpm for 1 minute in order to bind DNA.  The column was washed once by adding 0.75 ml 
wash buffer PE and centrifuging at 13,000 rpm for 1 minute.  An additional 1 minute 
centrifugation was done to remove residual buffer.  DNA was eluted by adding 30-50 µl water or 
TE to the column followed by incubation for 2 minutes at room temperature and then 
centrifugation at 13,000 rpm for 1 minute.  All the buffers were provided in the QIAquick Gel 
extraction kit. 
3.7.2.4. Restriction endonuclease digestion of DNA 
For sub-cloning cofilin into pQE-60 vector, 1-5 µg PCR amplified cofilin cDNA and pQE-60 
vector were digested with 1-20 U of restriction enzymes (BamHI and NcoI) in 10-50 µl of 
reaction buffer.  For construction of pQE-60-cofilin-GFP, the resultant pQE-60-cofilin plasmid 
and GFP cDNA were digested with BglII and BamHI restriction endonucleases.  Complete 
digestion was confirmed by agarose gel electrophoresis.  For analytical purposes, 0.2-1 µg DNA 
were digested with 1-5 U of enzyme in a volume of 10-20 µl of reaction buffer.  In both cases 
digests were incubated for 3 hours at 37°C.  Reaction buffers were supplied by the manufacturer.  
Enzymes were heat-inactivated as recommended by the supplier or removed by purifying the 
digested DNA using QIAquick PCR purification kit. 
3.7.2.5. Dephosphorylation of linearized plasmid DNA by CIP 
In order to prevent self-ligation of vector ends, linearized plasmid DNA was treated with calf 
intestine alkaline phosphatase (CIP).  CIP catalyzes the hydrolysis of 5'-phosphate to generate 5'-
hydroxyl ends.  T4 DNA ligase requires 5'-phosphate residues to catalyze new phosphodiester 
bonds.  After hydrolysis of vector’s 5'-phosphate ends, ligation is only possible between vector 
and inserts ends, but not between vector-ends themselves.  Dephosphorylation was carried out 
directly following plasmid linearization.  CIP was added to the digested mixture at a 
concentration of 1 U per pmole of linearized vector DNA and incubated at 37°C for 45 minutes. 
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3.7.2.6. Purification of the digested DNA 
To inactivate and remove the proteins e.g. restriction enzymes, digested DNA were purified using 
the QIAquick PCR purification kit (Qiagen) and according to the manufacturer’s instructions 
with slight modification.  Buffers were provided in the kit and all centrifugation steps were 
carried out at 13,000 rpm at 25°C using a tabletop micro-centrifuge.  To the DNA solutions 
sought purification, 5 volume of buffer PB and one volume of isopropanol were added.  The 
mixed solution was then applied to QIAquick spin column (Qiagen) and centrifuged for 1 minute 
in order to bind DNA. The column was washed with 0.75 ml buffer PE and centrifuged for 1 
minute.  Flow through was discarded and an additional centrifugation was done to remove the 
residual ethanol present in buffer PE.  The column was then placed into a clean 1.5 ml eppendorf 
tube and the purified DNA was eluted with 30-50 µl of buffer TE or water as described for 
QIAquick Gel extraction kit (section 3.7.2.3). 
3.7.2.7. Ligation of DNA fragments 
DNA fragments of bearing either sticky or blunt ends can be ligated in vitro with bacteriophage 
T4 DNA ligase.  This enzyme catalyzes the formation of new phosphodiester bonds between a 5'-
phosphate residue of one and a 3'-hydroxyl residue of another double-stranded DNA fragment 
generated by restriction endonucleases. 
Ligation was carried out using Rapid DNA ligation kit (Roche) according to the manufacturer’s 
instructions with slight modification.  All the buffers were provided in the kit.  A 2-5 molar 
excess of PCR amplified cofilin cDNA relative to the linearized and dephosphorylated pQE-60 
vector DNA were taken and mixed.  The vector and insert DNA mixture was diluted to a final 
volume of 10 µl using dilution buffer.  To the diluted mixture, 10µl of ligation buffer and 5 units 
of T4 DNA ligase were added and mixed thoroughly.  The ligation reaction mixture was then 
incubated at 20°C for 10 minutes subsequently used for transformation.  An aliquot of 5 µl was 
used for transformation of 200 µl DH5α competent cells.  Positive bacterial colonies were 
selected, screened by restriction digestion or PCR, and confirmed by DNA sequencing. 
3.7.2.8. Quantification of DNA solution 
The concentration of nucleic acid solutions was determined by spectrophotometry.  The UV 
absorption was measured at a wavelength of 260 nm (OD260) using a quartz cuvette of 1 cm 
width. For double-stranded DNA an OD260 =1.0 corresponds to approximately 50 µg DNA/ml.  In 
addition the OD260 was measured to estimate the purity of the nucleic acid sample.  A ratio 
OD260/OD280 of significantly less than 1.8-2.0 indicates protein contamination.  
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3.7.2.9. DNA sequencing 
The sequence of specific target regions in recombinant plasmid DNA was determined by a 
commercial sequencing service (Agowa GmbH Berlin, Germany).  The sequence data were 
verified on the basis of the corresponding fluorescence. 
3.7.3. In vitro expression of His-tagged cofilin 
The vector pQE-60 was selected for construction of recombinant cofilin and cofilin-GFP with 
6xHis tag placed at C-terminus of the protein.  The presence of 6 consecutive histidine residues 
facilitates the purification of protein by nickel-nitrilotriacetic acid (Ni-NTA) metal-affinity 
chromatography.  Plasmid DNA containing cofilin cDNA as insert was purified from 
DH5α bacterial culture by alkaline lysis of cells using QIAprep Spin miniprep kit according to 
the manufacture instructions.  
Purified plasmid DNA was transformed into E. coli M15 [pREP4] ultra-competent cells for high 
expression of his-tagged cofilin. Colonies resistant to kanamycin, as a selection marker for cells 
containing plasmid pREP4, were selected.  A small culture of bacteria (15 ml) was grown 
overnight in order to make starter culture.  A large volume of LB medium (500 ml) was 
inoculated with 10 ml of the starter culture and incubated at 37°C with vigorous shaking (250 
rpm) until OD600 reached ~0.5-0.6.  Cells were induced with 1 mM IPTG and incubated at 37°C 
for 5 hours.  Aliquots (100 µl) of samples before and after every hour of IPTG induction were 
collected and corrected for equal number of cells with PBS.  IPTG-induced samples were lysed 
with 1x SDS-PAGE buffer for analyzing expression of protein by gel electrophoresis.  The cells 
overexpressing cofilin-GFP were easy to identify since the pellet of these cells appeared 
fluorescent green in color.  The cells were harvested by centrifugation at 4000x g for 20 minutes 
and stored at -20°C until used. 
3.7.4. Purification by Ni-NTA affinity chromatography  
3.7.4.1. Working principle of Ni-NTA affinity chromatography 
Proteins containing one or more 6xHis affinity tags, located at either the amino and/or carboxyl 
terminus of the protein, can bind to the Ni-NTA groups on the matrix with an affinity far greater 
than that of antibody–antigen or enzyme–substrate interactions.  Binding of the 6xHis tag does 
not depend on the three-dimensional structure of the protein.  Untagged proteins that have 
histidine residues in close proximity on their surface could also bind to Ni-NTA, but in most 
cases these interactions are much weaker than the binding of the 6xHis tag.  These non-specific 
bindings can be reduced under conditions that introduce competition for the binding sites, i.e. at a 
slightly reduced pH or in the presence of low imidazole concentrations (10-20 mM).  The binding 
of untagged proteins can further be reduced by washing the matrix under stringent conditions 
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such as increased imidazole concentration (10-50 mM) in washing buffer or lowering the pH to 
6.3.  The histidine residues in the 6xHis tag have a pKa of approximately 6.0 and will become 
protonated if the pH is reduced to pH 4.5-5.3.  Under these conditions the 6xHis-tagged protein 
can no longer bind to the nickel ions and will dissociate from the Ni-NTA resin.  Similarly, if the 
imidazole concentration is increased to 100-250 mM, the 6xHis-tagged proteins will also 
dissociate because they can no longer compete for binding sites on the Ni-NTA resin. 
3.7.4.2. Preparation of Ni-NTA affinity column 
A Ni-NTA Superflow resin (Qiagen, Hiden, Germany) column was prepared for FPLC 
purification of the His-tagged cofilin in a cold room ambient.  Briefly, a chromatography glass 
column was cleaned, rinsed with isopropanol and dried.  The column was clamped in a test tube 
holder stand and slurry of 50% Ni-NTA Superflow beads was slowly poured avoiding any 
trapping of air bubbles into the column.  The column and bed size was calculated depending on 
the amount of His-tagged protein to be purified. Generally, the binding capacity of Ni-NTA 
superflow is 5-10 mg protein per ml resin. The resin was allowed to settle by allowing the buffer 
to flow through by uncapping the bottom outlet. After the column was nicely packed, it was 
attached to the peristaltic pump of Econo System (Bio-Rad) with a flow rate of 1ml/minute and 
equilibrated with 10 column volumes of the lysis buffer. 
3.7.4.3. Purification of His-tagged recombinant cofilins 
Lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 0.05% (w/v) NaN3, 10 mM 
imidazole, and complete mini EDTA-free protease inhibitor (2 
tablets/10 ml of buffer). 
Wash buffer: 50 mM NaH2PO4, 300mM NaCl, 0.05% (w/v) NaN3, and 50 
mM imidazole. 
Elution buffer: 50 mM NaH2PO4, 300 mM NaCl, 0.05% (w/v) NaN3, and 250 
mM imidazole. 
All buffers were adjusted to pH 8.0 and stored at 4°C. 
The cell pellet was thawed for 15 minutes on ice and resuspended in 2-5 ml of lysis buffer per 
gram wet weight.  Cells were lysed by adding lysozyme to 1 mg/ml (final concentration) and 
incubated on ice for 30 minutes.  After incubation, cell lysate was sonicated on ice for ten times 
with 20 seconds bursts of 200-300 W and a 20 seconds cooling period between each bursts.  
When the lysate was very viscous, DNaseI was added at concentration 5 µg/ml and incubated on 
ice for 10-15 minutes.  Lysate was centrifuged at 10,000x g for 1 hour in order to separate the 
cellular debris.  Supernatant was collected in ice-cold 50-ml plastic tubes applied to the Ni-NTA 
Superflow column with a flow rate of 0.5 ml/minute.  The eluate was passed through an Econo 
UV Monitor (280 nm) to check elution of proteins.  The column was washed with lysis buffer 
until the A280 became stable.  Binding of non-specific proteins to the Ni-NTA resin was 
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minimized by washing the column with wash buffer until the eluate showed a low and stable 
A280.  The bounded His-tagged proteins were eluted with elution buffer and eluate fractionated 
into approx. 1ml each was collected in clean glass tubes using Model 2110 Fraction Collector.  
All collected fractions were subjected to SDS-PAGE and those that contain high amount of 
purified his-tagged proteins (>97%) were selected.  The purified his-tagged cofilin is shown in 
Figure 3.5A (fraction 3+4).  The purified his-tagged cofilin and cofilin-GFP analyzed for protein 
degradation using anti-cofilin immunoblot are shown in Figure 3.5B.  Protein was concentrated 
using Centricon® Plus-20 centrifugal filter device (Millipore) with molecular weight cut off 
(MWCO) of 5-kDa at 4000 rpm, 4°C until a desired concentrated volume was achieved. Protein 
concentration was measured using dotMETRICTM protein assay kit. 
 
 
 
Figure 3.5 Purification of His-tagged cofilins by Ni-NTA affinity chromatography.  (A) Samples from different 
steps during protein purification of his-tagged cofilin were subjected to SDS-PAGE and probed with coomassie 
brilliant blue staining.  The purified his-tagged cofilin (20-kDa) was eluted in fraction 3+4.  (B) The purified his-
tagged cofilin and cofilin-GFP along with lysates of endothelial cell and platelets were subjected to anti-cofilin 
immunoblotting for analyzing protein degradation.  Single bands of his-tagged cofilin and cofilin-GFP indicate no 
degradation of these proteins. 
3.8. Peptide and protein delivery into platelets 
Platelets do not contain any defined transcriptional machinery and therefore the genetic 
manipulation methods to overexpress proteins of interest in platelet are not feasible. Moreover, 
platelets are very sensitive to their external milieu and therefore platelet is a difficult system to 
manipulate by delivering peptides and proteins using current transfection techniques. Recently, 
novel methods to deliver peptide or proteins into cells using cell-permeable peptides such as 
TAT, penetratin, and cationic poly-arginine have been reported and commercialized (Deshayes et 
al. 2005).  We chemically synthesized poly-arginine (R9) conjugated N-terminal cofilin peptide 
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(1-16 amino acids), a reverse peptide and a peptide mimicking cofilin phosphorylation (S3D).  
These peptides were used to study the regulation of LIMK-1 in intact platelets.  The N-terminal 
cofilin peptide has been shown to inhibit LIMK-1 in neuronal cells (Aizawa et al. 2001).  
Different concentrations of these peptides were incubated with platelets at 37°C for 30 minutes 
and 1 hr and then induced with thrombin (0.5 U/ml). Activated platelets were lysed by adding 
equal volume of SDS-PAGE lysis buffer and were analyzed for cofilin phosphorylation by 
immunoblotting.  
Chariot, a revolutionary new transfection reagent (Morris et al. 2001), which has been 
successfully used to deliver proteins into mammalian cells, was studied to deliver cofilin-GFP 
into platelets. Unlike current peptide based transfection techniques, which require covalent 
coupling of these membrane permeable peptides with peptide/proteins of interest, Chariot forms a 
non-covalent complex with protein, peptide or antibody of interest and is a comparatively faster 
method. The Chariot-macromolecule complex stabilizes the macromolecule and helps to protect 
it from degeneration during the transfection process. Upon internalization, the complex 
dissociates and the macromolecule becomes free to proceed to its target organelle.  Purified 
cofilin-GFP was delivered into platelets so that the efficiency of transfection could be easily 
monitored using confocal microscopy.  Chariot transfection reagent (10 µL) was diluted in 60 µl 
of 20% DMSO/H2O solution.  Cofilin-GFP (2 µg) was added to 50 µL of H20 and mixed with 60 
µl of diluted Chariot reagent.  In order to assemble Chariot-cofilin-GFP complex, the mixture 
(110 µl) was incubated at 37°C for 30 minutes.  After complex formation, the reaction mixture 
was added to 100 µl of platelet suspension (5% DMSO final concentration) and incubated for 2 
hours at 37°C.  Platelets were then washed twice with PBS and resuspended in 100 µl of buffer 
C. The transfected platelets were directly spun onto polylysine-coated coverslips at 800x g for 5 
minutes and allowed to spread for 15 minutes at 37°C.  Spread platelets were then fixed, 
permeabilized and probed for F-actin staining using Alexa-546, and observed by confocal 
microscopy as described in section 3.6.3 
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4. Results 
4.1. Identification of cofilin and LIMK-1 in human platelets 
4.1.1. Cofilin  
In cells, cofilin exists in two forms, unphosphorylated (cofilin) and phosphorylated at Ser3 
position (phospho-cofilin).  Platelets are known to contain cofilin in both forms (Davidson and 
Haslam 1994).  However, the extent of cofilin phosphorylation in resting platelets is not clear.  
These two different forms of cofilin have a different pI and can be easily separated by isoelectric 
focusing (IEF).  Phospho-cofilin due to the negatively charged phosphate group has a lower pI 
than cofilin and it therefore moves faster towards the anode.  The two forms present in lysates of 
resting platelets were separated using IEF and subsequently immunoblotted with anti-cofilin 
antibody to quantify the amount of phospho-cofilin by densitometry.  It was found that one third 
of the total cofilin is present in its phosphorylated form in resting platelets (Figure 4.1). 
 
 
Figure 4.1 Identification of cofilin in its unphosphorylated and phosphorylated states in resting platelets. 
Resting platelet lysates were subjected to IEF electrophoresis and subsequently immunoblotted with anti-cofilin 
antibody. 
4.1.2. LIMK-1 
It was not known, whether platelets contain LIM-kinases, and which type of LIM-kinase is 
expressed in platelets.  A polyclonal antibody against the recombinant kinase domain of LIMK-2 
was produced and used for immunoblotting.  A 72-kDa protein was identified in platelets, which 
shows that LIM-kinases are expressed in platelets (data not shown).  Since this antibody did 
probably not distinguish between LIMK-1 and LIMK-2 due to the high homology in the kinase 
domain, specific peptide antibodies against the two forms of LIMKs were used.  The specificity 
of the anti-LIMK-1 and anti-LIMK-2 was probed by immunoblotting endothelial cells transfected 
with different GFP-LIMK-2 constructs (Goyal 2005).  The anti-LIMK-2 antibody identified the 
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different GFP-LIMK-2 constructs at their respective positions in the immunoblot, while the anti-
LIMK-1 antibody did not.  After immunoblotting platelet lysates with these specific LIM kinase 
antibodies, only LIMK-1 but not LIMK-2 expression was found in platelets (Figure 4.2).  In 
contrast to platelets, endothelial cells contain both LIMK-1 and LIMK-2 (Goyal 2005).  
 
 
Figure 4.2 LIMK-1 but not LIMK-2 is expressed in platelets. Lysates of endothelial cells (EC) and platelets (PL) 
were immunoblotted with specific anti-LIMK-1 and anti-LIMK-2 antibodies. Endogenous LIMK-1 and LIMK-2 are 
expressed in endothelial cells but platelet expresses only LIMK-1 (both LIMK-1 and LIMK-2 have molecular mass 
of 72-kDa). The lower bands detected by both LIMK-1 and LIMK-2 in endothelial cells could be a truncated form of 
LIM-kinases. 
 
          
 
Figure 4.3 Specificity of phospho-LIMK-1/LIMK-2 antibody.  Lysates of endothelial cell, resting platelets and 
platelets stimulated for 120 seconds with thrombin (0.5U/ml) were immunoblotted with phospho-LIMK-1/LIMK-2 
antibody pre-incubated or not incubated with the 7.5µM of synthetic phospho-peptide (CKNDRKKRYTPVVG, P-
Pep) for 1 hour at 37°C.   
LIMK-1 in cells is activated by phosphorylation of Thr508 in the kinase domain.  In order to 
analyze the activation of LIMK-1 we used a specific anti-phospho-LIMK antibody raised against 
a KLH-coupled synthetic phospho-peptide corresponding to residues surrounding phospho-
Thr508 of human LIMK-1.  This antibody recognizes both LIMK-1 and LIMK-2 phosphorylated 
at Thr508 and Thr505, respectively.  In endothelial cells, the antibody recognized a 
phosphorylated 72-kDa protein, and an additional protein of approx molecular mass 56-kDa was 
detected.  The phosphorylation of the 72-kDa protein as well as three additional proteins was 
increased in thrombin-activated platelets.  The specificity of the anti-phospho-LIMK antibody 
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was probed using the respective synthetic unphosphorylated and phosphorylated peptides 
(CKNDRKKRYTVVGN; amino acid 500-512) of LIMK1.  Preincubation of phospho-LIMK 
antibody with the unphopshorylated peptide did not block the detection of these proteins (data not 
shown), whereas with the phospho-peptide the signal of phosphorylated LIMK-1 was suppressed 
in endothelial cells and platelets (Figure 4.3).  Additionally, the phospho-peptide also blocked the 
signals of the 56-kDa protein in endothelial cells and the other three proteins in resting and 
activated platelets (Figure 4.3).  These results show that the anti-phospho-LIMK antibody 
identifies phosphorylated LIMK-1 and other unknown proteins in endothelial cells and platelets.  
Some of these proteins could be truncated forms of LIMK-1 as observed by Soosairajah et al 
(Suppliment 1)(Soosairajah et al. 2005). 
4.2. Platelet shape change induced by thrombin 
4.2.1. Shape change studied by decrease in light transmission 
 
Figure 4.4 Rho-kinase-mediated platelet shape change induced by thrombin (0.075U/ml). Shape change was 
measured by the decrease in light transmission. Preincubation of platelets with the Rho-kinase inhibitor Y-27632 but 
not with BAPTA-AM/EGTA inhibited platelet shape change induced by this concentration of thrombin (black). For 
incubation conditions see section 3.2.4.1. 
Physiological stimuli such as thrombin at a low concentration range of 0.01-0.04 U/ml, induce 
shape change through a pathway that is apparently independent of an increase in cytosolic 
Ca2+(Bauer et al. 1999).  At higher concentrations of thrombin, Ca2+ influx through the plasma 
membrane and mobilization of Ca2+ from intracellular stores are observed.  However, I found 
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even a high concentration of thrombin (0.075U/ml) induced a Ca2+-independent Rho-kinase-
mediated shape change. Pretreatment of platelets with the Rho-kinase inhibitor Y-27632 
completely inhibited this shape change (Figure 4.4).  In contrast, preincubation of platelets with 
the intracellular Ca2+ chelator BAPTA-AM in combination with the extracellular Ca2+chelator 
EGTA did not affected thrombin-induced shape change indicating that Ca2+ influx through the 
plasma membrane or Ca2+ mobilization from intracellular stores is not involved (Figure 4.4). 
Serotonin, ATP and ADP secreted after platelet stimulation with thrombin might affect the 
platelet shape change by reinforcing signal transduction pathways through outside-in signaling by 
activating their respective platelet receptors.  However, no ATP secretion was observed, 
indicating that thrombin-induced shape change is independent of platelet activators released by 
dense granule secretion (e.g. ADP, serotonin). 
4.2.2. Shape change studied by confocal microscopy 
In the non-activated state platelets have a typical discoid shape, and activation of platelets by 
agonists such as thrombin leads to a spheroid shape with the formation of pseudopods.  Confocal 
microscopic studies of resting and thrombin-stimulated platelets (for 2 minutes) that were stained 
for F-actin with Alexa-546 phalloidin showed that the smooth and regular structure of disc-like 
resting platelets (diffusely stained for F-actin) changed to an irregular and smaller spherical 
structure (more intensely stained for F-actin) of activated platelets.  Pretreatment of platelets with 
the Rho-kinase inhibitor Y-27632 completely blocked the shape change further supporting that 
shape change induced by thrombin involves a Rho-kinase mediated signaling pathway (Figure 
4.5). 
 
 
Figure 4.5 Confocal fluorescence microscopy of platelets. Platelets in the absence or presence of Rho-kinase 
inhibitor Y-27632 are stimulated with thrombin (0.075U/ml). Platelets are stained for F-actin with Alexa Fluor 546 
phalloidin (Bar=2µm). 
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4.2.3. F-actin increase in thrombin-stimulated platelets 
Platelet activation is associated with changes in the actin cytoskeleton such as an increase of F-
actin content.  During the Rho-kinase-mediated platelet shape change induced by thrombin (0.075 
U/ml), the change in platelet F-actin was analyzed.  
Activation of F-actin depolymerizing and severing proteins like cofilin and gelsolin result in the 
formation of small F-actin filaments from the existing large filaments.  Moreover, stimulation of 
actin polymerization during shape change may also generate F-actin filaments of various lengths.  
Platelet F-actin, upon its sediment properties can be divided into a low-speed (15,000x g) and a 
high-speed (100,000x g) Triton X-100-insoluble fraction.  To measure the total F-actin content, 
platelets were lysed for 5 minutes on ice, and both the low-speed and high-speed Triton-X100 
insoluble fractions were pelleted together by centrifugation at 150,000x g for 30 minutes.  The F-
actin content of platelets undergoing shape change was measured by separation of proteins using 
SDS-PAGE, probing them with Coomassie brilliant blue (CBB®), and subsequent densitometry.  
The F-actin content was calculated as percentage of the total actin.  Thrombin induced an 
increase in F-actin from 43±2% of total in resting platelets to 55±3% (mean± SD, n= 4) 30 sec 
after thrombin stimulation. The increase of F-actin content in thrombin-stimulated platelets was 
inhibited by Y-27632 (Figure 4.6).  These results suggest that thrombin-stimulated platelet shape 
change is accompanied by an increase in F-actin content, which is Rho-kinase dependent.  
Interestingly, Y-27632 increased significantly the F-actin content in unstimulated platelets. 
 
 
Figure 4.6 Effect of Y-27632 on F-actin content during shape change induced by thrombin (0.075U/ml).  
Values are mean+SD of 4 independent experiments. Asterisks (*) denote statistical significance with respect to non-
activated controls (0 seconds); P<0.05. (†) Denotes significance between control (?) and Y-27632 (?) treated 
unstimulated platelets. 
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4.2.4. Activation of Rho-kinase (MYPT phosphorylation) 
In order to analyze Rho-kinase activation during thrombin-induced platelet shape change, 
phosphorylation of one of its substrates, the myosin phosphatase targeting subunit (MYPT) was 
measured.  The human MYPT has Thr696 and Thr853 as sites of phosphorylation for Rho-kinase 
(see Figure 1.6), which can be measured by specific anti-MYPT1 (Thr696) and anti-MYPT1 
(Thr853) antibodies. 
The measurement of MYPT phosphorylation at Thr696 (data not shown) and Thr853 (Figure 4.7) 
was used to estimate Rho-kinase activation during platelet shape change.  Thrombin induced a 
rapid increase of MYPT phosphorylation at Thr853, reaching a maximal (about 2-fold) within 1 
minute after platelet stimulation. The MYPT phosphorylation was irreversible after 2 minutes of 
thrombin stimulation. The established Rho-kinase inhibitor Y-27632 reduced the MYPT 
phosphorylation in non-activated platelets and completely abolished the thrombin-induced 
increase of MYPT phosphorylation. These results together with the results showed in section 
4.2.3 (Figure 4.6) indicate that Rho-kinase is activated during shape change and mediates the F-
actin increase underlying platelet shape change (Figure 4.7). 
 
 
Figure 4.7 MYPT phosphorylation during thrombin-stimulated platelet shape change. Platelet lysates were 
immunoblotted with anti-phopsho-Thr853-MYPT antibody. (Left) Graphical representation of the results evaluated 
by densitometry.  Values are mean + SD of 3 independent experiments. (Right) Representative immunoblots of 
MYPT phosphorylation. 
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4.2.5. LIMK-1 and cofilin phosphorylation 
Rho-kinase also phosphorylates LIMK-1 at Thr508 leading to the activation of this enzymes 
(Ohashi et al. 2000; Sumi et al. 2001).  Activated LIMK-1 phosphorylates cofilin at Ser3 and 
thereby inactivates cofilin for its actin binding, severing and actin depolymerization activities.  
LIMK-1 can also be phosphorylated by Rac-activated PAKs (p21 activated kinases) (Edwards et 
al. 1999).  Both Rac and PAK are stimulated during platelet activation (Teo et al. 1995; Azim et 
al. 2000).  We investigated whether Rho-mediated Rho-kinase activation or Rac-mediated PAK 
activation stimulates LIMK-1.  We also analyzed whether LIMK-1 activation leads to cofilin 
phosphorylation, and whether a Rho-kinase/LIM-kinase/cofilin pathway might regulate the 
increase of F-actin underlying platelet shape change stimulated by thrombin.  LIMK-1 
phosphorylation was quantified using a specific anti-phospho-LIMK antibody.  
LIMK-1-Thr508 phosphorylation increased during shape change.  LIMK-1 phosphorylation was 
rapid and irreversible reaching a maximum (4-5 fold) within 1 minute of thrombin stimulation.  
The kinetic of LIMK-1 phosphorylation was similar to the kinetics of MYPT1 phosphorylation 
(Rho-kinase activation) except LIMK-1 phosphorylation was slightly slower than MYPT 
phosphorylation (compare with Figure 4.7).  In platelets pre-treated with the Rho-kinase inhibitor 
Y-27632, which does not affect the activity of PAK even at high concentrations (Uehata et al. 
1997), the increase in LIMK-1 phosphorylation was completely blocked.  These results show that 
the increase of LIMK-1 phosphorylation during shape change was completely Rho-kinase 
dependent (Figure 4.8). 
 
Figure 4.8 LIMK-1 and cofilin phosphorylation during platelet shape change induced by thrombin 
(0.075U/ml).  Graphical representation of the result for LIMK-1 (-■-) and cofilin (-▲-) phosphorylation. Values are 
presented as mean + SD of three experiments with platelets from different donors. 
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To investigate whether LIM-kinase activation might phosphorylate cofilin in thrombin–
stimulated platelets, cofilin phosphorylation was measured by using a specific anti-phospho 
cofilin antibody.  Unexpectedly, despite the rapid and pronounced Rho-kinase activation and 
subsequent LIMK-1 phosphorylation, we could not observe a concomitant increase in cofilin 
phosphorylation during shape change.  Cofilin phosphorylation during thrombin-induced platelet 
shape change was unchanged (Figure 4.8 and Figure 4.9A, upper immunoblots). 
Preincubation of platelets with Y-27632, which completely inhibited LIMK-1 phosphorylation, 
decreased cofilin phosphorylation by (20%) in resting platelets (Figure 4.9).  A gradual 
dephosphorylation of cofilin was noticed when platelets pretreated with Y-27632 were stimulated 
by thrombin (Figure 4.9B).  In thrombin-stimulated platelets, cofilin phosphorylation decreased 
from 76±10% to 54±12% of control after 2 minutes of stimulation.  These results suggest that 
cofilin dephosphorylation by a cofilin phosphatase might mask the concomitant stimulation of 
cofilin phosphorylation by LIMK-1 during thrombin-stimulated platelet shape change.  
 
 
Figure 4.9 Effect of Y-27632 on LIMK-1 and cofilin phosphorylation during shape change stimulated by 
thrombin.  Platelet lysates from platelets treated or non-treated with Y-27632 and then stimulated with thrombin 
(0.075U/ml) were immunoblotted with anti-phospho-LIMK-1/LIMK-2, anti-LIMK-1, anti-P-cofilin and anti-cofilin 
antibodies. (Left) Representative immunoblots. (Right) Bar diagram showing cofilin phosphorylation of non-treated 
(?) and Y-27632 (?) treated platelets in control and after thrombin stimulation (120 sec). Values for cofilin 
phosphorylation in resting platelets and activated platelets are mean + S.D of eight and four independent 
experiments, respectively. Asterisks (*) denote statistical significance P<0.05 with respect to control, not treated with 
Y-27632 (right). 
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4.2.6. Rapid association of cofilin with F-actin during shape change 
Since there was no net increase in the total phospho-cofilin pool during the shape change, where 
an increase of F-actin was observed, we wondered whether the association of active 
unphosphorylated cofilin with F-actin was changed. We thus analyzed the cofilin association with 
F-actin at different time intervals during shape change.  A method described by Kovacsovics and 
Hartwig (Kovacsovics and Hartwig 1996) was used for isolating F-actin with few modifications 
such as platelet lysis time, centrifugation speed and omission of phalloidin from the platelet lysis 
buffer. Platelets were lysed only for 5 minutes and not for 1 hour on ice to avoid changes after 
lysis such as depolymerization of F-actin (Carlsson et al. 1979).   
 
 
 
Figure 4.10 Effect of phalloidin and platelet lysis time on platelets F-actin content and cofilin association with 
F-actin.  The total F-actin from platelets lysed for 5min (upper) and 1hr (lower) in lysis buffer containing increasing 
concentration of phalloidin was isolated by centrifugation at 150,000x g for 30 minutes and subjected to actin 
staining by coomassie brilliant blue, or immunoblotting with anti-cofilin antibody. Values determined by 
densitometry are presented in percent of control by setting 100% for platelets lysed for 5 minutes and 0 µM 
phalloidin. 
A decrease of 30% in F-actin content was observed when incubation time for lysis was 1 hour 
compared to the lysis for 5 minutes (Figure 4.10).  Phalloidin was omitted from the lysis buffer, 
because it was found that the presence of phalloidin in the lysis buffer increased the formation of 
F-actin depending on the incubation time for platelet lysis (Figure 4.10).  After 5 minutes of lysis, 
phalloidin (9.1 µM) increased F-actin from 100% to 121%, whereas after 1 hour of lysis, the 
same concentration of phalloidin increased F-actin from 67% to 125 %.  This effect of phalloidin 
was concentration dependent.  It was found that by increasing the phalloidin concentration in the 
lysis buffer the associated cofilin was displaced proportionally from F-actin, and concentrations 
above 6 µM completely removed cofilin from the F-actin (Figure 4.10).  Phalloidin, although it 
binds to F-actin at a position different than cofilin, has been reported to inhibit the binding of 
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cofilin to actin (Yonezawa et al. 1988).  Once phalloidin is bound and has stabilized the F-actin, 
cofilin is no longer able to interact with F-actin (McGough et al. 1997).  Therefore we used for 
the experiments subsequently shown a lysis time of 5 minutes and omitted phalloidin from the 
lysis buffer. 
 
 
 
Figure 4.11  Cofilin association with F-actin during thrombin-induced platelet shape change.  (A, left, top) 
Representative gel and immunoblot of F-actin and cofilin, respectively. Total indicate whole  platelets; F-actin, F-
actin fraction of the same number of platelets. (Left, bottom) Immunoblot of cofilin associated with F-actin during 
thrombin induced shape change in the absence or presence of Y-27632. (Right) Graphic representation of the results. 
Values are the mean + S.D for four independent experiments. Asterisks (*) denote statistical significance P<0.05 
with respect to time 0 sec in nontreated samples. (B) Bar diagram showing the ratio of cofilin associated with F-actin 
to F-actin in non-treated platelets (?) and platelets treated with Y-27632 (?) during thrombin-induced shape 
change. Values are the mean + S.D for four independent experiments.  
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Cofilin only in its unphosphorylated form binds with F-actin while the phosphorylated cofilin 
does not (Lee et al. 2000).  We also found in platelets that cofilin only in its unphosphorylated 
form bound with F-actin, while the phosphorylated cofilin did not (data not shown).  A small 
amount of cofilin (about 8% of total) was bound with F-actin in non-activated platelets.  During 
shape change, we found a significant small increase of cofilin association with F-actin (to about 
13% of total).  However, cofilin relative to F-actin did not significantly increase as measured by 
the ratio of F-actin- associated cofilin with F-actin at various time points of shape change (Figure 
4.11B). Furthermore, pre-treatment of platelets with Y-27632 increased significantly the cofilin 
association with F-actin in resting platelets, and the subsequent increase during thrombin-
stimulation was not significant.  Y-27632 which resulted in cofilin dephosphorylation of 40% 2 
min after thrombin stimulation (Figure 4.9B), rather decreased than increased the association of 
cofilin with F-actin at this time point (Figure 4.11 A and B).  These results indicate that the F-
actin increase and the association of the small pool of cofilin with F-actin (5%) during shape 
change are regulated by a mechanism other than cofilin phosphorylation.  No association of 
LIMK-1 and phospho-LIMK-1 with the actin cytoskeleton could be detected in resting or 
activated platelets (data not shown). 
4.3. Platelet secretion and aggregation induced by thrombin 
4.3.1. Effect of Y-27632 on platelet secretion and aggregation 
Stimulation of platelets with thrombin (0.5 U/ml) induced rapid dense granule secretion and 
platelet aggregation (Figure 4.12).  Pretreatment of platelets with Y-27632 (20 µM) inhibited 
thrombin-induced secretion and platelet aggregation.  Y-27632 reduced platelet aggregation and 
made it partly reversible during platelet stimulation with 0.5 U/ml thrombin, but failed to inhibit 
aggregation induced by higher concentration (1.0 U/ml) of thrombin (data not shown).  ADP 
secreted from dense granule during platelet stimulation with the low concentration of thrombin 
might augment the thrombin response.  To answer, whether the Rho-kinase inhibitor Y-27632 
inhibits primarily secretion or whether it affects integrin αIIbβ3 activation leading to a reduced 
ATP secretion, the integrin αIIbβ3 antagonist RGDS was used to inhibit platelet aggregation.  
Prevention of platelet aggregation by RGDS did not inhibit the thrombin-induced ATP secretion 
suggesting that the outside-in signaling through integrin αIIbβ3 does not regulate dense granule 
secretion in thrombin-stimulated platelets.  
Interestingly, even in the presence of RGDS, Y-27632 inhibited ATP-secretion from platelet 
indicating that inhibition of aggregation by Y-27632 is due to inhibition of secretion and thereby 
attenuating platelet aggregation.  These results suggest a role of Rho-kinase in dense granule 
secretion from activated platelets. 
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Figure 4.12 Inhibition of thrombin-induced aggregation and secretion by the Rho-kinase inhibitor Y-27632. 
Platelets were stimulated with thrombin (0.5 U/ml) in the absence or presence of the integrin αIIbβ3 blocker RGDS 
(0.5 mM) and the Rho-kinase inhibitor Y-27632 (20 µM). Representative tracings for change in light transmission 
(LT, red)) and ATP secretion (blue) are shown.  
4.3.2. Rho-kinase activation (MYPT phosphorylation) 
Rho-kinase activation was determined by measuring the MYPT phosphorylation at its Thr696 
and Thr853 residues as described previously during thrombin-induced platelet shape change 
(section 4.2.4).  Estimation of MYPT phosphorylation at both sites (Thr696 and Thr853) gave 
identical results.  MYPT phosphorylation was rapid reaching a maximum (2-3 fold) 5 seconds 
after thrombin (0.5 U/ml) stimulation and then decreased to the level below control after 1-2 
minutes.  The peak of MYPT phosphorylation was similar as during thrombin-induced shape 
change.  The rapid increase of MYPT phosphorylation at both Thr696 (Figure 4.13) and Thr853 
(data not shown) was not only inhibited by Y-27362 (Figure 4.15), but also by the new specific 
Rho-kinase inhibitor H-1152 (20 µM; data not shown).  The reversible MYPT phosphorylation 
pattern during platelet aggregation was different from the irreversible time course of MYPT 
phosphorylation during shape change.  These differences might be explained by an aggregation-
dependent stimulation of dephosphorylation of MYPT phosphorylated at Thr696 and Thr853.  To 
investigate the role of outside-in signaling through integrin αIIbβ3 in regulating MYPT 
phosphorylation, RGDS was used or platelets were activated in the absence of stirring.  Under the 
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conditions, which blocked platelet aggregation but not secretion, MYPT phosphorylation was 
irreversible (Figure 4.13).  Therefore in thrombin-aggregated platelets, the rapid increase of 
MYPT phosphorylation is due activation of Rho-kinase, and the subsequent and pronounced 
decrease of MYPT phosphorylation is due to activation of a phosphatase acting on MYPT Thr696 
and Thr853 phosphorylation sites that is activated by engagement of the integrin αIIbβ3. 
 
 
Figure 4.13 Thrombin induced a reversible or irreversible MYPT phosphorylation during aggregation or 
secretion, respectively.  Platelet suspensions were not treated (stirring (-?-) and non-stirring (-Δ-) conditions) or 
treated with RGDS (0.5mM) (-?-) for 2 minutes before stimulation with thrombin (0.5 U/ml). (A) Thrombin-induced 
MYPT phosphorylation.  Platelet lysates were immunoblotted with anti-phospho-Thr696-MYPT antibody. Left, 
graphic representation of results. Values are mean + SD or mean – SD of 3 independent experiments.  Right, 
representative immunoblot of MYPT phosphorylation. 
4.3.3. LIMK-1 phosphorylation and activation 
4.3.3.1. LIMK-1 phosphorylation measured by immunoblotting 
During thrombin-induced platelet aggregation, LIMK-1 phosphorylation was rapid and 
irreversible and reached a maximum after 15 seconds of stimulation.  The increase of LIMK-1 
phosphorylation was higher during aggregation (13-fold) than during shape change (5-fold) 
induced by thrombin (compare Figure 4.14 and Figure 4.8).  To examine, whether outside-in 
signaling through integrin αIIbβ3 could affect LIMK-1 phosphorylation, LIMK-1 activation was 
measured in the presence of RGDS or by the absence of platelet stirring.  LIMK-1 
phosphorylation during aggregation was independent of integrin αIIbβ3 engagement, since the 
pattern of LIMK-1 phosphorylation was unchanged in the presence of RGDS or by the absence of 
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platelet stirring. The phosphorylation of LIMK-1 in thrombin-stimulated platelets was Rho-
kinase dependent, since it was completely inhibited by Y-27632 and H-1152 (Figure 4.15A and 
data not shown). 
 
 
 
Figure 4.14 LIMK-1 phosphorylation during thrombin (0.5U/ml) induced platelet secretion/aggregation. 
Platelet lysates were immunoblotted with anti-phospho-LIMK-1/LIMK-2 (Thr508/505) antibody. Left, graphic 
representation of LIMK-phosphorylation during aggregation. Right, representative immunoblots for LIMK-1 
phosphorylation in platelets non-treated (stirring and non-stirring conditions) and treated with RGDS. 
4.3.3.2. LIMK-1 activation 
In cell lines, it has been shown that LIMK-1 can be activated by upstream kinases like PAK or 
Rho-kinase after phosphorylating LIMK-1 at Thr508 in its kinase domain (Edwards et al. 1999; 
Ohashi et al. 2000).  To confirm that LIMK-1 phosphorylation reflects its activation, LIMK-1 
from platelets was immunoprecipitated, and in parallel analyzed for its phosphorylation and 
kinase activity.  Platelets were stimulated and lysed in the presence of RGDS to avoid platelet 
aggregation and thereby reducing the possibility of insufficient lysis and trapping of proteins in 
these platelet aggregates.  Immunoprecipitates of LIMK-1 were immunoblotted with anti-
phospho-LIMK antibody to observe the LIMK-1 phosphorylation. LIMK-1 phosphorylation was 
increased in platelets stimulated with thrombin (0.5 U/ml) for 2 minutes.  Y-27632 completely 
inhibited LIMK-1 phosphorylation in unstimulated platelets and did not show any increase of 
LIMK-1 phosphorylation after stimulation with thrombin (Figure 4.15B).  Immunoblotting the 
total lysates of the same samples also showed inhibition of MYPT phosphorylation (Rho-kinase 
activation) and LIMK-1 phosphorylation by Y-27632 (Figure 4.15A). 
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Figure 4.15 Inhibition of MYPT and LIMK-1 phosphorylation during thrombin-stimulated platelet 
secretion/aggregation.  A) Platelet samples stimulated by thrombin (0.5 U/ml) in the absence or presence of Y-
27632 (20 µM) were immunoblotted with anti-phospho-MYPT, anti-phospho-LIMK-1/LIMK-2 (Thr508/505) and 
anti-LIMK-1 antibodies. B) Immunoprecipitates from platelets non-treated or treated with Y-27632 and stimulated 
with thrombin for 2 minutes were immunoblotted with ant-LIMK-1 and anti-phospho-LIMKs antibodies. 
The LIMK-1 immunoprecipitates were also analyzed for their kinase activity using His-tagged 
cofilin as substrate.  LIMK-1 immunoprecipitates from thrombin-stimulated platelets showed an 
increase in cofilin phosphorylation (after 2 minutes) confirming that increase in LIMK-1 
phosphorylation reflects its increased kinase activity.  In Y-27632-treated platelets LIMK-1 
activity stimulated by thrombin was drastically reduced (Figure 4.16).  These results show that 
LIMK-1 phosphorylation correlates with its activity, which is regulated in a Rho-kinase 
dependent manner. 
 
 
Figure 4.16 Effect of the Rho-kinase inhibitor Y-27632 on LIMK-1 activity.  LIMK-1 immunoprecipitates were 
subjected for LIMK-1 kinase reaction using His-tagged cofilin as substrate. The Rho-kinase inhibitor Y-27632 
inhibited the LIMK-1 activity. 
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4.3.4. Reversible cofilin dephosphorylation during thrombin-induced secretion 
and aggregation 
Despite Rho-kinase and LIMK-1 activation, cofilin phosphorylation rapidly decreased after 
thrombin-stimulation of platelets.  The decrease of cofilin phosphorylation was about 60% 30 
seconds after thrombin addition, and was followed by slow rephosphorylation (Figure 4.17).  
Blocking of the integrin αIIbβ3 by RGDS or in the absence of stirring during stimulation with 
thrombin did not change the kinetics of cofilin de- and rephosphorylation (Figure 4.17), 
indicating that they are independent of integrin αIIbβ3 engagement.  Cofilin phosphorylation in 
thrombin-stimulated platelets might be regulated either by activation and then inactivation of a 
cofilin phosphatase or by activation of a cofilin phosphatase and subsequently LIMK-1, which 
mediates cofilin rephosphorylation. 
 
 
Figure 4.17 Thrombin-induced reversible dephosphorylation of cofilin is independent of integrin αIIbβ3 
engagement.  Platelets samples were not treated (stirring (-?-) and non-stirring (-Δ-) conditions) or treated with 
RGDS (0.5 mM) (-?-) for 2 minutes before stimulation with thrombin (0.5 U/ml).  Lysates of thrombin-stimulated 
platelets were immunoblotted with anti-phospho-cofilin and anti-cofilin antibodies. Left, graphical representation of 
results. Values are mean + SD or mean – SD of three independent experiments. Right, representative immunoblots 
for cofilin phosphorylation.  
4.3.5. Inhibition of cofilin rephosphorylation by Rho-kinase inhibitors 
The result of the rapid and sustained activation of Rho-kinase and LIMK1, but rapid decrease of 
cofilin phosphorylation raised the question concerning the role of these kinases in regulating 
cofilin phosphorylation.  Preincubation of platelets with Y-27632 and H-1152, which inhibited 
Rho-kinase and LIMK-1 activation did not inhibit the initial cofilin dephosphorylation suggesting 
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that dephosphorylation of cofilin is not regulated by Rho-kinase and LIMK-1.  These results 
indicate that cofilin phosphatase is activated independently of this pathway in thrombin-
stimulated platelets.  However, thrombin-induced cofilin rephosphorylation was completely 
inhibited by Y-27632 (Figure 4.18) and H-1152 (data not shown), which inhibit LIMK-1 
phosphorylation and LIMK-1 activity (Figure 4.16).  Hence, these results strongly suggest that in 
thrombin-stimulated platelets the Rho-kinase/LIMK-1 pathway mediates cofilin 
rephosphorylation. 
 
 
Figure 4.18 Inhibition of cofilin rephosphorylation by the Rho-kinase inhibitor Y-27632 during stimulation of 
platelets with thrombin (0.5U/ml). Lysates of thrombin-stimulated platelets in the absence (-?-) or presence of Y-
27632 (-?-) were immunoblotted with anti-P-cofilin and anti-cofilin antibodies and analyzed by densitometry. 
Graphic representation of the results with values presented in mean + SD of three independent experiments. Inset, 
representative immunoblots against anti-P-cofilin antibody. 
4.3.6. F-actin increase in thrombin-stimulated platelet secretion/aggregation 
Platelet aggregation and secretion induced by thrombin (0.5 U/ml) is associated with a different 
actin reorganization pattern as compared to shape change induced by low concentration of 
thrombin (0.075 U/ml).  The rapid activation of cofilin during stimulation of platelets with a high 
concentration of thrombin (0.5 U/ml) could modulate F-actin content differently leading to 
secretion and aggregation.  The changes in F-actin content of unstimulated and stimulated 
platelets were analyzed in the presence of RGDS, which does not affect the kinetics of cofilin de- 
and rephosphorylation (Figure 4.17), to avoid possible artifacts described in section 4.3.3.2.  The 
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increase in F-actin was higher during platelet secretion as compared to shape change: F-actin 
increased from 34±1% in resting platelets to 56±5% of total 30sec after addition of thrombin 
(Figure 4.19).  These results suggest that the rapid cofilin dephosphorylation (maximum at 30sec) 
generating more active cofilin increases F-actin during platelet secretion.  However, the F-actin 
increase was irreversible and was not reduced during cofilin rephosphorylation 2 minutes after 
thrombin-stimulation.  Pretreatment of platelets with Y-27632 increased the total F-actin in 
resting platelets, reduced the increase after thrombin-activation, and made the F-actin increase 
reversible (Figure 4.19).  Inhibition of cofilin rephosphorylation by Y-27632 might destabilize F-
actin at 60 and 120 minutes of thrombin-stimulation.  Thus, these results indicate that a Rho-
kinase dependent pathway is involved in F-actin increase in thrombin-stimulated platelets. 
 
 
 
Figure 4.19 Inhibition of F-actin increase by Y-27632 during thrombin-induced platelet secretion. Platelets 
treated with H2O (?) or Y-27632 (?) were stimulated with thrombin (0.5 U/ml) in the presence of the integrin αIIbβ3 
blocker RGDS (0.5 mM) and lysed with 1% TritonX-100 for isolation of F-actin. F-actin and cofilin associated with 
F-actin (% of total) were measured. The result is presented in bar diagram. Values are the mean + S.D for four 
independent experiments. Asterisks (*) denote statistical significance P<0.05 with respect to non-treated samples at 
time 0 seconds, and (†) denotes significance between control (?) and Y-27632 (?) treated platelets. 
4.3.7. Cofilin association with F-actin 
Since cofilin was rapidly dephosphorylated during platelet secretion (in the absence or presence 
of aggregation), we wondered, whether the association of cofilin with F-actin was increased.  
Cofilin association with the total F-actin pool increased from 8±2% in resting platelets to 29±5% 
(Figure 4.20A).  This increase was a net increase because the ratio of F-actin-associated cofilin 
relative to F-actin increased 3-fold from 0.23 in resting platelets to 0.64 30 seconds after addition 
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of thrombin (Figure 4.20B).  These results suggest that the rapid cofilin dephosphorylation 
(maximum at 30 seconds) generating more active cofilin enhances its association with F-actin.  
Since at the same time, platelet F-actin content also increased (about 1.7 fold) after addition of 
thrombin it appears that cofilin association with F-actin might regulate F-actin increase during 
platelet secretion (Figure 4.19 and Figure 4.20).  Cofilin remained associated with F-actin 60 and 
120 seconds after thrombin stimulation, indicating that LIMK-1-mediated cofilin 
rephosphorylation did not cause cofilin dissociation from F-actin.  Inhibition of Rho-
kinase/LIMK-1 lead to a reduced F-actin increase at 30 seconds, did not reduce the rapid cofilin 
dephosphorylation and cofilin association with F-actin during the first 30 seconds, and reversed 
the increase of F-actin and the cofilin association with F-actin.  These results indicate that Rho-
kinase regulates the F-actin increase during platelet secretion through a mechanism other than 
cofilin phosphorylation and association with F-actin. 
 
 
 
Figure 4.20 Association of cofilin with F-actin during thrombin-induced secretion.  The total F-actin isolated 
from platelets pretreated with RGDS in the absence or presence of Y-27632 and stimulated with thrombin (0.5 U/ml) 
were immunoblotted with the anti-cofilin antibody. A) Top, representative immunoblots. Bottom, bar diagram 
showing association of cofilin with F-actin. B) Bar diagram for the ratio of F-actin-associated cofilin to F-actin. 
Values are mean + SD of 4 independent experiments. Asterisks (*) denote statistical significance P<0.05 with respect 
to nonstimulated samples at 0 seconds, and (†) denotes significance between control (?) and Y-27632 (?) treated 
platelets. 
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4.4. Platelet shape change induced by LPA 
4.4.1. LPA-stimulated platelet shape change and actin polymerization are 
Rho-kinase dependent  
LPA at low concentrations (10–100 nM) induces platelet shape change without any increase in 
the cytosolic Ca2+ concentration (Retzer and Essler 2000).  Washed platelets were stimulated with 
low concentrations of LPA (0.1 µM) to induce platelet shape change selectively without inducing 
platelet secretion or aggregation.  LPA induced a rapid and reversible platelet shape change with 
a maximum at 15 seconds after stimulation (Figure 4.21).  As previously observed, we also found 
that LPA-induced shape change is mediated by through the Rho/Rho-kinase pathway (Retzer and 
Essler 2000), since Y-27632 (20 µM) completely inhibited LPA-induced shape change.  
Latrunculin-A (10 µM), a small molecule that binds to the monomeric actin thereby facilitating 
actin cytoskeleton disassembly and inhibiting actin polymerization (Spector et al. 1999), 
completely blocked the LPA-induced shape change indicating that actin polymerization is 
required for shape change. 
 
 
Figure 4.21 LPA-induced shape change is Rho-kinase dependent and requires actin polymerization. A) Shape 
change studied by the decrease in light transmission. Platelets pre-incubated with H20, Y-27632, and latrunculin-A 
(Lat-A), were stimulated with LPA (0.1 µM). B) Shape change studied by the changes in FSC/SSC ratio using flow 
cytometry. The FSC/SSC ratio of unstimulated platelets not treated with Y-27632 was set to 100%. Values are mean 
+ SD of three independent experiments. 
Shape change was also measured by estimating the change in light scattering properties of 
platelets using flow cytometry.  During platelet shape change, the mean forward scattering (FSC) 
of light increases while the mean side scattering (SSC) of light decreases and hence, the ratio of 
FSC/SSC increases proportionally to the platelet shape change (Ruf and Patscheke 1995).  LPA-
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induced platelet shape change measured by flow cytometry correlated well with shape change 
measured by light transmission of the same samples (Figure 4.21 A and B).  Preincubation of 
platelets with Y-27632 (Figure 4.21B) as well as latrunculin-A (data not shown) inhibited the 
LPA-induced increase of FSC/SSC ratio confirming the study made by the turbidimetric method. 
We investigate, whether F-actin increased during LPA-induced shape change.  During shape 
change, LPA induced a reversible F-actin increase with a maximum at 15 seconds after 
stimulation.  Preincubation of platelets with Y-27632 inhibited the F-actin increase induced by 
LPA (Figure 4.22).  This suggests that the activation of Rho-kinase might be involved in 
regulation of actin polymerization underlying platelet shape change.  Interestingly, Y-27632 
increased the F-actin content significantly in unstimulated platelets. 
 
 
Figure 4.22 The Rho-kinase inhibitor Y-27632 inhibited the actin polymerization in LPA-stimulated platelets. 
F-actin content was quantified by Alexa Fluor 546 phalloidin binding. Values are mean + S.D of 4 independent 
experiments. Asterisks (*) denote statistical significance P<0.05 between untreated (?) and Y-27632-treated (?) 
platelets. 
4.4.2. Activation of Rho-kinase during LPA-induced shape change 
LPA induced a rapid (maximum after 5 seconds) and reversible increase of MYPT 
phosphorylation at Thr696 (4-5 fold) and Thr853 (4-5 fold) during shape change (Figure 4.23, 
and data not shown).  The rapid and reversible MYPT phosphorylation was Rho-kinase 
dependent.  The specific Rho-kinase inhibitors Y-27632 and H-1152 (20 µM) completely 
abolished the LPA-induced increase of MYPT phosphorylation (Figure 4.23, inset and data not 
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shown).  The rapid activation of Rho-kinase (5 seconds) preceded the maximum increase of F-
actin content (15 seconds) during shape change.  Together, these results indicate that LPA-
induced Rho-kinase activation is upstream of and mediates the F-actin increase underlying shape 
change.  
 
 
 
Figure 4.23 MYPT phosphorylation during LPA induced platelet shape change. Platelet lysates were 
immunoblotted with anti-phospho-MYPT antibody. Graphic representation of the result of MYPT phosphorylation in 
the absence (-?-) and presence (-?-) of Y-27632 evaluated by densitometry. Values are presented in mean + S.D, 
n=3. Inset, representative western blot of MYPT phosphorylation in the absence and presence of Y-27632. 
4.4.3. Regulation of LIMK-1 and cofilin phosphorylation during shape change 
To analyze, how Rho-kinase activation regulates the increase of F-actin in LPA-stimulated 
platelets, the activation of LIMK-1 known to phosphorylate and inactivate cofilin was analyzed.  
During LPA-induced shape change, a rapid and reversible LIMK-1 phosphorylation was 
observed.  LIMK-1 phosphorylation reached a maximum (5-fold) after 5 seconds and then 
decreased to the resting level after 2 minutes of platelet stimulation (Figure 4.24A).  The kinetics 
of MYPT phosphorylation and LIMK-1 phosphorylation induced by LPA were similar, rapid and 
reversible.  This observation suggests that Rho-kinase mediates phosphorylation of LIMK-1 
during LPA-induced shape change.  LIMK-1 phosphorylation was completely abolished in the 
presence of Rho-kinase inhibitors Y-27632 and H-1152 (Figure 4.24B and data not shown), 
indicating that Rho-kinase is upstream of LIMK-1 and is responsible for LIMK-1 
phosphorylation during shape change. 
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Figure 4.24 Rho-kinase dependent LIMK-1 phosphorylation but no subsequent cofilin phosphorylation during 
LPA-induced platelet shape change. A) LIMK-1 and cofilin phosphorylation during platelet shape change. Left, 
graphical representation of the result for LIMK-1 (-■-) and cofilin (-▲-) phosphorylation. Values are mean+SD for 
LIMK-1; n=3 and cofilin; n=3. Right, Representative immunoblots for LIMK-1 and cofilin in their unphosphorylated 
and phosphorylated states. B) Effect of Y-27632 on LIMK-1 and cofilin phosphorylation. Left, Cofilin 
dephosphorylation in the presence of Y-27632 in resting and LPA-stimulated platelet shape change Right, 
Representative immunoblots Asterisks (*) denote statistical significance P<0.05 between untreated (?) and Y-
27632-treated (?) platelets..  
During shape change, in spite of LIMK-1 activation, we could not observe a concomitant increase 
in cofilin phosphorylation (Figure 4.24A).  Preincubation of platelets with Y-27632 decreased 
cofilin phosphorylation in resting platelets.  Interestingly, a further significant decrease of cofilin 
phosphorylation (P<0.05) was observed in Y-27632 treated platelets 5 and 120 seconds after LPA 
stimulation (Figure 4.24B).  These results suggested that cofilin dephosphorylation by a cofilin 
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phosphatase occurs during shape change which is masked by the concomitant stimulation of 
cofilin phosphorylation due to Rho-kinase/LIMK-1 activation.  Thus, increased phospho-cycling 
of cofilin during LPA-induced shape change might occur reflecting an accelerated shuttling of 
this protein between its inactive and active forms. 
4.4.4. LPA-induced PAK phosphorylation does not regulate LIMK-1 
activation during shape change. 
LIMK-1 could also be phosphorylated and activated by Rac-activated PAK (Edwards et al. 
1999).  To examine whether PAK is activated during LPA-induced shape change, the specific 
phospho-PAK1/2 (Thr423/Thr402) antibody was used.  A significant increase of PAK 
phosphorylation was observed only at 30 seconds after platelet stimulation with LPA (0.1 µM).  
The kinetic of PAK phosphorylation was much slower (Figure 4.25) than LIMK-1 
phosphorylation (Figure 4.24A) indicating that PAK1/2 is unlikely to be involved in 
phosphorylating LIMK-1 during LPA-induced shape change.  In the presence of Y-27632, LPA-
stimulated PAK phosphorylation was, albeit but not significantly, reduced (Figure 4.25) 
indicating that Rho-kinase might be involved in PAK1/2 phosphorylation. 
 
 
Figure 4.25 PAK-1/2 phosphorylation during LPA-induced shape change.  Left, bar diagram showing PAK 
phosphorylation during LPA-stimulation of platelets untreated with (-?-) and treated with Y-27632 (-?-).  Asterisk 
denotes statistical significance P<0.05 with respect to non-treated control (mean + S.D, n=4).  Right, representative 
immunoblots showing non-significant reduction of PAK phosphorylation by the Rho-kinase inhibitor Y-27632 (20 
µM) during shape change induced by LPA (0.1 µM). 
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4.4.5. LPA induced a rapid association of cofilin with actin cytoskeleton 
It is known that active, unphosphorylated cofilin binds to the actin cytoskeleton, while the 
phosphorylated cofilin does not (Lee et al. 2000).  Because cofilin net phosphorylation during 
LPA-induced shape was not increased, we explored the possibility that cofilin might associate 
with the F-actin cytoskeleton during shape change.  The actin cytoskeleton of unstimulated and 
LPA-stimulated platelets was isolated and immunoblotted with anti-cofilin antibody.  In resting 
platelets 10±4 % (mean±SD, n=4) of total cofilin was associated with the actin cytoskeleton.  
LPA stimulation of platelets induced a rapid and reversible increase of cofilin in the actin 
cytoskeleton (Figure 4.26).  Cofilin association was maximal 2-fold already at 5 seconds after 
stimulation, and then decreased after 1 min below the level of resting platelets (50% of control).  
In contrast, the increase of F-actin in the platelet cytoskeleton was maximal at 15 seconds after 
stimulation (136 ± 12%) and showed a slow decline thereafter (117 ± 6%, after 2 minutes).  No 
association of phospho-cofilin, LIMK-1 and phospho-LIMK-1 with the actin cytoskeleton could 
be detected in resting or LPA-stimulated platelets (data not shown). 
 
 
Figure 4.26 Rapid association of cofilin with the actin cytoskeleton during platelet shape change.  Samples of 
actin cytoskeleton isolated from platelets stimulated with LPA (0.1 µM) for various times were immunoblotted with 
anti-actin and anti-cofilin antibodies. Amount of protein association with actin cytoskeleton was determined 
densitometrically. Values are mean ± SD (n = 4) with respect to control. PL, whole platelet lysate. 
4.5. LPA-mediated platelet secretion and aggregation 
4.5.1. Platelet secretion and aggregation studied in Lumi-aggregometer 
LPA at higher concentrations and in the presence of fibrinogen induces aggregation of washed 
platelets.  The LPA-mediated platelet aggregation is the result of synergism between LPA and 
secreted ADP during platelet activation (Haseruck et al. 2004).  Unlike platelet suspensions 
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prepared for analyzing LPA-stimulated platelet shape change, washed platelets were prepared to 
observe LPA-induced aggregation using a method described by Cazenave et al (Cazenave JP 
1993). This method was modified such as omission of heparin from the first wash buffer and the 
use of 0.1% albumin instead of 0.35% concentration in the final suspension (see method).  LPA 
(10 µM) alone induced platelet shape change, but no secretion of ATP and aggregation (Figure 
4.27).  However, when platelets were stimulated with LPA in the presence of fibrinogen (0.5 
µg/ml) they secreted ATP and underwent aggregation (Figure 4.27).  LPA induced platelet 
aggregation was reversible or irreversible depending on the extent of ATP secreted from the 
stimulated platelets (data not shown).  Preincubation of platelets with Y-27632 completely 
blocked the LPA-induced dense granule secretion and inhibited platelet aggregation (Figure 
4.27). These results indicate that the inhibition of LPA-mediated platelet aggregation is largely 
due to inhibition of dense granule secretion from stimulated platelets, which is mediated by Rho-
kinase activation.  Based on these results we concluded that Rho-kinase mediated signaling 
pathways might be upstream of secretion and subsequently, aggregation. 
 
 
Figure 4.27 Inhibition of dense granule secretion and platelet aggregation by Y-27632.  Platelets were 
stimulated with LPA (10 µM) in the absence and presence of fibrinogen (0.5 mg/ml) and the Rho-kinase inhibitor Y-
27632 (20 µM).  Representative tracings for change in light transmission (red) and ATP secretion (blue) by LPA. 
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4.5.2. MYPT phosphorylation during LPA-stimulated platelet secretion and 
aggregation 
MYPT phosphorylation at Thr853 was measured to analyze Rho-kinase activation during LPA-
stimulated platelet secretion and aggregation.  LPA (10 µM) in the absence of fibrinogen induced 
a rapid and partly reversible MYPT phosphorylation (Figure 4.28).  MYPT phosphorylation 
increased to a maximum of 3-fold after 5 seconds and then slowly decreased to 2 fold after 2 
minutes of platelet stimulation.  Platelets stimulated with LPA in the presence of fibrinogen 
showed similar kinetics for MYPT phosphorylation (data not shown).  This result indicates that 
Rho-kinase activation is upstream and independent of dense granule secretion and integrin αIIbβ3 
involvement.  MYPT phosphorylation at Thr853 was Rho-kinase dependent since Y-27632 
reduced the MYPT phosphorylation in non-activated platelets and further inhibited its increase 
during platelet secretion/aggregation induced by LPA (Figure 4.28).  
 
 
 
Figure 4.28 MYPT phosphorylation in LPA-stimulated secretion/aggregation.  Platelets stimulated with LPA 
(10µM) were immunoblotted with anti-phospho-MYPT and analyzed using densitometry.  Values are mean + SD of 
three independent experiments. Inset, representative immunoblots showing MYPT phosphorylation in LPA-
stimulated platelets in the absence or presence of Y-27632. 
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4.5.3. Regulation of LPA-induced cofilin de-and rephosphorylation  
Washed platelets used to study LPA-mediated platelet secretion/aggregation were resuspended in 
a buffer containing 0.1% BSA.  BSA of molecular mass 68-kDa co-migrated electrophoretically 
with LIMK-1 (72-kDa) and masked the detection of LIMK-1 in platelets by immunoblot and 
immunoprecipitation.  Therefore we could not measure LIMK-1 activation under these conditions 
of LPA (10 µM)-induced secretion/aggregation (data not shown).  
We observed that after platelet stimulation with 10 µM LPA, cofilin was rapidly 
dephosphorylated with a maximum at 60 seconds and then slowly rephosphorylated to the level 
of resting platelets (Figure 4.29).  This finding was similar to the one we observed for platelets 
stimulated with thrombin (0.5 U/ml).  Cofilin de- and rephosphorylation showed similar kinetics 
in the absence and presence of fibrinogen indicating that the kinetics of cofilin phosphorylation is 
independent of integrin αIIbβ3 engagement as well as of dense granule secretion.  Y-27632 
inhibited the cofilin rephosphorylation completely indicating that the Rho-kinase/LIMK-1 
pathway mediates cofilin rephosphorylation and might be involved in regulating LPA-stimulated 
secretion/aggregation. 
 
 
Figure 4.29  LPA (10 µM) induced cofilin de- and rephosphorylation in platelets is independent of secretion 
and aggregation. Cofilin rephosphorylation is inhibited by Y-27632.  Graphic representation of the results of cofilin 
phosphorylation after platelet stimulation with LPA in the presence (-▲-) and absence (-■-) of fibrinogen, and 
inhibition of cofilin rephosphorylation in Y-27632-treated (-□-) platelets. Values are mean + S.D for three 
independent experiments. 
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4.6. Signaling for cofilin dephosphorylation 
4.6.1. Effect of phosphatase inhibitors on cofilin dephosphorylation 
To explore which type of phosphatase is responsible for cofilin dephosphorylation, we tested the 
broad-spectrum protein phosphatase inhibitor sodium orthovanadate Na3VO4, and the PP1/PP2A 
type specific phosphatase inhibitor okadaic acid.  Pretreatment of platelets with Na3VO4 (1 µM) 
and okadaic acid (0.75 µM) inhibited thrombin-induced platelet aggregation (data not shown).  In 
the presence of Na3VO4, cofilin dephosphorylation was completely inhibited but no increase of 
cofilin phosphorylation in resting and platelets stimulated with thrombin was observed.  As 
vanadate is known to inhibit non-specifically ATPases and kinases, inhibition of cofilin 
dephosphorylation might be due to in fact inhibition of Rho-kinase/LIMK-1 pathway.  In the 
presence of okadaic acid, thrombin-induced initial cofilin dephosphorylation was not affected, 
but surprisingly the subsequent cofilin rephosphorylation was completely blocked.  These results 
indicate that cofilin phosphatase present in platelets is different from the conventional PP1/PP2A 
type phosphatase.  The inhibition of cofilin rephosphorylation by okadaic acid was similar to that 
we found in the presence of Rho-kinase inhibitors Y-27632 and H-1152 (compare Figure 4.30 
and Figure 4.18).  These results led us to investigate, whether okadaic acid might inhibit the Rho-
kinase-mediated LIMK-1 activation. 
 
Figure 4.30 Effect of phosphatase inhibitors on cofilin dephosphorylation during platelet stimulation by 
thrombin (0.5U/ml).  Lysates of platelets not treated (■) or pretreated with Na3VO4 (∆) and okadaic acid (OA, □), 
and then stimulated by thrombin were immunoblotted with anti-cofilin and anti-phospho-cofilin antibodies. Left, 
graphical representation of the results, values are mean +SD or mean – SD of three independent experiments. Right, 
representative immunoblots for cofilin phosphorylation. 
Results 
 
88
To examine the effect of okadaic acid on LIMK-1 activation, LIMK-1 immunoprecipitates from 
platelets non-treated or treated with okadaic acid and then stimulated with thrombin for 2 minutes 
were analyzed for LIMK-1 phosphorylation and LIMK-1 kinase activity.  Unlike Y-27632-
treated platelets, pretreatment of platelets with okadaic acid did not decrease, but increased the 
phosphorylation of LIMK-1 immunoprecipitates (Figure 4.31, left).  These results suggest that 
okadaic acid might lead to an inhibition of LIMK-1 phosphatase resulting in a further increase of 
LIMK-1 phosphorylation.  LIMK-1 immunoprecipitates from okadaic acid-treated platelets 
showed an increased phosphorylation of His-tagged cofilin when assayed for kinase reaction.  
Cofilin phosphorylation by LIMK-1 immunoprecipitates was proportional to the extent of LIMK-
1 phosphorylation.  These results indicate that inhibition of cofilin rephosphorylation by okadaic 
acid was not due to the inhibition of LIMK-1 activity.  Cofilin phosphatase is not a PP1/PP2A 
type phosphatase and an okadaic acid sensitive PP1/PP2A type phosphatase might be involved in 
regulating the cofilin phosphatase negatively in thrombin-stimulated platelets (Figure 4.31). 
 
 
Figure 4.31 Effect of okadaic acid (OA) on LIMK-1 phosphorylation and kinase activity in thrombin-
stimulated platelets.  Left, immunoprecipitates from platelets non-treated or treated with OA and stimulated with 
thrombin for 2 minutes were immunoblotted with anti-LIMK-1 and anti-phospho-LIMKs antibodies.  Right, LIMK-1 
immunoprecipitates were subjected for LIMK-1 kinase reaction using His-tagged cofilin as substrate.  Anti-cofilin 
and anti-phospho-cofilin antibodies were used to measure cofilin phosphorylation.  The PP1/PP2A type phosphatase 
inhibitor OA augmented the LIMK-1 activity. 
4.6.2. Inhibition of cofilin dephosphorylation by calcineurin inhibitor 
Various phosphatases act in a calcium dependent manner.  Many studies showed that an increase 
in sub-cellular Ca2+ concentration induces cofilin dephosphorylation in cells (Davidson and 
Haslam 1994; Wang et al. 2005).  Therefore, we studied whether calcineurin, a calcium-
dependent phosphatase, is involved in regulating cofilin dephosphorylation in thrombin-
stimulated platelets.  A cell-permeable peptide composed of the calcineurin (CaN) auto inhibitory 
domain (AID) fused with a poly-arginine-based protein transduction domain (11R) (CAID) was 
used inhibit calcineurin.  Preincubation of platelets with CAID-peptide (20 µM) blocked 
thrombin-induced platelet aggregation (data not shown).  The CAID-peptide also completely 
inhibited thrombin-induced cofilin dephosphorylation (Figure 4.32).  A peptide inhibitor of 
nuclear factor of activated T-cells (NFAT) fused with poly-arginine (11R) was used as a negative 
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control for CAID-peptide.  NFAT-peptide neither affected platelet aggregation nor the cofilin de- 
and rephosphorylation during platelets stimulation with thrombin (data not shown).  These results 
indicate that calcineurin or intracellular Ca2+ release might be involved in facilitating the initial 
cofilin dephosphorylation in thrombin-stimulated platelets.   
 
Figure 4.32 Effect of CAID on cofilin dephosphorylation in thrombin-stimulated platelets.  Platelet samples not 
treated (-■-) or pretreated with CAID (20 µM) (-□-) and stimulated with thrombin (0.5 U/ml) were immunoblotted 
with anti-cofilin and anti-phospho-cofilin antibodies. Left, graphical representation of the results. Values are mean + 
SD or mean – SD of three independent experiments. Right, representative immunoblots for cofilin phosphorylation. 
4.6.3. Inhibition of LPA-induced cofilin dephosphorylation by BAPTA-AM 
Since cofilin dephosphorylation induced by thrombin was inhibited by CAID peptide, which 
inhibits Ca2+-dependent calcineurin activation, we speculate that LPA-induced cofilin 
dephosphorylation might be due to increase in cytosolic Ca2+ after LPA stimulation.  In LPA-
stimulated platelets, cofilin dephosphorylation was observed only with 100-times higher 
concentration of LPA.  At these high concentrations LPA increases the cytosolic Ca2+ 
concentration mainly through Ca2+ influx across the plasma membrane (Maschberger et al. 2000; 
Rother et al. 2003). In order to investigate whether an increase of cytosolic Ca2+ could mediate 
the rapid dephosphorylation of cofilin, platelets were pre-treated with the intracellular Ca2+ 
chelator BAPTA-AM, which blocks the cytosolic Ca2+ increase in activated platelets, as 
described previously (Bauer et al. 1999).  BAPTA-AM (20 µM) inhibited ATP secretion, and 
blocked the aggregation and cofilin dephosphorylation in LPA-stimulated platelets indicating that 
a Ca2+-dependent phosphatase might be involved in dephosphorylating cofilin, which in turn 
might regulate secretion and aggregation (Figure 4.33). 
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Figure 4.33 Inhibition of LPA (10µM)-induced secretion, aggregation and cofilin dephosphorylation by 
BAPTA-AM.  (A) Tracings for light transmission (red) and ATP secretion (blue) of LPA-stimulated platelet 
aggregation and dense granule secretion in the presence of DMSO (0.1%, control) or BAPTA-AM (20 µM), 
respectively.  (B) Graphical representation of the results of cofilin phosphorylation after platelet stimulation with 
LPA in the absence (-?-) and presence (-?-) of BAPTA-AM.  Values for cofilin phosphorylation are mean + S.D of 
three independent experiments. Inset, representative immunoblots showing inhibition of LPA-induced cofilin 
dephosphorylation by BAPTA-AM.  
4.6.4. Inhibition of cofilin dephosphorylation by PI3-kinase inhibitor  
A recent study showed that PI3-kinase is involved in the regulation of slingshot (a cofilin 
phosphatase) activation in insulin-stimulated cells (Nishita et al. 2004).  In order to analyze the 
role of PI3-kinase in regulating cofilin dephosphorylation, an irreversible inhibitor of PI3-kinase, 
wortmannin, was used.  Wortmannin, which is a fungal metabolite, acts as a potent, selective and 
cell-permeable inhibitor for PI3-kinase without affecting the upstream signaling events.  
Pretreatment of platelets with wortmannin (50 nM) resulted in a reduced and reversible 
aggregation of platelets stimulated with thrombin.  Wortmannin (50 nM) blocked PI3-kinase 
completely as measured by the inhibition of Akt phosphorylation at Ser473 (data not shown).  
The initial cofilin dephosphorylation in thrombin-stimulated platelet was inhibited in the presence 
of wortmannin indicating that PI3-kinase might be involved in regulating the activity of cofilin 
phosphatase (Figure 4.34).  We also analyzed the role of Akt kinase, which is activated 
downstream of PI3-kinase, for cofilin dephosphorylation induced by thrombin.  We pretreated 
platelets with Akt inhibitors (Akt inhibitor IV and Triciribine, 20 µM each) and then stimulated 
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with thrombin.  These inhibitors blocked the Akt activation as measured by the inhibition of 
phosphorylation of its substrate, glucose synthase kinase (GSK), at Ser21.  However, inhibition 
of Akt did not block the thrombin-induced cofilin dephosphorylation (data not shown).  
Therefore, it seems that PI3-kinase mediated cofilin dephosphorylation does not involve the PI3-
kinase/Akt pathway.   
 
 
Figure 4.34 Effect of wortmannin on platelet aggregation and cofilin dephosphorylation induced by thrombin.  
Platelet samples not treated (-■-) or pretreated with wortmannin (50 nM) (-□-) and stimulated with thrombin (0.5 
U/ml). Left, light transmission tracings showing platelet aggregation. Right top, representative immunoblots blotted 
with anti-phospho-cofilin antibody. Right bottom, graphical representation of the results.  Values are mean + SD or 
mean – SD of three independent experiments. 
4.7. Peptide or protein transfection into platelets 
4.7.1. Poly-arginine based peptide transfection 
A peptide with consecutive nine L-arginine residues (R9) can be efficiently taken up into the cells 
(Wender et al. 2000).  In order to inhibit LIMK-1 mediated cofilin phosphorylation in platelets, a 
peptide corresponding to the N-terminal of cofilin containing the Ser3 (underlined) 
phosphorylation site (MASGVAVSDGVIKVFN) and coupled to R9 peptide at its C-terminal was 
synthesized.  In a similar manner, the reverse peptide (NFVKIVGDSVAVGSAM) and the 
pseudo-phosphorylated peptide (Ser3 replaced by Asp, MADGVAVSDGVIKVFN) were 
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synthesized and used as control peptides.  Incubation of platelets with these R9-peptides (80 µM) 
did not change the phosphorylation level of cofilin (data not shown). These results indicate that 
either the R9-peptides did not penetrate the platelets or they did not reached the site of action of 
LIMK-1 inside the platelets. 
4.7.2. Protein transfection by ChariotTM 
ChariotTM is a commercial transfection reagent that efficiently transports biologically active 
proteins, peptides and antibodies directly into cultured mammalian cells (Morris et al. 2001).  In 
order to standardize and observe the protein transfection by ChariotTM into platelets, His-tagged 
cofilin coupled to the green fluorescent protein (GFP) at its C-terminal was subcloned, expressed 
and purified, and used for transfection.  Incubation of cofilin-GFP-ChariotTM mixture with 
platelet suspension successfully transferred cofilin-GFP into platelets as observed by confocal 
microscopy of spread platelets.  Cofilin-GFP was present as clusters, and not evenly distributed in 
the spread platelets (Figure 4.35).  Although this method for proteins transfection into platelets 
needs further standardization, it seems to be a good tool to transfer proteins into platelets, which 
is otherwise difficult to perform using the existing transfection methods.  
 
       
Alexa 546-phalloidin  GFP-cofilin   Merge 
 
Figure 4.35 Transfection of GFP-cofilin into platelets using ChariotTM protein/peptide transfection reagent.  
GFP-cofilin transfected platelets were allowed to spread for 15 minutes on glass cover slip and then probed with 
Alexa 546 phalloidin to stain F-actin. Right, F-actin staining with Alexa-546 phalloidin. Middle, GFP-cofilin 
fluorescence. Left, merge of Alexa-546 phalloidin and GFP-cofilin fluorescence. 
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5. Discussion 
5.1. Role of Rho-kinase in activated platelets 
The alteration of the actin cytoskeleton leads to morphological changes underlying the different 
platelet responses, i.e., shape change, secretion of granule contents and aggregation.  Members of 
the Rho family GTPases such as Rho, Rac, and Cdc42 are involved in reorganizing the actin 
cytoskeleton during platelet activation.  However, the downstream signaling pathways regulating 
the reorganization of the actin cytoskeleton through these Rho family GTPases in activated 
platelets have only been partially characterized. In this study, the role of Rho-kinase in regulating 
LIMK-1 activity and cofilin phosphorylation leading to changes in the actin cytoskeleton during 
shape change, secretion and aggregation was studied using functional and biochemical 
approaches. 
Along with the classical turbidimetric method for measuring platelet shape change and 
aggregation, shape change was also monitored by two other methods, flow cytometry and 
microscopy.  The microscopic analysis of platelets immunostained for F-actin showed that the 
discoid platelets with a smooth surface got transformed into spheroid cells with an irregular 
surface after activation.  The spheroid form and irregularity of the platelet surface during shape 
change result in changes in the light scattering properties of platelets.  The analysis of platelets by 
flow cytometry showed that activated platelets scattered more light in forward direction (FSC) 
and less in perpendicular (SSC) to the incident light (see method section 3.4.1).  Thus, the ratio of 
FSC/SSC increased proportionally to the extent of platelet shape change.  The flow cytometry 
method can also be applied to easily measure platelet shape change in whole blood (Haseruck et 
al. 2004).  Pre-treatment of platelets with the specific Rho-kinase inhibitor Y-27632 blocked the 
platelet shape change in blood (Haseruck et al. 2004) and also the shape change of washed 
platelets monitored by all three methods (present thesis) indicating that the activation of Rho-
kinase is important for platelet shape change. 
5.1.1. Activation of Rho-kinase 
Rho-kinase activation is known to augment MLC phosphorylation directly or indirectly by 
phosphorylating the MYPT and thereby inhibiting myosin phosphatase activity.  Taking this into 
consideration, the activation of Rho-kinase in platelets was measured using a new approach, i.e. 
by quantifying the phosphorylation of the substrate MYPT on Thr696 or Thr853 (Ito et al. 2004).  
During shape change induced by LPA as well as by low concentration of thrombin, a rapid 
phosphorylation of MYPT at Thr696 and Thr853 was observed.  Phosphorylation of these Rho-
kinase-targeted sites were inhibited by specific inhibitors of Rho-kinase, Y-27632 and H-1152, 
confirming and extending previous results that Rho-kinase activation mediates Ca2+-independent 
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shape change induced by thrombin and LPA (Bauer et al. 1999; Retzer and Essler 2000).  The 
kinetics of MYPT phosphorylation was similar during platelet stimulation with low (0. 1µM) as 
well as high (10 µM) concentrations of LPA (both in the presence and absence of fibrinogen), 
except that the extent of MYPT phosphorylation with 0.1 µM LPA was comparatively higher 
than with 10 µM LPA.  Probably, this reduction is caused by the activation of a MYPT 
phosphatase after platelet stimulation with the high dose of LPA. 
MYPT phosphorylation during shape change induced by thrombin was slower and irreversible as 
compared to a rapid and reversible MYPT phosphorylation during aggregation induced by 
thrombin.  The difference in kinetics of MYPT phosphorylation induced by different 
concentrations of thrombin might be due to the different sensitivity of PAR receptors.  Out of the 
two thrombin-stimulated receptors on human platelets, PAR-1 is easily cleaved and activated by 
low thrombin concentrations while PAR-4 requires 10- to 100-fold higher concentrations of 
thrombin (Covic et al. 2000; Brass 2003).  Probably, the slow MYPT phosphorylation during 
shape change is due to the partial activation of PAR-1 and the more rapid response during 
secretion and aggregation is due to the complete activation of PAR-1 and additional activation of 
PAR-4.  After the rapid increase, MYPT phosphorylation at Thr696 and Thr853 decreased due to 
integrin αIIbβ3 engagement during thrombin-stimulated platelet aggregation. This indicates that 
the engagement of the integrin αIIbβ3 during platelet activation might stimulate a phosphatase 
acting on these Rho-kinase specific sites in MYPT and thus, this method to measure Rho-kinase 
activity is not appropriate.  The initial increase in MYPT phosphorylation was independent of 
integrin αIIbβ3 engagement, which in agreement with a previous study, shows that Rho and Rho-
kinase activation in platelets are upstream of integrin αIIbβ3 (Gratacap et al. 2001). 
LPA-stimulated MYPT phosphorylation was more rapid and reversible as compared to 
irreversible MYPT phosphorylation during thrombin-induced platelet shape change.  This 
difference in MYPT phosphorylation indicates that LPA (through LPA receptors) and thrombin 
(through PAR-1 receptor) activate Rho-kinase with different kinetics during platelet shape 
change. 
5.1.2. Rho-kinase activation mediates F-actin increase during shape change 
Platelet stimulation by agonists induces a rapid increase in actin polymerization (Kometani et al. 
1986; Oda et al. 1992).  These new actin filaments fill in the filopodia and form a contractile 
network underlying platelet shape change.  It was observed that thrombin as well as LPA induced 
a rapid increase in F-actin content during platelet shape change.  The inhibition of F-actin 
increase by latrunculin A, which binds to G-actin and thereby facilitates F-actin depolymerization 
and inhibits further actin polymerization, blocked the shape change induced by LPA.  Similar 
studies that explore the alteration of actin dynamics by other actin-assembly inhibitors the 
cytochalasins, which bind to the barbed end of filament and inhibit actin polymerization, showed 
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an inhibition of platelet shape change and pseudopod extensions after stimulation with agonists 
(Kometani et al. 1986; Natarajan et al. 2000).  Therefore, actin polymerization is a vital process 
for platelet shape change.  Together with an increase in F-actin, other cytoskeletal events such as 
an increase in actin-myosin filament formation and contraction due to MLC phosphorylation 
(Retzer and Essler 2000) and disruption of the microtubule ring (Paul et al. 2003) are equally 
involved in the transformation of discoid platelets into spheroid cells.  Preincubation of platelets 
with Y-27632, a specific Rho-kinase inhibitor, abolishes MLC phosphorylation and disassembly 
of the microtubule ring (Paul et al. 2003).  In the present study, the Ca2+-independent platelet 
shape change and increase of F-actin induced by low concentrations of thrombin and LPA were 
inhibited by Y-27632.  Together, our results and results of previous studies show that Rho-kinase 
acts as a central molecule signaling to actin polymerization, actomyosin contraction and 
microtubule disruption underlying platelet shape change.  Furthermore, the kinetics of Rho-
kinase activation, F-actin increase and shape change, which were irreversible after platelet 
activation with thrombin and reversible after platelet activation with LPA suggest that the kinetic 
of Rho-kinase activation determines the pattern of F-actin increase and platelet shape change. 
5.1.3. Rho-kinase is involved in secretion and platelet aggregation 
The actin polymerization during dense granule secretion is substantially more than during shape 
change (Lefebvre et al. 1993).  Confirming this previous observation, a higher increase of F-actin 
during secretion (170% of control) as compared during shape change (128% of control) in 
platelets stimulated with thrombin was observed.  Although many signaling pathways induced 
during secretion might contribute to the cytoskeletal changes, the inhibition of F-actin increase 
and a reduction in dense granule secretion in thrombin-stimulated platelets by Y27632 indicate 
that the Rho-kinase-mediated actin polymerization is involved in dense granule secretion.  This 
conclusion is supported by recent studies where secretion induced by agonists was blocked by 
inhibiting actin polymerization using cytochalasins (Diaz-Ricart et al. 2002; Flaumenhaft et al. 
2005).  However, earlier studies also using cytochalasins contradicted the necessity of F-actin 
formation for dense granule secretion, and even suggested that an intact actin cytoskeleton acts as 
barrier for granule secretion (Kirkpatrick et al. 1980; Cox 1988). In addition to inhibition of F-
actin formation, Y-27632 also inhibits actomyosin contraction, which is an important process for 
secretion and therefore Rho-kinase activation might be needed for efficient actin dynamics 
underlying dense granule secretion from platelets. 
Previously, it was observed that Rho-kinase is involved in irreversible platelet aggregation, but 
not in secretion after platelet stimulation with the PAR-1 activating peptide, SFLLRNP (Missy et 
al. 2001).  However, another study showed that Y-27632 and H-1152 inhibited dose-dependently 
dense granule secretion induced by the thromboxane A2 mimetic SAT2 and low, but not higher 
concentrations of thrombin (≥0.1U/ml) (Suzuki et al. 1999).  In our study, Y-27632 dose-
dependently inhibited ATP secretion (data not shown) and reduced the secretion induced by 
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thrombin concentrations as high as 0.5U/ml.  The difference in inhibition of thrombin-induced 
secretion by Rho-kinase inhibitors in these two studies might be for two reasons.  First, in our 
platelet preparation the presence of apyrase (ADPase) in the final resuspension buffer could 
degrade ATP and hence these Rho-kinase inhibitors could effectively block secretion induced by 
higher concentrations of thrombin as compared to the study by Suzuki et al.  Second, in our 
study, platelet suspensions were incubated with these inhibitors at 37°C for 30 minutes, whereas 
in study by Suzuki et al., they were incubated for 3 minutes, which might result in inefficient 
inhibition of Rho-kinase.  The inhibition of secretion by Y-27632 was incomplete suggesting that 
apart from Rho-kinase other signaling pathways are important in dense granule secretion induced 
by thrombin. 
Inhibition of thrombin-induced secretion by the Rho-kinase inhibitor Y-27632 was accompanied 
by a reduced and reversible platelet aggregation.  To distinguish whether in thrombin-stimulated 
platelets Rho-kinase regulates secretion or aggregation the integrin αIIbβ3-blocker RGDS was 
used to inhibit aggregation.  No reduction of ATP secretion was observed under these conditions.  
These results indicate that Rho-kinase regulates primarily secretion, which then amplifies platelet 
aggregation.  Stimulation of platelets with strong physiological agonist thrombin induces the 
release of fibrinogen and thrombospondin from α-granules, which are known to initiate and 
stabilize platelet aggregation, respectively (Leung 1984; Bornstein 2001).  Inhibition of 
thrombin-induced platelet aggregation by Y-27632 might then be due to less fibrinogen release 
from α-granules, and the reversibility of platelet aggregate formation might be a consequence of 
less secretion of thrombospondin from these granules. 
It has been observed that Rho-kinase contributes to a greater extent for platelet secretion induced 
by weaker agonists.  LPA is a weak agonist as compared to thrombin and induces only shape 
change of washed platelets even at high concentrations (10 µM).  However, LPA in the presence 
of external fibrinogen, induced secretion and platelet aggregation.  Pretreatment of platelets with 
Y-27632 completely abolished the secretion and reduced platelet aggregation induced by LPA.  
The complete inhibition of LPA-induced secretion by Y-27632 indicates that dense granule 
secretion is mainly regulated by Rho-kinase in LPA-stimulated platelets. 
LPA-induced platelet aggregation in platelet suspensions and blood is mediated by synergism 
with ADP secreted from dense granules (Haseruck et al. 2004).  We also showed a reduced and 
reversible platelet aggregation after complete inhibition of dense granule secretion by Y-27632 in 
LPA-stimulated platelets supporting that ADP secreted from dense granules potentiates LPA-
induced platelet aggregation by positive feedback through purinergic ADP receptors.  However, 
on the other hand there are evidences that αIIbβ3-mediated outside-in signaling elicits secretion 
induced by physiological agonists such as ADP and thromboxane A2 (Krishnamurthi et al. 1989; 
Moritani et al. 2002; Li et al. 2003).  The lack of ATP secretion observed after platelet 
stimulation with LPA in the absence of fibrinogen supports these previous findings.  Thus, 
fibrinogen binding to the αIIbβ3 integrin and signaling pathways activated due to this binding are 
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required for ADP secretion, which then can amplify, propagate and perpetuate platelet 
aggregation in LPA-stimulated platelets.  Together these studies also show that granule secretion 
and platelet aggregation are interdependent events, and are difficult to arrange in hierarchy after 
platelet stimulation.  These studies also infer that Rho-kinase activation is an important signaling 
event for shape change, granule secretion and platelet aggregation and thus can be a target for the 
development of anti-thrombotic drugs. 
5.2. Identification and regulation of LIMK-1 in human platelets 
5.2.1. LIMK-1 but not LIMK-2 expressed in platelets 
In other cell types, Rho-kinase is known to phosphorylate and activate LIM-kinases, a target 
other than MLC and myosin phosphatase (Maekawa et al. 1999).  There exist two types of LIM 
kinases namely, LIMK-1 and LIMK-2 that are widely expressed in all tissues and cell types 
(Foletta et al. 2004; Acevedo et al. 2006).  The similar function of LIMKs to phosphorylate 
cofilin suggests that they might be redundant in cells expressing both enzymes, but might be 
essential in cells expressing only one of them.  So far, the presence of different LIM kinase 
isoforms in platelets was not known.  This study using specific antibodies against LIMK-1 and 
LIMK-2 showed that only LIMK-1 is expressed in platelets.  In addition, endothelial cells that 
contain both LIMK-1 and LIMK-2 showed an extra lower band recognized by both of these 
antibodies, which were absent in platelets.  These bands might be similar to the spliced variants 
of LIMK-2, described in mouse tissues (Ikebe et al. 1997; Ikebe et al. 1998).  Exclusive 
expression of LIMK-1 in platelets suggests that megakaryocytes that produce platelets might also 
contain only LIMK-1.  The other possibility is that megakaryocytes express both LIMK-1 and 
LIMK-2, and that these cells suppress LIMK-2 expression during differentiation.  Concerning the 
first possibility, the expression of LIMK-1 is found in human erythroleukaemia cell line, which is 
thought to differentiate into megakaryocytes (Konakahara et al. 2004).  Supporting the second 
possibility that selective proteins are expressed in megakaryocytes and platelets, it has been 
shown that the cytosolic protein paxillin is expressed in megakaryocytes, but is lost during 
maturation of megakaryocytes into platelets, and is functionally replaced by another homologous 
protein hic-5 in platelets (Hagmann et al. 1998).  Our results also infer that LIMK-1 might be the 
only relevant LIM-kinase for physiological activation of platelets.  It would be interesting to 
know whether also mouse platelets express only LIMK-1 or both forms of LIMKs.  Dependent on 
this result, the physiological role of LIMK-1 and LIMK-2 could be probed in the future by 
performing functional studies on platelets from LIMK-1 and LIMK-2 null mice.  LIMK-1 
deficient mice are viable, but have abnormal spine morphology, synaptic regulation, and brain 
functions (Meng et al. 2002).   LIMK-2 knockout mice are also viable, but showed impaired 
spermatogenesis and an increase in apoptosis of germ cells (Meng et al. 2004).  Mice lacking 
both LIMKs have the same defects, but are also viable and fertile suggesting that other kinases 
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such as TESK-1 and 2 might functionally compensate for the lack of LIMKs in these mice.  The 
LIMK-1/2 double knockout mice were, however, more severely impaired in cofilin 
phosphorylation and synaptic functions (Meng et al. 2004).  LIMK-1/2 deficiency causes 
apparently no major bleeding problems leading to premature death indicating that in these mice 
the platelet number was not drastically reduced, and therefore platelet production from 
megakaryocytes is not severely impaired. It remains an open question, however, whether LIMK-1 
plays a function for specific platelet responses or is involved in pathological thrombus formation.  
5.2.2. Rho-kinase activation leads to LIMK-1 phosphorylation 
Most of the studies suggest that during physiological cell activation, Rho-kinase-mediates LIMK-
2 activity, whereas PAKs are responsible for LIMK-1 activity. Our study is to our knowledge the 
first to provide evidence that Rho-kinase activates LIMK-1 in LPA- and thrombin-stimulated 
platelets.  LIMK-1 was rapidly phosphorylated during shape change and secretion/aggregation.  
The kinetics of LIMK-1 phosphorylation during shape change and secretion were similar to the 
kinetics of Rho-kinase activation as measured by MYPT phosphorylation, suggesting that Rho-
kinase phosphorylates LIMK-1 in intact platelets.  Moreover, LIMK-1 phosphorylation was 
completely inhibited by two different Rho-kinase inhibitors, Y-27632 and H-1152.  These Rho-
kinase inhibitors completely blocked LIMK-1 phosphorylation during thrombin-induced platelet 
shape change, secretion and aggregation, and inhibited the activity of LIMK-1 in 
immunoprecipitates from thrombin-stimulated platelets. 
It has been reported using transfected cells that LIMK-1 can be phosphorylated and activated 
either by PAKs (Edwards et al. 1999) or Rho-kinase (Ohashi et al. 2000).  PAK2 has been shown 
to be activated during platelet shape change (Teo et al. 1995) and aggregation (Vidal et al. 2002).  
Moreover, LPA that mainly activates the Rho/Rho-kinase pathway has also been reported in few 
studies to stimulate PAK in a Rac- or Cdc42-dependent manner (Schmitz et al. 2002; Rhee and 
Grinnell 2006).  These studies raised the possibility that PAK might also be activated and 
contribute to LIMK-1 activation in LPA-stimulated platelets.  In our study, LPA induced rapidly 
Rho-kinase activation and slower PAK activation during shape change.  We found that during 
LPA-stimulated platelet shape change LIMK-1 activation coincides with and was completely 
dependent on Rho-kinase activation, whereas PAK activation was unlikely to be involved.  These 
results also infer that PAK activation in platelets might have targets other than LIMK-1, for 
example MLC-kinase or directly MLC (Bokoch 2003).  However, since specific cell-permeable 
PAKs inhibitors are not available, we cannot rule out a transient Rho-kinase dependent, PAK-
mediated LIMK-1 phosphorylation in LPA-stimulated platelets.  Supporting this possibility we 
found that PAK1/2 phosphorylation was reduced by Y-27632, albeit not significantly.  Y-27632 
is a specific inhibitor of Rho-kinase and does not inhibit PAK activation in vitro even at high 
concentrations (100 µM) (Uehata et al. 1997).  Recently, Rac activation in TRAP-stimulated 
platelets was reported to be slightly enhanced by Y-27632 pretreatment suggesting that Rho-
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kinase down-regulates Rac and possibly PAK activation (Soulet et al. 2005).  However, our study 
suggests that Rho-kinase might rather stimulate then inhibit PAK-activation in LPA-stimulated 
platelets.   
Rac and Cdc42 in platelets regulate distinct morphological structures, spreading and filopodia 
formation, respectively (Vidal et al. 2002; Chang et al. 2005).  This difference in their specific 
role indicates that they might be regulated differently.  In activated platelets, the Gq/PLCβ/Ca2+ 
pathway and Gi activation mediate stimulation of Rac (Azim et al. 2000; Gratacap et al. 2001; 
Suzuki-Inoue et al. 2001; Vidal et al. 2002; Soulet et al. 2005), whereas Cdc42 activation was 
independent of the PLC/Ca2+ pathway (Soulet et al. 2001) and could contribute to filopodia 
formation during Ca2+-independent platelet shape change after LPA and thrombin stimulation.  
Low concentrations of LPA do not stimulate Gq and Gi, and do not increase cytosolic Ca2+ during 
shape change (Maschberger et al. 2000; Haseruck et al. 2004), raising the possibility that Cdc42, 
and not Rac stimulates PAK phosphorylation.  Another possibility is that PAK is stimulated 
through the PI3-kinase/Akt pathway, which is activated by Gβγ subunits independently of 
Rac1/Cdc42 (Menard and Mattingly 2004).  Whether Cdc42/PAK pathway contributes to 
filopodia formation during the LPA-induced platelet shape change is an open question, since 
inhibition of Rho-kinase reversed the spheroid morphology but could not block the filopodia 
formation during ADP-induced platelet shape change (Paul et al. 2003).  These authors observed 
that Y-27632-treated platelets after ADP stimulation returned to discoid shape, but still possessed 
extended filopodia.  It is possible that Rho-kinase- and Rac/Cdc42-mediated pathways 
specifically controls the spheroid and filopodia formation during agonists-induced shape change, 
respectively. 
LIMK-1 phosphorylation was not changed by the integrin αIIbβ3 blocker RGDS and by the 
absence of stirring during thrombin-stimulation of platelets.  This indicates that unlike MYPT, 
LIMK-1 activation is not influenced by integrin αIIbβ3 engagement and occurs therefore upstream 
of integrin αIIbβ3 activation in thrombin-stimulated platelets.  Hence, measuring LIMK-1 
(Thr508) phosphorylation might be a better tool than MYPT (Thr696 and Thr853) 
phosphorylation for analysis of Rho-kinase activation in stimulated platelets, since MYPT is 
dephosphorylated in aggregated platelets. 
5.3. Regulation of cofilin activities 
Cofilin phosphorylation by LIMKs inhibits its actin depolymerizing activity and modulates its 
binding to F-actin.  In agreement with observations made previously (Davidson and Haslam 
1994), we found that about one third of the total cofilin is phosphorylated in resting platelets.  We 
observed a significant decrease of cofilin phosphorylation in resting platelets after treatment with 
Y-27632 indicating that the Rho-kinase/LIMK-1 pathway is needed to maintain this basal level of 
cofilin phosphorylation.  The presence of both cofilin and phospho-cofilin suggests that cofilin 
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phosphorylation in resting platelets is under influence of both Rho-kinase/LIMK-1 and a cofilin 
phosphatase. 
Surprisingly, the activation of LIMK-1 failed to increase cofilin phosphorylation during shape 
change induced by LPA as well as thrombin.  The lack of subsequent increase in cofilin 
phosphorylation could be explained by simultaneous activation of a cofilin phosphatase.  In 
support of this explanation, we found that inhibition of the Rho-kinase/LIMK-1 pathway revealed 
a further decrease of phospho-cofilin during shape change 5 seconds to 120 seconds after 
stimulation with LPA and thrombin, indicating that the simultaneous activation of a cofilin 
phosphatase counteracts the effect of LIMK-1 for phosphorylating cofilin during shape change.  
Thus, the phosphocycling on cofilin might be increased without any substantial changes in cofilin 
net phosphorylation due to the simultaneous activation of these counteracting pathways.  In 
support of this hypothesis, Meberg et al showed that EGF-induced membrane ruffling in human 
epithelial cells was not associated with a changed ratio of phosphorylated to dephosphorylated 
cofilin, however the rate of phosphocycling on cofilin was increased (Meberg et al. 1998).  A 
further possibility for the lack of stimulation of cofilin phosphorylation by LIMK-1 during shape 
change is the presence of another LIMK-1 substrate in platelets, such as destrin, another protein 
of the ADF family and known to be phosphorylated by LIM-kinases.  However, in thrombin-
stimulated platelets destrin was observed to be dephosphorylated after 60 sec along with cofilin 
(Marcus et al. 2003).  Thus, destrin behaves similar to cofilin in activated platelets, not being well 
accessible to phosphorylation by LIMK-1. 
During platelet aggregation and secretion induced by thrombin, cofilin was rapidly 
dephosphorylated and subsequently rephosphorylated; the latter phase was due to Rho-kinase and 
LIMK-1 activation.  Cofilin dephosphorylation/ rephosphorylation occurred independently 
whether platelets aggregated or not indicating that the regulation of cofilin phosphorylation was 
independent of the integrin αIIbβ3 involvement.  The rapid cofilin dephosphorylation observed in 
thrombin-stimulated platelets is similar to a previous study and recent findings (Davidson and 
Haslam 1994; Falet et al. 2005).  However, in TRAP-stimulated platelets no decrease of cofilin 
phosphorylation, only an increase 3 to 5 minutes after activation was found (Kashiwagi et al. 
2005).  In contrast to our results, the study of Falet et al showed that during thrombin-induced 
platelet aggregation, cofilin remained dephosphorylated suggesting that integrin αIIbβ3 activation 
leads to sustained cofilin dephosphorylation.  Also, a recent study in epithelial cells showed that 
β3 overexpression reduced phospho-cofilin levels (Danen et al. 2005).  A possible explanation for 
the discrepancies between the study of Falet et al and our study might be the different methods 
used to isolate washed platelets such as use of a metrizamide gradient in the study of Falet el al.  
We further validated the independency of cofilin dephosphorylation from integrin αIIbβ3 
engagement by our results in LPA-stimulated platelets.  Platelets stimulated with a high 
concentration of LPA (10 µM), did not show any dense granule secretion and no platelet 
aggregation, but exhibited cofilin de- and rephosphorylation, similar to that observed for platelets 
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stimulated with high concentration of thrombin.  These data clearly indicate an integrin αIIbβ3-
independent regulation of cofilin phosphorylation in activated platelets. 
In thrombin-stimulated platelets, the possible role of dense granule secretion in inducing the rapid 
cofilin dephosphorylation was not clear.  Davidson and Haslam had previously shown that cofilin 
dephosphorylation occurs later than dense granule secretion in thrombin-stimulated platelets 
suggesting that dephosphorylation of cofilin is a consequence of secretion (Davidson and Haslam 
1994).  However, in the same study the dephosphorylation of cofilin in the absence of secretion 
after platelet stimulation with ionophore A23187 was not explained.  Our study clearly shows 
that cofilin dephosphorylation is independent and upstream of secretion since the onset of cofilin 
dephosphorylation is as rapid as secretion in thrombin-stimulated platelets and also occurs in the 
absence of dense granule secretion, when platelets were stimulated with LPA (10 µM) in the 
absence of fibrinogen.  Moreover, a very recent study using the quench-flow technique showed 
that thrombin (0.1 U/ml) evoked a rapid cofilin dephosphorylation that commenced within 100 
milliseconds, reached a maximum at 0.9 seconds, which was then followed by subsequent 
rephosphorylation exceeding the resting level about 1.5 seconds after platelet activation 
(Redondo et al. 2006).  Secretion-like store-operated calcium entry (SOCE) occurred later than 
cofilin dephosphorylation in that study supporting our data of secretion-independent regulation of 
cofilin dephosphorylation in activated platelets. 
Cofilin dephosphorylation during platelet stimulation with high concentrations of LPA and 
thrombin was followed by Rho-kinase/LIMK-1-mediated cofilin rephosphorylation to the level 
observed in resting platelets within 2 minutes.  The results of inhibition of the Rho-kinase/LIMK-
1-mediated cofilin rephosphorylation with Y-27632 indicate that this pathway regulates primarily 
secretion, not aggregation.  Y-27632 did not inhibit cofilin dephosphorylation up to 30 seconds.  
These results also suggest that during platelet secretion/aggregation, the two counteracting 
pathways regulating cofilin phosphorylation, i.e. cofilin phosphatase and LIMK-1, sequentially 
act on cofilin.  The rapid and large dephosphorylation of cofilin shows that a cofilin phosphatase 
is activated very rapidly, and that this enzyme has a better access to its substrate phospho-cofilin 
than LIMK-1 (which is also activated rapidly) to cofilin.  Since LIMK-1 is rapidly activated in 
thrombin-stimulated platelets, but cofilin is rapidly dephosphorylated, one has also to assume a 
compartmentalization in order to explain these results.  LIMK-1 is known to bind to a number of 
different proteins including the cofilin phosphatase slingshot (Soosairajah et al. 2005), 14-3-3 
(Birkenfeld et al. 2003), heat shock protein 90 (Li et al. 2006) and some transmembrane receptors 
(Foletta et al. 2003), so even in its activated form it may not have direct access to cofilin.  Based 
on our results, we interpret the cofilin phosphorylation data in platelets stimulated with high 
concentrations of thrombin (0.5 U/ml) and LPA (10 µM) by a rapid activation of a cofilin 
phosphatase generating active cofilin, which after 30-60 seconds is rephosphorylated and 
inactivated by LIMK-1.  However, the presence of other kinases than LIMK-1 that can 
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phosphorylate cofilin in intact platelets cannot be excluded, since LIMK-1 was not inhibited 
directly, only indirectly through Rho-kinase inhibition.  
Our study shows that cofilin is maximally dephosphorylated at 30 seconds and then 
rephosphorylated to the basal level within 2 minutes of platelet stimulation with thrombin (0.5 
U/ml). The kinetics of cofilin phospho-cycle in LPA (10 µM)-stimulated platelets was similar 
except the maximal dephosphorylation occurred at 60 sec after LPA induction.  The study by 
Falet et al, showed that cofilin after initial dephosphorylation is rephosphorylated slowly and 
commencing not later that 2 minutes of platelet stimulation with thrombin (1 U/ml) in the 
presence of RGDS and in the absence of stirring (Falet et al. 2005).  Using rapid quench-flow 
technique, Redondo et al showed that in thrombin (0.1 U/ml)-stimulated platelets the phospho-
cycle of cofilin is completed within 1.5 seconds (Redondo et al. 2006).  This very early onset and 
shorter time frame for the cofilin phospho-cycle in the study by Redondo et al might be explained 
by the use of different experimental set-ups.  Similarity in these studies, first de- and 
rephosphorylation of cofilin although with different kinetics, suggests that cofilin phospho-cycle 
is an important regulatory process for rapid actin dynamics underlying different morphological 
and functional changes of platelets. 
5.3.1. Cofilin association with F-actin 
Cofilin in its dephosphorylated and activated form binds with filamentous actin (Nagaoka et al. 
1996).  We investigated, how cofilin phosphorylation was related to the increase of F-actin, and 
to the association of cofilin with F-actin.  The results with Y-27632 in resting platelets suggested 
that LIMK-1-mediated cofilin phosphorylation might reduce F-actin content and cofilin 
association with F-actin.  However, during thrombin-induced shape change there was no relation 
of the unchanged phospho-cofilin levels in platelets with the rapid increase of F-actin (11%) and 
the increase of cofilin association with F-actin (5 %) of platelets.  During the initial phase of 
thrombin-induced secretion (up to 30 seconds), cofilin dephosphorylation was associated with a 
larger increase of F-actin (22 %) and a higher amount of cofilin associated with F-actin (21 %) as 
compared to shape change. Confirming our results, Falet et al (Falet et al. 2005) showed that only 
cofilin but not phospho-cofilin binds to F-actin and the initial cofilin dephosphorylation was 
accompanied with an increase in F-actin content and increased association of cofilin with F-actin 
in thrombin-stimulated platelets.  However, cofilin rephosphorylation after 30 seconds did not 
decrease F-actin, and cofilin association with F-actin.  Moreover, Y-27632 pre-treatment reversed 
the increase of F-actin and cofilin association with F-actin, which was associated with an 
inhibition of cofilin rephosphorylation.  These results show that LIMK-1-mediated cofilin 
phosphorylation does not regulate the F-actin increase and cofilin association with F-actin in 
thrombin-activated platelets.  In contrast, the study by Falet et al contradicts our findings showing 
that cofilin rephosphorylation 5-10 minutes after thrombin stimulation was paralleled by its 
dissociation from F-actin.  This difference in the study by Falet et al and ours might be due to 
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different lysis methods used for isolation of F-actin.  We observed that phalloidin, which was not 
used in our method but in the study by Falet et al, displaced cofilin from F-actin and caused F-
actin increase during lysis.  The incubation time for platelet lysis is also critical to avoid changes 
that occur after platelet lysis (Carlsson et al. 1979). 
During LPA-induced platelet shape change, we studied the association of cofilin with F-actin of 
the actin cytoskeleton instead of association of cofilin to the whole F-actin content of platelets.  
We found that cofilin very rapidly associated with the actin cytoskeleton.  The maximal cofilin 
association with actin cytoskeleton occurred before the maximal F-actin increase, suggesting that 
cofilin association with F-actin might regulate the turnover and actin polymerization during 
platelet shape change.  Cofilin association with actin filaments during shape change might 
generate more free barbed ends that can be utilized for further polymerization of actin filaments 
by the Arp2/3 complex (Pollard and Beltzner 2002).  In contrary to the actin depolymerizing 
activity of cofilin, such a concept might also explain the simultaneous increase rather than 
decrease in F-actin content accompanied with the activation of cofilin during thrombin-stimulated 
dense granule secretion.  Such an explanation is supported by a recent data demonstrating that 
cofilin promotes rather than decreases actin polymerization, generates protrusions, and 
determines the direction of cell migration (Ghosh et al. 2004). 
5.3.2. Possible factors regulating cofilin dephosphorylation 
Even after years of study, the identification of specific cofilin phosphatases and signaling 
pathways regulating cofilin dephosphorylation remain unclear.  Cofilin dephosphorylation could 
result from either the inactivation of cofilin kinases (LIMKs), activation of the cofilin 
phosphatase, or a combination of these reactions.  Some recent studies in human cell lines and 
neurons suggested that down-regulation of the Rho-kinase/LIMK-1 pathway induces cofilin 
dephosphorylation (Jung et al. 2006; Zhang et al. 2006).  In agreement to this observation, we 
found that the inhibition of Rho-kinase reduced cofilin phosphorylation in resting platelets and 
subsequently unrevealed cofilin dephosphorylation in activated platelets.  However, even when 
Rho-kinase and LIMK-1 were rapidly activated during platelet stimulation with thrombin and 
LPA, either no increase in cofilin phosphorylation during shape change or a rapid cofilin 
dephosphorylation during secretion and aggregation was observed.  A similar observation of 
cofilin net dephosphorylation in parallel to LIMK-1 activation induced by insulin in human 
epidermoid carcinoma KB cells has been reported (Arai and Atomi 2003).  However, they found 
that the apparent insulin-induced cofilin dephosphorylation was due to suppression of cofilin 
phosphorylation and not due to enhanced cofilin dephosphorylation.  In contrast, our results 
suggest that cofilin dephosphorylation is the result of stimulation of a phosphatase and not due to 
the inhibition of Rho-kinase/LIMK-1 pathway, since the cofilin dephosphorylation was not 
affected by Y-27632. 
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Davidson and Haslam observed that GTPγS induced cofilin dephosphorylation in electro-
permeabilized platelets suggesting that GTP-binding proteins are involved in this process 
(Davidson and Haslam 1994).  Recently, a study by Tanaka et al showed that constitutively active 
RhoA induced slingshot-mediated cofilin dephosphorylation in Xenopus zygote (Tanaka et al. 
2005).  The activation of slingshot was dependent on an increase of F-actin induced by Rho 
signaling.  Inhibition of actin polymerization by latrunculin A (sequesters G-actin) and 
facilitation of actin polymerization by jasplakinolide (stabilizes F-actin) resulted in inhibition and 
augmentation of cofilin dephosphorylation, respectively (Tanaka et al. 2005).  This observation 
might explain our findings of simultaneous increase in F-actin and enhanced cofilin 
dephosphorylation during thrombin-induced secretion.  F-actin formation might enhance cofilin 
phosphatase activity and thereby induce cofilin dephosphorylation.  However, by using Y-27632 
we did not observed an effect on cofilin dephosphorylation in thrombin-stimulated platelets, 
despite of the inhibition of F-actin increase. 
Another recent study on axon growth in Drosophila showed that Rac through a PAK-independent 
pathway antagonizes the effect of LIMK-1 over-expression on cofilin phosphorylation, probably 
due to activation of a cofilin phosphatase (Ng and Luo 2004).  These studies altogether suggest 
that signaling induced by agonists bifurcate downstream of Rho-GTPases into simultaneous 
activation of a Rho/Rho-kinase/LIMK-1 and cofilin phosphatase that later converge on a common 
downstream target, cofilin and thus, influencing its phosphorylation. Whether and how Rho-
GTPases are involved in regulating cofilin dephosphorylation and which Rho-GTPase is actually 
involved in this process would be of great interest in future studies. 
Cofilin dephosphorylation was inhibited by the non-specific phosphatase inhibitor sodium 
orthovanadate but not by the PP1/PP2A type phosphatase inhibitor okadaic acid suggesting that 
cofilin phosphatase is not a PP1/PP2A type phosphatase.  Earlier, Davidson and Haslam also 
made a similar observation in thrombin-stimulated platelets (Davidson and Haslam 1994).  In 
contrast to these observations, few studies suggested that these okadaic acid-sensitive 
phosphatases are capable of associating with cofilin and dephosphorylating it, for example in T-
lymphocytes (Samstag et al. 1996; Ambach et al. 2000).  However, in other cell types okadaic 
acid failed to inhibit cofilin dephosphorylation (Takuma et al. 1996; Heyworth et al. 1997).  Our 
results showing that okadaic acid did not affect the cofilin dephosphorylation support the idea 
that cofilin might be dephosphorylated by a specific cofilin phosphatase such as the recently 
identified “slingshot”, which is insensitive to inhibition by okadaic acid (Niwa et al. 2002) or 
“chronophin”, a novel HAD-type serine protein phosphatase (Gohla et al. 2005).  However, the 
presence of slingshot family (SSH) proteins and chronophin in platelets is not known.  Recently, 
a transcriptome study identified the presence of SSH2 mRNA in platelets, whereas mRNA of 
SSH1 and SSH3 was not found indicating that SSH2 might be present in platelets (Bugert and 
Kluter 2006). 
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Surprisingly, in some studies inhibitors of PP1/PP2A type phosphatases (okadaic acid and 
calyculin A) themselves induced cofilin dephosphorylation (Okada et al. 1996; Takuma et al. 
1996; Djafarzadeh and Niggli 1997).  In our study, also okadaic acid and calyculin A induced 
cofilin dephosphorylation in resting platelets (data not shown), and cofilin rephosphorylation was 
completely abolished in thrombin-stimulated platelets that were pretreated with okadaic acid, 
although LIMK-1 immunoprecipitates from okadaic acid-treated platelets showed an increased 
LIMK-1 activity towards cofilin.  Hence, these results rule out the possibility of okadaic acid 
inhibiting LIMK-1-mediated cofilin rephosphorylation in thrombin-stimulated platelets.  These 
observations suggest that PP1/PP2A type phosphatases might negatively regulate the cofilin 
phosphatase either by dephosphorylation of some mediator protein or the cofilin phosphatase 
itself. 
Davidson and Haslam had shown that calcium ionophore A23187 induces cofilin 
dephosphorylation in platelets (Davidson and Haslam 1994).  The cAMP-stimulated 
dephosphorylation of cofilin in a neuronal cell line was inhibited by PP1 and PP2A phosphatases 
inhibitor calyculin A (Meberg et al. 1998).  In addition, cofilin dephosphorylation by chemotactic 
peptide in leukocytes was inhibited by the PI3-kinase inhibitor wortmannin.  However, 
wortmannin did not block phorbol ester-induced cofilin dephosphorylation, which was inhibited 
by inhibitors of calcium-independent forms of PKC (Okada et al. 1996).  Thus, these studies 
show that multiple signaling pathways involving calcium, cAMP, PKC and PI3-kinase can 
mediate stimulus-induced cofilin dephosphorylation in different cell types.  Recently, most of 
these cofilin-dephosphorylating pathways have now been linked to the activation of slingshot.  
One study showed that insulin-induced cofilin dephosphorylation in MCF-7 cells is due to PI3-
kinase-mediated activation of slingshot.  Our results of inhibition of thrombin-induced cofilin 
dephosphorylation by wortmannin in platelets similarly suggest that a PI3-kinase mediates cofilin 
dephosphorylation.  However, the lack of inhibition of cofilin dephosphorylation by specific 
inhibitors of Akt, a downstream protein kinase target of PI3-kinase, indicates that PI3-kinase 
regulates cofilin dephosphorylation not through the Akt signaling pathway.  One possibility is 
that the lipid target of PI3-kinase-mediated signaling PIP2 is involved.  PIP2 is known to bind 
cofilin (inhibiting its activity) as well as phospho-cofilin (Moriyama et al. 1996).  PIP3, the 
product of PIP2 phosphorylation by PI3-kinase has a slightly lower affinity towards cofilin 
binding as compared to PIP2 (Ojala et al. 2001).  Phosphorylation of PIP2 to PIP3 might lead to 
dissociation of phospho-cofilin from the complex and thereby could facilitate cofilin 
dephosphorylation. In support of such a relation of PIP3/cofilin dephosphorylation and 
PIP2/cofilin phosphorylation, it has been shown that cells overexpressed with PTEN (phosphatase 
and tensin homolog deleted in chromosome 10), which dephosphorylates PIP3 to PIP2, showed an 
increase of cofilin phosphorylation, whereas PTEN deficient cells showed a decrease in cofilin 
phosphorylation (Nishita et al. 2004).   
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Cofilin undergoes dephosphorylation in response to extracellular stimuli that elevate intracellular 
Ca2+ concentrations.  An increase of cytosolic Ca2+ concentration after platelet stimulation with 
Ca2+ ionophores leads to cofilin dephosphorylation and secretion (Siess 1989; Davidson and 
Haslam 1994; Wang et al. 2005).  Platelets stimulated with high concentrations of LPA (>1µM) 
and thrombin, which showed a rapid cofilin dephosphorylation, are associated with a rise in 
intracellular Ca2+ (Maschberger et al. 2000).  Preincubation of platelets with the intracellular Ca2+ 
chelator BAPTA-AM completely blocked the LPA-stimulated cofilin dephosphorylation 
suggesting a role of Ca2+ for regulating cofilin phosphatase.  Recently, calcium-induced cofilin 
dephosphorylation was observed being mediated via calcineurin-dependent activation of 
slingshot (Wang et al. 2005).  Calcineurin is a calcium-regulated protein phosphatase, also known 
as PP2B.  In our study, the treatment of platelets with the calcineurin autoinhibitory domain 
(CAID) coupled to a membrane penetrating peptide sequence completely blocked the thrombin-
induced cofilin dephosphorylation suggesting that calcium-mediated activation of calcineurin is 
involved in stimulating the cofilin phosphatase in platelets.  Vice versa, it has recently been 
shown in thrombin-stimulated platelets that the rapid cofilin dephosphorylation could through 
changes in actin dynamics enhances cytosolic Ca2+ concentration through stimulation of the 
store-operated Ca2+ entry (Redondo et al. 2006). 
The present study shows that the activation of cofilin phosphatase in platelets is regulated by 
several factors: an increase in intracellular Ca2+ and an activation of calcineurin and PI3-kinase 
positively regulates, whereas the activation of PP1/PP2A type phosphatase negatively regulates 
the activity of cofilin phosphatase (Figure 5.1). 
 
 
Figure 5.1  Possible factors regulating the activity of the unknown cofilin phosphatase in platelets.  Cofilin 
dephosphorylation during platelet activation seems to be regulated by an increase in intracellular Ca2+ and by 
activation of calcineurin and PI3-kinase, whereas the activation of PP1/PP2A type phosphatase negatively regulates 
the activity of cofilin phosphatase.  These factors might regulate cofilin phosphatase directly or indirectly through 
unidentified intermediates. Calcineurin auto inhibitory domain; CAID. 
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5.4. Two-step model for cofilin phospho-cycle 
In conclusion, this study shows that Rho-kinase mediates rapid LIMK-1 activation and the 
increase of F-actin during shape change and aggregation/secretion induced by platelet activating 
agents such as thrombin and LPA.  The rapid LIMK-1 activation did, however, not lead to an 
increased cofilin phosphorylation during shape change and the early phase of secretion.  This 
might be explained by the simultaneous activation of two counteracting pathways regulating 
cofilin phosphorylation, cofilin phosphatase and LIMK-1, and by compartmentalization of 
LIMK-1 with reduced accessibility to cofilin in intact platelets.  During secretion and aggregation 
the simultaneous activation of cofilin phosphatase and LIMK-1 resulted in a sequential 
dephosphorylation and then rephosphorylation of cofilin.  LIMK-1 activation and the pathways 
regulating cofilin de- and rephosphorylation were independent of dense granule secretion and 
integrin αIIbβ3 activation.  The early cofilin dephosphorylation by an okadaic-acid insensitive 
cofilin phosphatase seems to be regulated at least in part by an increase in intracellular Ca2+ and 
by PI3-kinase, and it will be interesting to examine how these pathways regulate the cofilin 
phosphatase, which is still to be identified (Figure 5.1).  Cofilin rephosphorylation by Rho-
kinase/LIMK-1 activation suggests a late influence of this pathway on cofilin-mediated 
rearrangement of actin cytoskeleton during platelet activation.  At last, since the kinetics of 
cofilin phospho-cycle is similar in LPA- as well as in thrombin-stimulated platelets, we 
hypothesize a general two-step regulatory process for cofilin phospho-cycle underlying primarily 
secretion, and subsequently platelet aggregation: dephosphorylation by a cofilin phosphatase and 
then rephosphorylation by the Rho-kinase/LIMK-1 pathway (Figure 5.2).  
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Figure 5.2.  Model for regulation of cofilin phospho-cycle in platelets. Top left, graphical representation for 
cofilin phospho-cycle during LPA-stimulated secretion and platelet aggregation.  Top right, graphical representation 
for cofilin phospho-cycle during thrombin-stimulated secretion and aggregation.  Bottom center, based on these two 
results, the hypothetical two-step model for cofilin-phosphocycle: initial dephosphorylation (step I) and then 
rephosphorylation (step II), for regulating actin dynamics beneath various platelet responses. 
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6. Summary  
The activation of platelets is a central step during the physiological process of hemostasis and its 
understanding may lead us to control the pathophysiological process of intra-arterial thrombus 
formation and vascular occlusion, which can cause acute coronary syndrome and myocardial 
infarction.  One of the important aspects of platelet activation is to understand the dynamic 
regulation and rearrangement of the cytoskeleton after stimulation.  The morphological and 
functional changes of platelets require a drastic remodeling of the actin cytoskeleton regulated by 
numerous actin-binding proteins and signaling molecules such as the family of Rho-GTPases.  
The small GTPase Rho can regulate several aspects of cellular function, predominantly through 
its downstream effector Rho-kinase.  One of the well established Rho-kinase-mediated signaling 
pathways is the phosphorylation of myosin light chain (MLC) and its counteracting MLC 
phosphatase.  Rho-kinase regulates a second pathway that involves activation of LIM-kinases 
(LIMKs) and subsequent phosphorylation and inactivation of cofilin, an actin dynamizing 
protein.  Dephosphorylation and activation of cofilin lead to severing and depolymerization of 
existing actin filaments.  The signaling pathway Rho-kinase/LIMKs/cofilin phosphorylation 
during platelet activation and the question, how the phosphorylation of cofilin affects the actin 
dynamics underlying platelet activation, has not previously been studied.  The physiological 
agonist thrombin and the pathophysiological relevant agonist lysophosphatidic acid (LPA), which 
is the main platelet-activating lipid in atherosclerotic plaque, were used as platelet stimuli to 
address these questions. 
It was found that the activation of Rho-kinase is important for an increase in F-actin content 
underlying Ca2+-independent platelet shape change.  The activation of Rho-kinase was found to 
be upstream to secretion and integrin αIIbβ3 activation.  The rapid activation of Rho-kinase during 
secretion leads to a further increase in F-actin content as compared to shape change.  It was 
observed that LPA-stimulated dense granule secretion is mainly regulated by Rho-kinase, 
whereas secretion induced by thrombin was only in part Rho-kinase-dependent.  Together, these 
results show that Rho-kinase regulates the F-actin increase underlying shape change and 
secretion, but it is not directly involved in aggregation. 
This study for the first time demonstrates that platelet expresses only LIMK-1 and not LIMK-2.  
LIMK-1 can be activated by Rho-kinase as well as by p21-activated kinases (PAKs).  Our study 
shows that LIMK-1 activation was mainly Rho-kinase dependent in LPA- and thrombin-
stimulated platelets.  Although, PAK-1/2 activation was observed during LPA-stimulated platelet 
shape change, PAKs are unlikely to be involved in LIMK-1 activation in these cells.  Like Rho-
kinase activation, it was also found that LIMK-1 activation was independent and upstream of 
integrin αIIbβ3 activation. Surprisingly, the activation of LIMK-1 failed to increase cofilin 
phosphorylation during shape change induced by LPA as well as by thrombin.  Inhibition of the 
Rho-kinase/LIMK-1 pathway unmasked cofilin dephosphorylation suggesting that during shape 
change the simultaneous activation of a cofilin phosphatase counteracts the effect of LIMK-1 for 
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phosphorylating cofilin.  During secretion and aggregation induced by LPA and thrombin, cofilin 
was rapidly dephosphorylated and subsequently rephosphorylated; the latter phase was due to 
Rho-kinase/LIMK-1 activation.  After stimulation with LPA and thrombin under conditions, 
where platelet aggregation could not occur, the kinetics of cofilin de- and rephosphorylation were 
unperturbed indicating their independence of integrin αIIbβ3 engagement.  Furthermore, the 
results clearly showed that cofilin dephosphorylation is also independent and upstream of 
secretion, since the onset of cofilin dephosphorylation was as rapid as secretion in thrombin-
stimulated platelets and also occurred in the absence of dense granule secretion in LPA (10 µM)-
stimulated platelets.  Since the kinetics of cofilin phospho-cycle was similar during secretion and 
platelet aggregation in LPA- and thrombin-stimulated cells, I propose a general two-step 
regulatory process for cofilin phospho-cycle underlying primarily secretion, and subsequently 
platelet aggregation: dephosphorylation by a cofilin phosphatase and then rephosphorylation by 
the Rho-kinase/LIMK-1 pathway. 
Our results showing that only dephosphorylated (activated) cofilin binds with F-actin support 
previous observations that the state of cofilin phosphorylation determines its association with F-
actin.  The effect of Y-27632 in resting platelets showing a reduction in cofilin phosphorylation, 
and an increase of F-actin content and cofilin association with F-actin suggested that LIMK-1-
mediated cofilin phosphorylation reduces the F-actin content and cofilin association with F-actin 
in resting platelets.  In contrast, during shape change, cofilin that showed no change in its 
phosphorylation was rapidly associated with the actin cytoskeleton.  The maximal cofilin 
association with actin cytoskeleton occurred before the maximal F-actin increase, suggesting that 
cofilin association with F-actin might regulate the turnover and actin polymerization during 
platelet shape change.  It is an open question, whether cofilin is locally dephosphorylated before 
binding to F-actin during shape change. 
Previous studies in other cells could correlate cofilin dephosphorylation (activation) with the 
depolymerization of F-actin.  However, in our studies cofilin dephosphorylation during the initial 
phase of thrombin-induced secretion (up to 30 seconds) was associated with a large increase of F-
actin and a high amount of cofilin association with F-actin.  Cofilin rephosphorylation after 30 
seconds did not decrease F-actin content and cofilin association with F-actin.  Together, in 
activated platelets the association of cofilin with F-actin and the F-actin increase do not simply 
correlate to the cofilin phosphorylation state: it seems to be more complex.  It is assumed that the 
cofilin phosphorylation and actin dynamics are regulated in specific compartments during platelet 
activation. 
The rapid cofilin dephosphorylation in platelets was mediated by an okadaic-acid insensitive 
phosphatase.  The activation of the cofilin phosphatase seemed to be regulated at least in part by 
an increase in intracellular Ca2+ and by PI3-kinase.  Cofilin de- and rephosphorylation occurring 
upstream of secretion and platelet aggregation suggests that the enzymes regulating the cofilin 
phospho-cycle could be potential targets for the development of anti-thrombotic drugs. 
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7. Zusammenfassung 
Die Aktivierung von Blutplättchen spielt sowohl während der physiologischen Hämostase als 
auch bei pathologischen Prozessen wie der intraarteriellen Thrombenbildung und des damit 
verbundenen Gefäßverschlusses eine zentrale Rolle. 
Einer der wichtigen Aspekte der Plättchenaktivierung ist die Dynamik und Umorganisation des 
Zytoskelettes nach Stimulation der Thrombozyten.  Die morphologischen und funktionellen 
Veränderungen der Plättchen erfordern eine drastische Umorganisation des Aktin-Zytoskelettes, 
welches durch eine Vielzahl Aktin-bindender Proteine und Signalmoleküle, wie zum Beispiel 
Moleküle der Familie der Rho-GTPasen, gesteuert wird.  Die kleine GTPase Rho reguliert 
verschiedenste Zellfunktionen, hauptsächlich durch ihren nachgeschalteten Effektor Rho-Kinase.  
Einer der Signaltransduktionswege der Rho-Kinase verläuft über die Phosphorylierung der 
myosin light chain (MLC) und deren Gegenspieler der MLC-Phosphatase.  Ein zweiter 
Signalweg involviert die Aktivierung von LIM-Kinasen (LIMK) und die nachfolgende 
Phosphorylierung und Inaktivierung von Cofilin, einem Aktin dynamisierendem Protein.  
Dephosphorylierung und Aktivierung von Cofilin resultiert in einer Spaltung und 
Depolymerisation von Aktinfilamenten. 
Es ist bisher nicht untersucht worden, ob während der Thrombozytenaktivierung der Signalweg 
über die Rho-kinase/LIM-kinase/Cofilin-Phosphorylierung aktiviert wird und wie die 
Cofilinaktivierung die Aktindynamik, welche der Plättchenaktivierung zugrunde liegt, 
beeinflusst.  Um diese Fragestellungen zu beantworten wurde der physiologische Agonist 
Thrombin und der pathophysiologisch relevante Agonist Lysophosphatidsäure (LPA), welche als 
thrombogene Substanz in atherosklerotischen Plaques enthalten ist, als Plättchenstimuli 
eingesetzt und die nachfolgende Regulierung des Rho-Kinase/LIM-Kinase/Cofilin-
Phosphorylierungsweges untersucht. 
In unseren Untersuchungen konnten wir zeigen, dass die Aktivierung der Rho-Kinase für einen 
Anstieg des F-Aktin-Gehaltes während der kalziumunabhängigen Konformationsänderung der 
Thrombozyten, induziert durch LPA oder Thrombin, von Bedeutung ist.  Die Aktivierung der 
Rho-Kinase war einer Sekretion der Plättchengranula und einer Integrin αIIbβ3-Aktivierung 
vorgeschaltet.  Die schnelle Aktivierung der Rho-Kinase führte während der Sekretion der 
Granulainhaltstoffe und der Thrombozytenaggregation zu einem vermehrten Anstieg des F-
Aktin-Gehaltes im Vergleich zum shape change.  Es konnte beobachtet werden, dass die durch 
LPA stimulierte Sekretion der dichten Granula in den Plättchen hauptsächlich durch Rho-Kinase 
reguliert wurde, während die Sekretion die durch Thrombin induziert wurde, nur teilweise Rho-
Kinase abhängig war.  Diese Resultate zeigen zusammen, dass Rho-Kinase den F-Aktin-Anstieg, 
der einer Formänderung und der Sekretion der Plättchen zu Grunde liegt, reguliert, aber nicht 
direkt an der Aggregation beteiligt ist. 
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Zum ersten Mal konnte durch diese Arbeit gezeigt werden, dass Plättchen nur LIMK-1 
exprimieren und nicht LIMK-2.  Erstere kann durch die Rho-Kinase sowie durch p21-aktivierte 
Kinasen (PAKs) aktiviert werden.  Wir konnten zeigen, dass die LIMK-1 Aktivierung in 
stimulierten Plättchen ausschließlich von der Rho-Kinase abhängig ist.  Obwohl eine PAK1/2 
Aktivierung während des LPA-stimulierten shape change beobachtet werden kann, sind in LPA-
stimulierten Plättchen PAKs wahrscheinlich nicht an einer LIMK-1-Aktivierung beteiligt.  Es 
wurde gezeigt, dass die LIMK-1-Aktivierung genau wie die Rho-Kinase-Aktivierung unabhängig 
von der Integrin αIIbβ3-Aktivierung ist und die  Rho-Kinase-Aktivierung einer LIMK-1-
Aktivierung vorgeschaltet ist. 
Überraschenderweise führte die durch Thrombin und LPA aktivierte LIMK-1 nicht zu einem 
Anstieg der Phosphorylierung von Cofilin während des shape change.  Durch Hemmung des 
Rho-Kinase/LIM-Kinase Signalweges wurde eine Cofilin-Dephosphorylierung deutlich, was 
darauf hindeutete, dass die gleichzeitige Stimulierung von Cofilin-Phosphatasen der Wirkung 
einer LIMK-1 vermittelten Cofilin-Phosphorylierung entgegenwirkt.  Während der LPA- und 
Thrombin-induzierten Plättchensekretion und Aggregation wurde Cofilin zuerst sehr schnell 
dephosphoryliert und anschließend, infolge der LIMK-1 Aktivierung, rephosphoryliert.  Nach 
Stimulation mit LPA und Thrombin unter Bedingungen, unter denen keine Plättchen-aggregation 
auftritt, war die Cofilin-Phosphorylierung und Dephosphorylierung unverändert, was zeigt, dass 
Kinetik des Cofilin-Phosphorylierungszyklus unabhängig von der Integrin αIIbβ3 Einbindung ist. 
Weiterhin wird durch diese Ergebnisse gezeigt, dass die Cofilin-Dephosphorylierung unabhängig 
von der Sekretion abläuft und dieser vorgeschaltet ist, da die Dephosphorylierung von Cofilin 
ebenso schnell wie die Sekretion in Thrombin-stimulierten Plättchen auftrat und auch in 
Abwesenheit einer dichten Granula-Sekretion nachgewiesen werden konnte, wenn Plättchen ohne 
Fibrinogen mit LPA (10 µM) stimuliert wurden.  Da die Kinetik des Cofilin 
Phosphorylierungszyklus ähnlich in LPA- als auch in Thrombin-stimulierten Plättchen ist, 
schlage ich einen generellen Zwei-Schritt Regulationsmechanismus vor: Zuerst eine 
Dephosphorylierung durch eine Cofilin-Phosphatase und nachfolgend eine Rephosphorylierung 
durch den Rho-Kinase/ LIMK-1 Signalweg.  Dieser Cofilin-Phosphorylierungszyklus reguliert 
primär die Sekretion und sekundär die Aggregation.  
Unsere Beobachtungen, die zeigen, dass nur dephosphoryliertes, aktiviertes Cofilin an F-Aktin 
bindet, stützen vorherige Resultate, dass der Cofilin-Phosphorylierungsstatus die F-Aktin-
Assoziation bestimmt.  Der Effekt von Y-27632 in  ruhenden Plättchen, welches eine Reduktion 
der Cofilin Phosphorylierung, einen F-Aktin-Anstieg und eine Steigerung in der Cofilin-Aktin-
Assoziation bewirkt, lässt vermuten, dass die LIMK-1 vermittelte Cofilin-Phosphorylierung den 
F-Aktin Gehalt und auch die Cofilin-Aktin-Assoziation in ruhenden Plättchen reduziert.  Die 
Situation ist anders als in aktivierten Thrombozyten: hier zeigte das Cofilin, welches keine 
Veränderung seiner Phosphorylierung während des Gestaltwandels von Plättchen aufwies, eine 
schnelle Assoziation mit F-Aktin.  Die maximale Cofilin-Aktinzytoskelett-Interaktion fand vor 
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dem maximalen F-Aktin-Anstieg statt, was auf eine Regulation des Aktin-turnover und der 
Aktinpolymerisation durch Cofilin während der Konformationsänderung der Thrombozyten 
hinweist.  In bisherigen Studien an anderen Zellen wird die Dephosphorylierung von Cofilin, also 
dessen Aktivierung, vor allem mit einer Aktindepolymerisation in Verbindung gebracht.  
Hingegen konnten wir in unseren Studien belegen, dass während der Anfangsphase der Thrombin 
induzierten Sekretion eine Cofilindephosphorylierung mit einem enormen Anstieg des F-Aktin-
Gehaltes und einer starken Cofilin-F-Aktin-Interaktion assoziiert war.  Durch die 
Rephosphorylierung von Cofilin 30 Sekunden bis 2 min nach Stimulation zeigte sich kein 
Rückgang im F-Aktin-Gehalt oder in der Assoziation von Cofilin mit dem Aktin-Zytoskelett.  
Zusammengenommen zeigen diese Ergebnisse die Komplexität der Regulation der Cofilin-
Phosphorylierung und dessen Assoziation  mit F-Aktin. 
Die schnelle Cofilin-Dephosphorylierung in Plättchen wurde durch eine Okadaic-Säure 
insensitive Phosphatase katalysiert.  Die Aktivierung dieser Phosphatase schien zumindest 
teilweise durch einen Anstieg des intrazellulären Kalziums und durch die PI3-Kinase reguliert zu 
sein. Die Enzyme, die den Cofilin-Phosphorylierungs-Dephosphorylierungszyklus regulieren, 
welcher der Sekretion der Plättchengranula und der Plättchenaggregation vorgeschaltet ist, 
könnten als potentielle medikamentöse Ziele für antithrombotische Medikamente dienen 
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